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ABSTRACT 
 
THE ROLE OF P120CATENIN IN THE INITIATION AND DISSEMINATION OF PANCREATIC 
CANCER 
Basil S. Bakir 
Anil K. Rustgi, MD 
Pancreatic cancer is the third leading cause of cancer mortality, the overwhelming majority of 
which is due to metastasis. The mechanisms of dissemination have been intensively studied, but 
questions remain as to how epithelial properties are regulated between the primary tumor site 
and destination as well as to how organotropic patterns of metastasis are determined. We 
demonstrate, using multiple complementary mouse models, that liver and lung metastatic 
organotropism in pancreatic cancer is dependent on p120catenin (p120ctn)-mediated epithelial 
identity. Monoallelic p120ctn loss accelerates KrasG12D-driven PanIN/PDAC formation and 
metastasis to the liver as well as being sufficient for E-CADHERIN-mediated cell adhesion. In 
contrast, cells with biallelic p120ctn loss demonstrate marked lung organotropism, although 
rescue with p120ctn restores liver metastasis. In a p120ctn-independent PDAC model, mosaic E-
cadherin knockout shows selective pressure for E-cadherin-positive liver metastasis and E-
cadherin-negative lung metastasis. Furthermore, human PDAC and liver metastases support the 
premise that liver metastases exhibit predominantly epithelial characteristics. RNA-seq 
demonstrates differential induction of pathways associated with metastasis and epithelial-to-
mesenchymal transition in p120ctn-deficient versus p120ctn-wild-type cells. Taken together, 
p120ctn-mediated epithelial plasticity may be added to the list of emerging concepts underlying 
metastatic organotropism. 
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Solid Tumor Metastasis 
The Metastatic Cascade 
 Solid tumor metastasis is the process by which tumor cells disseminate from their primary 
site and colonize distant organs (Valastyan and Weinberg 2011). The purpose of this section is to 
introduce the concept that this process is divided into discrete steps; that each step requires 
certain adaptations; and that these steps together form the metastatic cascade. Sections 2 and 3 
will discuss the controversies and nuances that I gloss over in this section; therefore, the 
idealized, cartoon-like process described below is a prelude to an in-depth discussion of the 
molecular and cellular properties that regulate tumor growth and metastasis. 
The metastatic cascade can be broken down into intravasation, circulation, extravasation, 
survival, and reactivation from dormancy and outgrowth. In order for a macrometastatic lesion to 
form, a primary tumor cell must successfully complete all the steps, which goes some ways 
toward explaining why metastasis is such an inefficient process. 
Each step is associated with certain canonical properties that are needed in order to 
successfully navigate the process. The first step, intravasation – or the entry of delaminated 
tumor cells into vasculature – is strongly associated with the acquisition of invasive properties 
granted by the phenomenon of epithelial-to-mesenchymal transition, a topic discussed at length 
in section 2. 
The second step, circulation, requires tumor cells to hematogenously disseminate. As 
(Chaffer and Weinberg 2011) point out, this is not quite the simple process one might imagine. 
Circulating tumor cells (CTCs), with diameters between 20 and 30 µm, have to navigate through 
8 µm diameter capillaries, which they suggest means successful CTCs are those that are 
exceptionally flexible. Interactions with vasculature and platelets are also important, with platelet-
mediated interactions with endothelium important mediators of successful metastasis. Platelet 
depletion, for example, significantly reduces lung metastatic burden in melanoma cell tail vein 
injections (Camerer et al. 2004). The theme of vascular interactions as key mediators of 
metastasis will recur throughout this dissertation and will be discussed in depth in section 3. 
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The third step, extravasation, involves CTCs exiting the circulation after attachment to the 
vasculature. Intravital imaging of human breast cancer cells injected into the portal vein (Tsuji et 
al. 2006) showed, as Sahai (2007) summarizes, evidence of “cell protrusions and deformation of 
the nucleus…implying that it is an active process.”  
The fourth step, survival, is based on the observation that the overwhelming majority of 
tumor cells “at secondary sites undergo apoptosis within 24 hours” (Sahai 2007). Intravenously 
transplanted melanoma cells demonstrated 1% survival in the mouse lung 24 hours post-injection 
(Fidler 1970). Similarly, fluorescent labeling of the apoptosis-regulating protein BAD showed that 
metastasis-incompetent versus metastatic-competent cells are differentiated by susceptibility to 
apoptosis following arrest in the lung vasculature (J. Kim et al. 2004). Sahai (2007) notes that the 
same is seen liver vasculature, with colon cancer cells exhibiting nuclear breakdown (Tsuji et al. 
2006). This suggests that at the junction between extravasation and entry into the liver 
parenchyma, survival may be a rate-limiting factor for successful metastasis formation. 
 The fifth step, reactivation from dormancy, is based on the observation that even cells 
that complete all the previous steps successfully may enter a period of quiescence at the 
secondary site (Giancotti 2013; Sosa, Bragado, and Aguirre-Ghiso 2014). Portal vein injection of 
melanoma cells, for example, reveals remarkable persistence of extravasated cancer cells as 
solitary quiescent cells up to 13 days post-injection (Luzzi et al. 1998). Mechanisms for 
quiescence and reactivation have been worked out, with breast cancer dormancy in the lung 
being a particularly well-described example. A cDNA screen identified a tumor-cell secreted 
factor, Coco, as a reactivator of dormant breast cancer cells through inhibition of lung TGF-β 
signaling (H. Gao et al. 2012). Crucially for this dissertation, the importance of epithelial 
properties in promoting metastatic outgrowth have been studied (Brabletz 2012). The connection 
between epithelial properties and outgrowth will be discussed extensively in section 2. 
I have outlined this cascade and described both the canonical understanding as well as 
questions relevant for this dissertation in Figure 1-1.  
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Figure 1: The 
Metastatic 
Cascade. A 
schematic of 
the metastatic 
cascade 
broken down 
into canonical 
steps and 
relevant 
questions. 
For relevant 
questions, the 
introductory 
section that 
covers that 
topic is 
indicated. 
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Early Versus Late Dissemination 
 Each step in the above cascade is understood to occur due to the stepwise accumulation 
of genetic aberrations and adaptations that promote the properties necessary to accomplish a 
specific task – EMT for invasiveness and intravasation; resistance to shear stress and 
interactions with the vasculature for circulation and extravasation; pro-survival signaling at the 
metastatic site for survival; proliferative signaling for outgrowth. Every stage of progression, 
therefore, should correlate with the accumulation of an additional genetic perturbation or 
adaptation. The final step of a cancer cell’s career – metastatic outgrowth – would therefore be 
defined by the most genetically aberrant state because, if the model is correct, the cells that 
spread would be defined by the acquisition of the entire spectrum of genetic properties needed.  
 There are, however, two major problems with this model. First, metastases are often 
remarkably similar to their paired primary tumors (Brabletz 2012). Second, early dissemination of 
cancer cells, even at the stage of preneoplastic lesions, has been repeatedly observed in multiple 
models. The first of these observations will be discussed in section three, as it will fit more 
naturally in that setting; however, here, I will focus on the second. 
 The reason why this topic is important is that metastatic organotropism, a concept 
covered in detail later in this introduction and which this dissertations is built on, implicitly argues 
for unique metastatic properties – in fact, not just unique metastatic properties, but unique 
properties for organ-specific metastasis. Therefore, even though this dissertation does not directly 
address the controversy between early and late stage disseminations models, any data that 
suggests metastasis is not the result of genetic aberrations above and beyond those of the 
primary tumor is relevant for contextualizing this dissertation. To that end, this section will briefly 
cover the topic of early versus late dissemination. 
For our purposes, some of the most compelling data in favor of early dissemination 
derive from a fluorescently-labeled pancreatic cancer mouse model that permits detection of 
mesenchymal-appearing cancer cells that would otherwise be difficult to differentiate from stroma 
(Rhim et al. 2012). This model demonstrated that preneoplastic lesions in the pancreas can give 
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rise to delaminated cells that are competent enough to disseminate, suggesting that metastasis is 
not a genetic program distinct from that of tumor initiation and that they proceed hand-in-hand 
(the topic of primary tumor growth versus metastasis is discussed in detail in section 3). Human 
data corroborates early dissemination in pancreatic pathology (Agarwal, Correa, and Ho 2008; 
Rhim et al. 2014; Sakorafas and Sarr 2003). Most powerful of all is data demonstrating that 
patients resected for tumors less than 2 in cm size exhibit metastasis years later despite there 
being no sign of dissemination at the time of surgery. 
Similar to Rhim et al. (2012), multiple groups have demonstrated spread of breast cancer 
cells prior to detection of tumors in spontaneously metastatic models (Harper et al. 2016; 
Hosseini et al. 2016; Hüsemann et al. 2008). Additionally, tumor cells in the bone marrow of 
breast cancer patients do not demonstrate any chromosomal abnormalities, strongly suggesting 
that the genetic derangements present later in primary tumor growth can be dispensed with in 
certain instances (Schardt et al. 2005). I have summarized in Table 1-1 relevant mouse and 
human data on early dissemination for both breast and pancreas cancer.  
Cancer Experimental Set-up Observation Reference 
Pancreas Microfluidic chip 
capture of circulating 
pancreas epithelial 
cells in blood of 
patients  
Patients with cystic lesions but no 
tumor or metastasis by CT or MRI 
harbor circulating epithelial cells 
(Rhim et al. 2014) 
Pancreas Lineage labeling of the 
KPC mouse 
Lineage-labeled cells are present 
in the blood and liver during the 
preneoplastic PanIN stage 
(Rhim et al. 2012) 
Pancreas Retrospective analysis 
of patients who 
underwent endoscopic 
ultrasound-FNA  
Even patients who undergo 
pancreatectomy for very small 
primary tumors (under 2 cm) with 
no evidence of dissemination at 
time of surgery exhibit metastasis 
years later 
(Agarwal et al. 2008) 
Pancreas Retrospective analysis 
of patients who 
underwent surgery for 
chronic pancreatitis 
Patients without tumor, as 
determined by histological 
analysis post-surgery for chronic 
pancreatitis, will develop 
pancreatic cancer metastasis 
years later 
(Sakorafas and Sarr 
2003) 
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Breast Intravital imaging of 
MMTV-Her2 GEMM 
A subpopulation of cells in mice 
that have only preneoplastic 
lesions can metastasize  
(Harper et al. 2016) 
Breast Her2 GEMM Cells disseminate from the breast 
soon after Her2 transgene 
activation; cell dissemination is 
inversely related to tumor size 
through a progesterone-
dependent mechanism 
(Hosseini et al. 2016) 
Breast Lymph nodes and 
bone marrow from 
patients with ductal 
carcinoma in situ.  
Isolated tumor cells are present in 
bone marrow and, less often, 
lymph nodes at the preneoplastic 
stage. Consistent with (Hosseini et 
al. 2016; Hüsemann et al. 2008) 
that tumor size does not mean 
greater dissemination. 
(Banys et al. 2012) 
Breast HER2 GEMM and 
patient samples. 
HER2 GEMM: HER2+ cells are 
detected in the lung before any 
abnormalities are detectable in the 
breast, and these cells grow into 
metastases later.  
Patient Samples: There is no 
association between number of 
tumor cells in the bone marrow 
between patients with ductal 
carcinoma in situ or T1-stage. 
(Hüsemann et al. 
2008) 
Breast Karyotyping and CK19 
staining of tumor cells 
in bone marrow of 
breast cancer patients. 
Disseminated cancer cells exhibit 
normal karyotyping, suggesting 
spread prior to the start of 
chromosomal instability. 
(Schardt et al. 2005) 
Breast Isolation of 
disseminated tumor 
cells in the bone 
marrow of M0 and M1 
patients 
Tumor cells in bone marrow at M0 
harbor fewer chromosomal 
abnormalities than at M1, 
suggesting that dissemination is 
not a late-stage event favoring the 
most genetically-aberrant clones 
(Schmidt-Kittler et al. 
2003) 
Review 
Article 
- - (Klein 2009) 
 
Table 1-1: Evidence for Early Dissemination 
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Epithelial-to-mesenchymal and Mesenchymal-to-
epithelial Transition 
Epithelial-to-mesenchymal Transition in Cancer 
 Epithelial-to-mesenchymal transition (EMT) is a known embryological process by which 
polarized cells arranged in a sheet delaminate and become motile and spindle-shaped (Nieto 
2011; Thiery et al. 2009). This phenotypic change, from polarized epithelium to motile 
mesenchyme, was first recognized as a distinct biological process when epithelial cells seeded in 
collagen acquired both the appearance and motility characteristic of mesenchymal cells 
(Greenburg and Hay 1982). 
 The molecular basis of EMT is thought to depend on transcription factors responsible for 
repressing epithelial genes and/or inducing mesenchymal ones (Craene and Berx 2013; 
Lamouille, Xu, and Derynck 2014). One of the initially described molecular hallmarks of EMT was 
repression of E-cadherin, the adherens junction protein responsible for lateral polarity in 
epithelium. It is this hallmark, repression of E-cadherin, which was used as a proxy to study many 
of the first transcription factors now known as EMT transcription factors (EMT-TFs). The very first 
one to be linked to E-cadherin repression was Snail (Batlle et al. 2000; Cano et al. 2000), which 
was followed thereafter by others such as Slug (Bolós et al. 2003),  Zeb1 (Eger et al. 2005), Zeb2 
(Comijn et al. 2001), and Twist (Yang et al. 2004). 
 Even though the phenomenon of EMT has been extensively defined on a molecular and 
phenotypic basis and despite the obvious link between mesenchymal phenotypes and motility 
that make EMT such an obvious and interesting phenomenon for cancer research, the sparse in 
vivo data that EMT occurs during cancer progression has led some to doubt EMT’s putative role 
in dissemination (Ledford 2011). In fact, a series of recent papers, discussed later, make the 
claim that EMT is dispensable for dissemination. This, combined with the debate over the role of 
epithelial plasticity in carcinomas and potential for mesenchymal-to-epithelial transition (MET) 
(Brabletz 2012; Tsai and Yang 2013), provides an opportunity to contextualize our understanding 
of EMT in three ways.  
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First, in the two following sections, I will review the evidence for EMT in vivo and its 
connection to stemness. Second, I will focus on the reverse and attempt to summarize our 
understanding of MET. Third, I will review the controversy over the possibility that EMT is 
dispensable for cancer progression.  
In Vivo Evidence for EMT 
 As suggested by Beerling et al. (2016), one of the central problems for the claim that 
EMT is a normal physiologic process in cancer is that many studies rely on artificial manipulation 
of EMT-TFs. This means that a whole range of studies that overexpress or delete EMT-TFs and 
then report the appropriate phenotype may be reporting artificial results. This certainly does not 
mean that the reported phenotype after EMT-TF perturbation is not real – it simply means that it 
does not prove this happens in vivo, under unperturbed conditions. As an added dilemma, 
Beerling et al. (2016) remind us that EMT-TFs have oncogenic effects that are independent of 
promoting EMT, with Twist1 being an example (Beck et al. 2015). Therefore, it is important to 
step back from the plethora of perturbed in vitro (e.g., TGF-β stimulated cells) and in vivo (e.g., 
overexpressing an EMT-TF in a cell line and transplanting it) model systems and assess the 
strength of the evidence that EMT occurs during unperturbed cancer progression.  
 Fluorescently labeled, spontaneously metastatic mouse models that allow identification of 
cancer cells at any stage in their development are a powerful tool to study in vivo EMT. Such a 
breast cancer model, which depends on polyomavirus middle T antigen (PyMT) under the control 
of a mammary mouse tumor virus promoter (MMTV) (MMTV-PyMT), revealed that fluorescently-
labeled cells with no membranous E-cadherin could be detected from digested primary using a 
dual FACS approach (YFP to exclude non-cancer cells and a fluorescently-labeled E-cadherin 
antibody to detect extracellular E-cadherin domains) (Beerling et al. 2016). These E-cadherin 
deficient cells exhibited an upregulation of classic EMT genes relative to the E-cadherin positive 
cells, including increases in EMT-TFs such as Snail, Slug, Twist, Zeb1, and Zeb2. Importantly, 
using orthotopic transplantation and intravital imaging, it was the E-Cadherin deficient EMT cells 
that migrated, demonstrating the in vivo functional effects of EMT.  
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 Using a lineage-labeled pancreatic cancer mouse model, Rhim et al. (2012) demonstrate 
that delaminated preneoplastic cells destined for early dissemination express Zeb1 but not E-
cadherin. Remarkably, this shows EMT at the preneoplastic stage; however, using a pancreatitis-
mediated model of dissemination, they also demonstrate, based on Zeb1 and EpCAM markers, 
that there is a population of predominantly epithelial (EpCAM+, Zeb1-) circulating tumor cells 
(CTCs) as well as a mixed mesenchymal-epithelial population (EpCAM+, Zeb1+). Together, 
these two groups make up just under half of all CTCs and suggests that, while EMT does occur, it 
is not necessarily defined by a loss of all epithelial traits, even in circulation. Interestingly, about 1 
in 8 CTCs were neither EpCAM nor Zeb1 positive. These cells might be in a transition state 
where they have shut off one program and are turning on another. 
 To interrogate the plastic nature of EMT, the authors isolated E-Cadherin+ or E-
Cadherin-tumor cells from their lineage-labeled pancreatic ductal adenocarcinoma (PDAC) 
model. Orthotopic transplantation demonstrated that both populations are competent at 
tumorigenesis and that tumors arising from each set looked remarkably similar. Interestingly, this 
plasticity was not found to exist between E-Cadherin+ or E-Cadherin- preneoplastic cells. Unlike 
PDAC cells, at the preneoplastic stage, E-Cadherin positivity appears to be a significant 
hindrance to tumorigenesis in an orthotopic model. This suggests that epithelial properties are not 
a hindrance to tumor formation – as long as there are added genetic aberrations that can drive 
malignancy. 
 In addition to mouse models, human studies have revealed evidence for EMT in both 
breast and pancreas cancer. Circulating breast cancer cells in human patients exhibit 
heterogeneous patterns of epithelial and mesenchymal markers (Yu et al. 2013), similar to the 
heterogeneous EpCAM/Zeb1 patterns in Rhim et al. (2012). PDAC CTCs in human patients also 
exhibit dual epithelial-mesenchymal properties, though this does not extend to E-cadherin, whose 
loss is a virtually universal event (Ting et al. 2014). This is consistent with Rhim et al. (2012), who 
showed that E-cadherin was not present in any significant amount on mouse CTCs. The 
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combined mouse and human data demonstrate that even though EMT does occur, it likely leads 
to a dual nature epithelial-mesenchymal cancer cell and is possibly a plastic, reversible state. 
EMT and Stemness 
 The connection between EMT, motility, and metastasis is conceptually clear; however, 
here I want to pose a separate question – if EMT promotes some metastasis-supporting cell 
properties, does it inhibit others? As discussed in section one, during the metastatic cascade, not 
only does a cell have to acquire the properties necessary to disseminate but also the properties 
necessary to reactivate from dormancy and proliferate at the metastatic site. The data on whether 
EMT promotes these properties of reactivation from dormancy and proliferation are contradictory 
and form a conceptually important hinge in our discussion of EMT-MET in cancer for this reason: 
if EMT does in fact need to be reversed at some point in metastasis, it is plausible that it is this 
point – the transition from a single mesenchymal cell at a foreign site into a macrometastatic 
epithelial lesion – when the MET process begins. As discussed in the next section, tracing of 
metastasis in breast (Beerling et al. 2016) and pancreatic cancer (Aiello et al. 2016) models 
shows a size-dependent increase in epithelial properties. 
This brings us to the contradictory data on EMT, MET, and stemness. First, there is 
significant data that certain EMT-TFs do promote the stemness and renewal capacity that a 
single, isolated tumor cell at a distant site would need to form a macrometastatic lesion.  
 Human mammary epithelial cells (HMECs) that have been induced to undergo EMT 
through either TGF-β treatment or Snail/Twist overexpression exhibit stem cell properties as 
evidenced by increased CD44, a stemness marker, and increased capacity for self-renewal in 
mammosphere assays (Mani et al. 2008). Additionally, non-induced HMEC’s that exhibit high 
CD44 and low CD24, a pattern consistent with stemness, naturally have higher EMT-TF levels 
compared to those cells with low CD44 and high CD24. These findings were relevant in vivo, as 
serial limiting dilution transplantations showed that Twist and Snail overexpression in transformed 
HMLE cells increased tumor incidence relative to transformed cells only.  
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Similarly, the original work that identified Twist1 as promoter of EMT in breast cancer 
demonstrated a correlation between higher expression and metastasis in orthotopic models, and 
knockdown of Twist1 resulted in fewer CTCs (Yang et al. 2004). The role of EMT in promoting 
stemness in the context of breast cells has been corroborated by others. Morel et al. (2008) 
reported synergistic roles for oncogenic RAS and TGF- β in the induction of stem cells markers, 
and Santisteban et al. (2009) demonstrated a similar role for T-cell induced EMT.  
 Crucially for us, Zeb1 promotes stemness in the context of pancreatic cancer. 
Knockdown of Zeb1 in multiple human pancreatic cancer lines lowers tumorigenic capacity as 
determined by serial dilution transplantations (Wellner et al. 2009). In vitro assays of stem cell 
properties, such as sphere formation, show stem cell property correlation with higher Zeb1 levels 
in human cancer cell lines, and Zeb1 knockdown abrogates these properties. Mechanistically, 
Zeb1 appears to suppress microRNAs, such as mIR-183/203, that inhibit stemness factors such 
as KLF4 or Sox2. Lower Zeb1 levels in the primary tumor also correlate with significantly less 
likelihood of tumor relapse post-resection. 
 Consistent with the crucial role for Zeb1 in PDAC reported by Wellner et al. (2009) and 
with the presence of Zeb1 in delaminated preneoplastic cells by Rhim et al. (2012), knockout of 
Zeb1 in the context of a genetic PDAC mouse model dramatically abrogates PDAC formation and 
metastasis (Krebs et al. 2017). Importantly for this section, PDAC cells with or without Zeb1 
showed no differences after subcutaneous transplantation but demonstrated significantly 
decreased lung colonization capacity after intravenous injection. The authors interestingly noted 
what when comparing PDAC cell lines alone, the more epithelial lines had higher tumorigenic 
potential than the more mesenchymal ones, which they comment is consistent with a series of 
high-profile papers on the role of MET in metastasis (Korpal et al. 2011; Ocaña et al. 2012; Tsai 
et al. 2012). These papers will be discussed in the sections that follow. For the purposes of our 
discussion here on EMT and stemness, the loss of Zeb1 in the context of a PDAC mouse model 
results in stem cell marker loss (Krebs et al. 2017). Therefore, there is significant data in the 
pancreas that certain EMT-TFs promote stemness and metastasis. 
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If, then, there is significant evidence that EMT occurs in vivo and can promote cell 
properties associated with metastasis, such as motility and stemness, how does one reconcile 
this with the evidence that carcinoma metastases are frequently epithelial in nature? There are 
two broad ways to conceptually square this circle:  
1) First, we could hypothesize that EMT is a plastic state that is reversed during a 
subsequent MET. 
2) Second, we could hypothesize that, while EMT occurs, it is not absolutely necessary 
and, for a variety of reasons, may be dispensed with at any point in the metastatic 
cascade. 
The next section discusses the MET hypothesis, and the following discusses the EMT 
dispensability hypothesis. 
Mesenchymal-to-epithelial Transition in Cancer 
This section will focus on evidence that demonstrates a pro-metastatic role for E-
Cadherin and MET (Rodriguez, Lewis-Tuffin, and Anastasiadis 2012). Three cancers – breast, 
ovarian, and pancreas – have been chosen on the basis of the depth of the literature as well as 
relevance to this dissertation.  
Breast Cancer 
 Certain subtypes of breast cancer are an intriguing exception to the “E-Cadherin-as-
tumor-suppressor” model. In particular, the histological subtype invasive ductal carcinoma has 
repeatedly been shown to robustly express E-Cadherin, especially at metastatic sites. One study 
(Kowalski, Rubin, and Kleer 2003) showed that of 23 paired primary tumor-metastasis samples in 
patients with invasive ductal breast cancer, all metastases expressed E-cadherin and that 10 of 
these had higher E-cadherin expression at the metastatic site than at the primary site, an 
observation recapitulated in other studies (Bukholm, Nesland, and Borresen-Dale 2000; Jeschke 
et al. 2007).  
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 Inflammatory breast cancer (IBC), a clinical diagnosis which can be either ductal or 
lobular, has also been shown to express E-cadherin virtually uniformly at primary and metastatic 
sites. In one cohort of IBC tissue (Kleer et al. 2001), all 20 patient samples (18 invasive ductal 
carcinoma and 2 invasive lobular carcinoma) expressed E-cadherin at the primary site and at all 
tumor emboli found in the lymphatics.  These findings are supported by another IBC tissue cohort 
(Colpaert et al. 2003).  
 The findings of retained E-cadherin in IBC are especially interesting in light of how well 
studied the functional effects of this expression are, especially in metastasis. In short, IBC is 
remarkable for its propensity to form microemboli that enter the dermal lyphmatic system (Gong 
et al. 2008). This suggests that intravasation, the entry of tumor cells into the lymphovascular 
system, is accelerated. Using a novel transplantation model created specifically to model IBC 
(Tomlinson, Alpaugh, and Barsky 2001), E-cadherin antibody injections caused the dissolution of 
the metastases seen in transplanted mice. Additionally, the metastatic properties of IBC lines 
could be abrogated through transfection with a dominant-negative E-cadherin. Therefore, these 
tumor microemboli, characterized by their incredibly compact form, are dependent on functional 
E-cadherin, which assists in passive dissemination and survival. 
 The regulation of E-cadherin may be driven by environmental factors that control E-
cadherin promoter methylation. Primary human breast cancers exhibit, early in their development, 
heterogeneous E-cadherin promoter methylation (Graff et al. 2000). In in vitro culture systems, 
methylation increases during invasion but decreases during spheroid cultures, suggesting that 
environmental cues determine epigenetic patterns regulating epithelial-mesenchymal 
phenotypes, a mechanism that would support the decreased primary E-cadherin and increased 
metastatic E-cadherin seen in the human tissue studies described above. Supporting this 
hypothesis are co-culture studies showing that mesenchymal breast cancer cells (MDA-MB-231), 
when grown alongside hepatocytes, exhibit E-cadherin promoter demethylation (Chao, Shepard, 
and Wells 2010). 
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 Additional functional evidence that MET is affected by environmental clues was observed 
in spontaneous lung metastasis models that illustrated the role of the pre-metastatic niche in 
modulating EMT-MET (D. Gao et al. 2012). In brief, myeloid cells in the pre-metastatic lung 
deposit the ECM component versican, which induces MET by attenuating SMAD2 levels and 
promoting proliferation. This demonstrates both the role of the environment in modulating EMT 
and the reasons why EMT might be turned off at the metastatic site, namely the increased 
proliferative capacity of epithelial cells. This functional proliferative effect is especially interesting 
in light of the earlier evidence that EMT also promotes stemness. 
In addition to myeloid cells, fibroblasts have been implicated in fostering a MET-
promoting environment at the metastatic site. Using the same spontaneous lung metastasis 
model as Gao et al. (2012), del Pozo Martin et al. (2015) demonstrate that disseminated 
metastatic cells that express AXL, a receptor related to the EMT phenotype, activate lung 
fibroblasts through THBS2. These activated fibroblasts, in turn, inhibit EMT in the disseminated 
cancer cells. The now MET-like cancer cells demonstrate a decrease in TGF-β signaling through 
SMAD2-3. Consistent with Gao et al. (2012), these MET-like cells show higher proliferation 
levels, suggesting a possible reason why MET fosters metastatic growth. Remarkably, forced 
expression of AXL, the EMT receptors the authors identified as being upregulated in 
disseminated mesenchymal cells, leads to a significant inhibition of metastatic outgrowth in a tail 
vein injection model. 
Another group observed supporting patterns in spontaneous lung metastasis, where, 
while circulating tumor cells showed a mixture of E-cadherin low and high states, the metastases 
were overwhelmingly E-cadherin high (Beerling et al. 2016). Interestingly, those metastases that 
are 3 cells of more are entirely E-cadherin positive, suggesting that E-cadherin turns on as a 
metastatic lesion increases in size – or, to put it in a different way, that while EMT-MET may be in 
balance during circulation, MET becomes predominant at the metastatic site. (Of note, Aiello et 
(al. 2016) demonstrate a similar pattern in pancreatic liver metastases).  
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Ovarian Cancer 
 The ovarian surface epithelium, from which most ovarian cancers derive, is normally E-
cadherin negative (Sundfeldt et al. 1997), but it shows a remarkable upregulation of E-cadherin 
during ovarian cancer progression (Daraï et al. 1997; Inoue et al. 1992; Soler et al. 1997; 
Sundfeldt et al. 1997). This acquisition of E-cadherin at the primary site in ovarian cancers is not 
reversed during omental metastasis (Köbel et al. 2011), and ovarian cancer cells in pleural and 
peritoneal effusions show high E-cadherin levels (Davidson et al. 2000). Functionally, E-cadherin 
transfection into normal ovarian epithelial lines is associated with the production of the tumor 
antigen CA-125 (Auersperg et al. 1999), and, much like in the case of IBC, the use of E-cadherin 
antibody results in dissociation of spheroid ovarian cancer cell clusters with hypothesized effects 
on their ability to survive in effusions (Elloul et al. 2010).    
 Ovarian cancer is also particularly interesting because of the pro-tumorigenic signaling 
that E-cadherin-mediated adhesion may drive. Normally, E-cadherin binds and negatively 
regulates epidermal growth factor receptor (EGFR) (Hoschuetzky, Aberle, and Kemler 1994; 
Perrais et al. 2007), a negative regulation mediated in part by recruitment of the 
neurofibromatosis type 2 tumor suppressor Merlin to the adherens junction upon cell-cell contact 
(Curto et al. 2007). 
 This E-cadherin-mediated negative regulation of EGFR, however, only functions if the 
appropriate tumor suppressors can be recruited to the cell junction. As Rodriguez et al. (2012) 
hypothesize, if this tumor suppressor is lost, the “dark side” of E-cadherin may appear. 
Specifically, E-cadherin is known, through β-catenin, to associate with parts of the PI3K signaling 
pathway (Woodfield et al. 2001), which means that EGFR-E-cadherin interactions also result in 
close proximity of PI3K pathway components and EGFR. Upon loss of the tumor suppressors 
recruited to the cell junctions, the close proximity of EGFR-E-cadherin may result in EGFR 
activation of PI3K signaling. In fact, in ovarian cancer cells, it’s known that E-cadherin contributes 
to PI3K signaling (De Santis et al. 2009) and that this signaling is not necessarily ligand-
dependent – E-Cadherin adhesion itself is sufficient to activate PI3K-AKT/MAPK signaling (Reddy 
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et al. 2005). Incidentally, our group (Stairs et al. 2011) has seen AKT activation upon loss of the 
E-cadherin-stabilizing protein p120ctn, which might hint at upregulated EGFR signaling upon 
adherens junction destabilization.  
Pancreatic Cancer 
 Consistent with the data above, pancreatic cancer metastasis has also been linked to 
MET. Using a lineage labeling approach to track dissemination in a spontaneous metastatic 
model, CTCs were observed to express the epithelial marker EpCAM (Rhim et al. 2012). 
Additionally, consistent with data on MET correlating with metastasis size in the breast 
(Bonnomet et al. 2012), this same PDAC model demonstrated that the epithelial properties of 
metastatic liver lesions increased in proportion to their size (Aiello et al. 2016). Specifically, 
epithelial markers such as E-Cadherin and Claudin-7 increased as disseminated cells went from 
isolated tumor cells to micrometastatic and then macrometastatic clusters. Conversely, 
mesenchymal markers such as FSP1 and ZEB1 showed decreases. Human staining confirmed 
the FSP1 pattern, with micrometastatic lesions having the highest FSP1 compared to both the 
primary tumor and the macrometastatic lesions. This suggests that the larger the liver metastasis 
becomes, the more it recapitulates the epithelial properties of the primary tumor. 
 Functional studies with the EMT-TF Prrx1 have corroborated the notion of MET in PDAC. 
Specifically, dissemination is modulated by isoform-switching between an MET-promoting 
isoform, Prrx1a, and a EMT-promoting isoform, Prrx1b (Takano et al. 2016). Activation of Prrx1a 
(i.e., activation of MET) or suppression of Prrx1b (i.e., suppression of EMT) in orthotopic 
transplantation models promoted liver metastatic outgrowth. 
Dispensability of Epithelial-to-mesenchymal Transitions in 
Cancer 
 If MET is required, then, by definition, there would have to be a disseminated cancer cell, 
at least partially mesenchymal in nature, that would need to repress mesenchymal properties and 
express epithelial properties. However, there is another, more radical proposition: what if the 
disseminated cancer cell – as motile as it is – can do without EMT?  
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 To demonstrate the dispensability of EMT to metastasis, work in breast, pancreas, skin, 
and lung has all used a similar paradigm: delete EMT-TFs in transplantation or genetic mouse 
models and demonstrate that metastatic burden is not decreased. This body of work has 
generated controversy by those who favor the traditional understanding that EMT is required for 
cancer progression. 
 In the pancreas, either Snail or Twist1, knocked out independently, does not affect 
primary tumor histology, tumor progression, or dissemination in the Pdx1-cre; KRASG12D; p53R172H 
model (Zheng et al. 2015). Even though compensation by other EMT-TFs cannot be ruled out 
entirely, each model shows decreases in Zeb1, Zeb2, Sox4, and Slug, showing that, at the 
minimum, those EMT-TFs are not compensating. One could imagine a situation where EMT-TF 
loss does not impair preneoplastic lesions, which are still epithelial and differentiated, but does 
impair dissemination, which is, presumably, where the motility-promoting effects of EMT are 
necessary. This, however, is not the case – the entire cascade from preneoplasia, tumor 
formation, dissemination, colonization, and outgrowth is unimpaired. Interestingly, however, EMT-
TF knockout was correlated with chemosensitivity due to increased nucleoside transporter 
expression, suggesting a possible explanation for the clinical observation that patients with more 
mesenchymal tumors have worse outcomes. 
 While Snail or Twist are dispensable individually, Zeb1 knockout in the same genetic 
background does impair the entire gamut of tumorigenesis, ranging from precursor lesion 
formation to metastasis (Krebs et al. 2017). Corroborating the importance of Zeb1 in pancreatic 
cancer, shorthairpin knockdown on Zeb1 in two human pancreatic cancer lines decreases 
disease progression in an orthotopic model (Wellner et al. 2009).This suggests that, at least in 
the context of pancreatic cancer, EMT dispensability is dependent on which EMT-TF is driving the 
process. Confusingly, in the Snail and Twist knockout models, the authors state that, among 
other EMT-TFs, Zeb1 was also decreased and therefore not compensating. This argues for 
testing whether there is a time-dependent requirement for EMT-TFs – for example, whether an 
inducible Zeb1 knockout would show different effects on long-term metastatic potential depending 
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on whether Zeb1 was knocked out at the early/late preneoplastic or neoplastic stages. In any 
case, the dispensability of EMT may not be so much a dispensability for EMT itself but a 
dispensability, in different tumors and at different stages, of specific EMT-TFs. However, the 
studies are consistent in this regard: Krebs et al. (2017) show that in a lung colonization assay, 
Snail is dispensable. 
 Whatever the temporal relationship is and whatever the specific EMT-TF that is 
unnecessary in a particular context, it is clear that the possible dispensability of EMT extends to 
cancers other than pancreas. This was interrogated in breast using a triple transgenic breast 
cancer mouse model (Fischer et al. 2015). The components of this complex model included the 
following: 
1) Mouse mammary tumor virus (MMTV) driving the expression of Polyoma Virus 
middle T antigen (PyVT), thereby giving rise to breast cancer. 
2) A Rosa26 promoter driving expression of a loxP-RFP-STOP-loxP-GFP lineage 
labeling element, thereby irreversibly turning the cell green when Cre recombinase is 
active. 
3) A Cre recombinase driven by Fsp1, thereby turning cells green when Fsp1 drives Cre 
expression. Since Fsp1 expression is a very early event in EMT (Okada et al. 1997), 
cells will irreversibly turn green when they enter this stage even if they undergo MET 
at a later stage. 
Using this system, the authors demonstrate that spontaneous lung metastatic lesions at 12 weeks 
of age stay RFP-positive/E-cadherin-positive. Since any cell that underwent EMT would have 
turned on Cre recombinase and therefore irreversibly lost RFP expression, this demonstrates that 
these metastatic cancer cells never expressed the early-EMT protein Fsp1.  
In a landmark study, the positive predictive value of high mir-200, an inhibitor of Zeb1 and 
Zeb2, for successful breast cancer metastasis was established in both mouse models and human 
tissue (Korpal et al. 2011). Metastatic free survival was significantly associated with higher levels 
of mir-200 family members, meaning lower Zeb1/Zeb2 correlated with less metastasis; 
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intriguingly, however, E-cadherin was not prognostic for survival – low or high E-cadherin did not 
differentiate between those with or without relapse. This shows 3 crucial things: (1) not only is 
Zeb1/Zeb2-driven EMT dispensable, but (2) suppression of EMT promotes metastasis through (3) 
E-cadherin independent mechanisms.  
The authors were able to recapitulate the finding above that mir-200 ectopic 
overexpression enhances metastasis in a mammary fat pad injection model. They additionally 
showed that E-cadherin ectopic expression alone enhances metastasis but not as effectively as 
mir-200 demonstrating that restoration of E-cadherin is only part of the MET program and that 
suppressing EMT-TFs promotes metastasis through other mechanisms as well, including 
modulation of secreted factors. 
The dispensability of Zeb1 here stands in contrast to the requirement for Zeb1 discussed 
above (Krebs et al. 2017) in pancreatic cancer, though there are two obvious differences: the 
pancreatic cancer model above was a direct genetic knockout while this breast cancer data point 
here depends on mir-200 inhibition of Zeb1 in a transplantation model. It does however serve as 
a reminder that not only could different EMT-TFs be variably important, but that different cancers 
might have different hierarchies of EMT-TF importance. 
However, there is one important points of overlap that creates a sense of coherence 
between these studies: much like the Snail/Twist1 knockout model in the pancreas, this breast 
cancer model demonstrates that chemoresistance is a feature associated with EMT. In this case, 
treatment with cyclophosphamide showed that it was only the RFP-positive cells (i.e., the ones 
who at no point underwent EMT) that showed higher apoptotic profiles, whereas GFP-
positive/EMT cells were unaffected.  
Remarkably, chemotherapy also changed the EMT profiles of the metastatic lesions. 
Whereas control mice exhibited entirely RFP-positive/non-EMT lung metastasis, chemotherapy-
treated mice showed significant GFP-positive/EMT lung metastasis, suggesting that EMT is 
turned on under certain conditions.  
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The work presented in this dissertation does not directly interrogate EMT-TFs; however, 
this does not lessen the necessity of keeping the above summarized data for two reasons: 
1) EMT dispensability, by definition, implies that motile cells with partial epithelial 
characteristics can complete all the steps of the metastatic cascade. As will become 
clear, this observation is of paramount importance to this dissertation. 
2) If EMT is dispensable but still occurs, it suggests the EMT may have occurred not for 
the precise purpose of dissemination but other reasons. As demonstrated by the 
work on chemotherapy, there may be certain environmental stressors (exogenous 
such as treatment or endogenous such as metabolic requirements) that drive EMT. 
This requires us to keep in mind that while EMT may be correlated with metastasis, it 
is not synonymous with metastasis. 
The literature on the dispensability of EMT is new and, in some cases, quite 
controversial. I have summarized some of the most important papers of the past 5 years in Table 
1-2. 
 
Cancer Transcription 
Factor 
 Experimental Set-up Observation Reference 
Breast and 
Lung 
Prrx1, Twist1  Short hairpin 
knockdown of Prrx1 and 
Twist1 in BT-549 breast 
cancer cells injected 
into the tail vein 
Prrx1 loss alone 
dramatically 
accelerates lung 
metastasis with or 
without Twist1 loss 
However, Twist1 
loss alone does not 
accelerate 
dissemination 
(Ocaña et al. 
2012) 
Skin Twist1  Carcinogen-induced 
model of skin cancer 
with doxycycline-
controlled Twist1 
expression 
Withdrawal of 
doxycycline, which 
turns off Twist1 
(i.e., EMT), 
promotes lung 
metastasis 
(Tsai et al. 
2012) 
Pancreas Snail, Twist1  Knockout of Snail or 
Twist1 in a KPC 
Loss of either Snail 
or Twist1 does not 
alter tumor growth, 
(Zheng et al. 
2015) 
22 
 
background dissemination, or 
survival 
Breast General 
lineage 
labeling model 
that tracks 
EMT by Fsp1 
expression 
 
 
miR-200 
downregulation 
of Zeb1/Zeb2 
 
 
 Lineage tracing of 
breast cancer cells in a 
triple transgenic mouse 
that generates lung 
metastasis 
 
 
Orthotopic 
Transplantation 
Spontaneous lung 
metastases do not 
undergo EMT at 
any point in their 
dissemination 
 
 
miR-200 
overexpression, 
which inhibits EMT 
by downregulation 
of Zeb1 and Zeb2, 
in mammary fat 
pad-injected cells 
does not inhibit 
metastasis 
(Fischer et 
al. 2015) 
Pancreas Zeb1  Knockout of Zeb1 in 
KPC Background 
Zeb1 loss does 
inhibit tumor 
generation and 
invasion 
(Krebs et al. 
2017) 
Perspective 
Article 
-  - - (Brabletz 
2012) 
 
Table 1-2: Evidence for Dispensability of EMT 
KPC – Pdx1-cre; KRASG12D; p53R172H 
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Primary Tumor Growth, Metastasis, and 
Organotropism 
Conceptual Framework 
Is a metastatic cell a cancer cell that has just, stochastically, left the primary tumor? Or, 
rather, are metastatic cells in fact primary tumor cells that have acquired a metastatic profile that 
differentiates them from the primary tumor? The distinction is crucial, as the former suggests the 
search for a “metastasis program” is not necessarily worthwhile, while the latter suggests that the 
study of primary tumor genetics is insufficient to understand the cancer cells both at the primary 
site and at the secondary sites. The conceptual framework for this section is outline in Figured 1-
2. 
  
Figure 1-2: Conceptual Decision Tree. These are the three questions that I will cover in this 
section and the possible outcomes at each stage. 
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Is primary tumor growth distinct from metastasis? 
In 2002, Rene Bernards and Robert Weinberg co-authored an editorial arguing against a 
model of tumor evolution in which genetic alternations promoting primary tumor growth are 
acquired early and metastatic gene alternations are acquired later (Bernards and Weinberg 
2002a). Instead, they suggest that the early genetic lesions acquired in cancers are sufficient for 
both primary tumor growth and metastasis and that the search for a unique metastatic gene 
signature that differentiates the rare and special metastatic cells in a primary tumor was not a 
necessarily fruitful endeavor. 
 This view is experimentally supported, and, as discussed in section 1, the evidence for 
early dissemination provides a set of data arguing against the sequential, stepwise progression 
model. Beyond the study of early dissemination, however, are other data that argue in this 
direction, and, in particular, paired sequencing of primary tumors and metastases demonstrate 
high levels of genomic similarity. For example, in a study comparing multiple metastatic 
carcinomas to their primary tumors, the metastatic gene signature was found in a portion of the 
primary tumors (Ramaswamy et al. 2002). This, the authors argued, suggests that the metastatic 
potential is not encoded in a small, rare fraction of cells but is a property of the tumor as a whole. 
One of the possible reasons for this is that the same oncogenes that promote the initial steps of 
the metastatic cascade are crucial in the later steps. Oncogenic RAS, discussed in detail in 
section 4, appears to be crucial not just at the primary site but in promoting proliferation at the 
secondary site (Sahai 2007; Varghese et al. 2002). The role of tumor-initiating oncogenes in 
metastatic outgrowth conceptually supports the argument put forth by Bernards and Weinberg. 
Multiple studies conducted in the context of breast cancer demonstrate similar results as 
to Ramaswamy et al. (2002). A poor prognosis signature (i.e., metastasis) in breast cancer 
patients can be determined from the primary tumor profile alone, suggesting that the metastatic 
signature is encoded in the primary tumor generally (van’t Veer et al. 2002). Importantly, this 
signature was derived from metastasis-free patients with small primary tumors, demonstrating 
that, even at that early stage, the metastasis gene program is present. This same group, 
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validating their signature, reported in a 295-patient cohort that their poor-prognosis signature was 
an accurate way of stratifying lymph node-positive versus -negative patients (van de Vijver et al. 
2002), and they argue that their “data indicate that the ability to metastasize to distant sites is an 
early and inherent genetic property of breast cancer. Our findings argue against the widely 
accepted idea that metastatic potential is acquired relatively late during multistep tumorigenesis.” 
Wang et al. (2005) were able to develop another gene panel to predict metastasis from lymph-
node negative breast cancer patients, and despite differences in the microarray platform used, 
they showed overlap with some of the genes described in the poor prognosis signature from van 
de Vijver et al. (2002).  Weigelt et al. (2003), after profiling primary breast cancer with paired 
metastasis from ovary, lung, lymph node, and arm, reached the conclusion that “gene expression 
profiles of primary breast tumors are maintained in their distant metastases” and that there was 
no “metastasis-specific gene set.”  
Similar results, however, have been found from more recent work. Lee et al. (2015) 
demonstrate that while there are differences in frequency of mutations, primary breast cancer 
shows mutations in the same genes as paired brain metastasis. In non-small cell lung cancer 
(NSCLC), “genomic profiles of primary tumor reflect the genomic spectrum of the patient's 
metastatic disease” (Vignot et al. 2013). Paired primary hepatocellular carcinoma and lung 
metastasis reveal similar genomic profiles (Ouyang et al. 2014), and paired melanoma with 
metastasis demonstrated remarkable similarity in “gene copy number alterations, loss of 
heterozygosity and single nucleotide variation” (Turajlic et al. 2012).  
There have been several recent efforts that have sequenced paired primary PDAC and 
metastasis. Yachida et al. (2010) sequenced metastases from 7 patients in order to understand 
clonal relationships. They find that the primary tumor is defined by a parental clone that already 
contains most mutation the cancer will acquire, termed “founder” mutations, and subclones that 
incrementally add additional mutations, termed “progressor” mutations. On average, 64% of all 
mutations in any given subclone came from the initial parental clone, and these founder 
mutations happen to be more serious genetically – “nonsense, splice site, or frameshift 
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mutations” – than the types seen in the progressor mutations. Most importantly for us, they 
demonstrate that while metastases exhibit the founder mutations and their own distinct patterns 
of progressor mutations, very large sections of the primary tumor harbor similar patterns. They 
thus say that “the genetic heterogeneity of metastases reflect heterogeneity already existing 
within the primary carcinoma” and that “no consistent genetic signature of metastatic subclones 
could be identified.” From this, we can begin to see why sequencing primary tumor and 
metastasis does not easily yield a “metastatic signature,” and it supports the conclusion from 
Ramaswamy et al. (2002) that metastatic properties belong to the tumor as a whole – or, at the 
very least, to a very large subpopulation of the tumor.  
Notta et al. (2016) contribute additional data confirming this observation. By sequencing 
15 metastatic lesions from 6 patients and focusing on copy number and chromosomal 
rearrangements, they noted that the majority of genomic instability occurs in the primary tumor 
and is a property of the primary tumor, which “support[s] the notion that the majority of genetic 
instability precedes metastases.”  Their phylogenetic classification of metastases additionally 
shows some, but not striking, differences between different metastases, and very few metastases 
harbor truly unique genetic changes.  
Campbell et al. (2010), however, emphasize differences between metastases and the 
primary tumor and not their similarity. In their study of paired primary tumor and metastases for 
ten patients, they suggest that while a core set of initial mutations seem to be ubiquitously 
present in all metastases, there is continuing clonal evolution. They surmise that the differences 
between primary tumors and metastases suggest that “one or more driver mutations…have 
conferred selective advantage for metastatic spread.” To support their hypothesis of metastasis-
driving genes, they reference work in breast cancer, which demonstrates that breast cancer 
metastases are highly-enriched for mutations present at only low prevalence in the primary tumor 
(Ding et al. 2010). 
The answer to the first question – is primary tumor growth distinct from metastasis – is 
therefore equivocal: while differences can be found between primary tumors and metastases 
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using sequencing, these differences are neither consistent nor is the functional effect of these 
differences proven. This should lead us to ask whether we can find metastasis-regulating genes 
through efforts other than paired primary tumor and metastasis sequencing.  
Do metastases exhibit organotropic profiles? 
A remarkably successful method for discovering mediators of metastasis has been 
through selection for ultra-fit metastatic clones. In the following sections, I will review breast 
cancer metastatic organotropism across lung, brain, and bone followed by a summary across 
other cancers.  
Breast Tropism to Lung 
If one accepts that the metastasis-promoting program is an invalid idea, then one would 
expect that single cells from breast cancer, confirmed to have similar poor prognosis signatures, 
would behave similarly in metastatic assays. This, it turns out, is not the case.  Breast cancer 
cells show very different metastatic ability in mice even if they harbor that “poor prognosis 
signature” (Minn, Kang, et al. 2005). In fact, not only was their overall metastatic ability different, 
but they exhibited distinct single or multiple organotropic patterns.  
Using serial transplantation of human breast cancer cell lines which were then subject to 
genomic analysis (Minn, Gupta, et al. 2005), two subsets of genes were discovered: one which 
endowed advantages in both the primary tumor and in the lung and another set which seems to 
uniquely promote growth in the lung. Notably, the second set is only sporadically found within 
primary tumors, arguing against Bernards and Weinberg (2002) and instead suggesting their 
acquisition is a late-stage genetic evolution that rapidly leads to exit from the primary site – in 
other words, a metastatic signature that is also organotropic in nature.  
Interestingly, the uniquely lung metastatic gene signature involved numerous genes that 
encode for extracellular proteins, suggesting that one of the key factors mediating a successful 
metastatic cascade is the ability to interact with the target tissue and perhaps shape it. Along 
these same lines, metadherin (metastasis adhesion protein), was discovered from cDNA libraries 
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of breast cancer cells as a mediator of adhesion to lung vasculature (Brown and Ruoslahti 2004). 
More broadly, again in breast cancer, a panel of 4 genes mediating a “vascular remodeling 
programme” were found to be important in allowing both intravasation at the primary site as well 
as extravasation into the lung (Gupta et al. 2007). In addition to interacting with the vasculature, 
micrometastatic lesions in the lung secrete Tenascin C, which fosters lung metastatic outgrowth 
but is dispensable for primary tumor growth (Oskarsson et al. 2011). 
Breast Tropism to Brain 
Interestingly, breast cancer organotropism to the brain was also shown to mediated by 
endothelial adhesion through the expression of ST6GALNAC5 (Bos et al. 2009), and serial 
transplantation of MDA-231 breast cancer cells into the carotid artery in order to select for brain-
tropic clones revealed enrichment for vascular endothelial growth factor (L. S. Kim et al. 2004). 
Tumor-associated macrophages in breast metastasis to the brain, as well as the brain-tropic 
tumor cells themselves, express high levels of cathepsin S, which Sevenich et al. (2014) showed 
promotes traversal of the blood-brain barrier through cleavage of adhesion molecules. 
As pointed out by Smith and Kang (2017) in a very useful review, a theme in breast 
cancer metastasis to the brain appears to be the role of astrocytes in shaping cancer cell 
colonization. Valiente et al. (2014) demonstrated that astrocytes inhibit breast cancer metastasis 
to the brain through plasmin, which prevents cancer cell endothelial adhesion. Successful breast 
cancer metastasis to the brain, additionally, was dependent on cancer cell expression of the anti-
plasmin class of molecules such as serpins. Zhang et al. (2015), meanwhile, show a pro-
metastatic role for astrocytes through suppression of tumor cell PTEN expression. Remarkably, 
cancer cells disseminated to other organs do not lose PTEN expression, and brain metastatic 
cancer cells restore PTEN expression when taken out of the brain. The role of astrocytes, 
therefore, is an example of why different cancers may have similar mechanisms in colonizing the 
same organ: namely, because they have to interact with the same resident cells.  
The work in breast tropism to the brain reinforces the themes of metastasis-specific 
genes, organotropic patterns, and, the crucial and perhaps rate-limiting role of the target organ 
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vasculature as a barrier to metastasis. The discovery of lung- and brain-organotropic genes that 
function through organ-specific endothelial adhesion opens up the tantalizing prospect that a 
master regulator of organotropism is the endothelial-adhesion step. As we will demonstrate in this 
dissertation, it is possible that the lung organotropic patterns we describe in pancreatic cancer 
also depend on vascular interactions.  
Breast Tropism to Bone 
Using a serial transplantation approach to enrich for highly-metastatic genes, Kang et al. 
(2003) found a metastatic signature that enhanced bone metastasis but not adrenal medulla 
metastasis. This bone-specific metastatic signature was enriched for genes that encode 
membrane proteins and secreted proteins, a theme consistent with the aforementioned gene 
signature found in breast cancer lung organotropism (Minn, Gupta, et al. 2005; Oskarsson et al. 
2011). Additionally, Casimiro et al. (2012) validated expression of six of the bone tropic genes 
from Kang et al. (2003) in human bone metastases – and, interestingly, bone metastases from 
cancers other than breast showed similar patterns, suggesting that the organ destination 
determines the properties required for colonization. Further evidence for genetic determinants of 
metastatic organotropism in breast cancer comes from using bone- or lung-tropic lines, where it 
was shown that cell fusion – and, presumably, the genetic and phenotypic diversity arising from it 
– endowed cells with increased ability to metastasize to more than one organ (Lu and Kang 
2009).  
 It is additionally possible to genetically differentiate metastatic cancer cells to bone from 
those to lung or brain. Tavazoie et al. (2008) also report that they could correctly classify MDA 
231 breast cancer cells as lung or bone tropic on the basis of microRNA expression, and, 
similarly, Klein et al. (2009) demonstrated that they could classify breast cancer metastasis as 
either from bone or brain on the basic of a 73-gene panel. 
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Metastatic Organotropism in Other Contexts 
I have used breast cancer as my model to discuss metastatic organotropism because of 
the rich literature in that context (Lu and Kang 2007) and will not go through other cancers in 
depth. Here, I will only reference a select number of papers that are of value for either reinforcing 
key concepts or explaining new ones.  
1) Urosevic et al. (2014) demonstrate that colon cancer metastases to the liver and lung 
have differing requirements for mitogen-associated protein kinase signaling. 
Specifically, hepatic metastases are promoted by ERK2, whereas hepatic metastasis 
secondary seeding of the lung is dependent upon shutting down of MAPK. This 
signaling is relevant because it mediates endothelial cell interactions, as the shutting 
of ERK2 promotes tumor-cell mediated release of factors that induce death in lung 
vasculature, a process that facilitates extravasation. Using grafted leukemia cells, 
Sipkins et al. (2005) show that bone marrow vasculature E-selectin is used for bone 
marrow homing. The idea of vascular interactions as key mediators of organotropism, 
therefore, appears in contexts other than breast.  
2) Campbell et al. (2010) observed in their phylogenetic trees of pancreatic cancer 
metastases that metastases within organs segregated together. They provide 
possible explanations for this phenomenon, one of which is that specific genetic 
mutations may be required for effective colonization of certain organs. This, then, 
reinforces the concept of metastatic organotropism in pancreatic cancer. 
3) Successful colonization of the liver is enhanced by secretion of creatinine kinases 
that convert creatinine to phosphocreatinine, which is then absorbed and used by the 
tumor cells for survival (Loo et al. 2015). Human pancreatic cancer cells knockdown 
of creatine kinases show lowered hepatic colonization. This introduces the concept 
that metabolic requirements in specific organs dictate requirements of colonization.  
4) While beyond the experimental scope of this dissertation, exosome-mediated 
shaping of the metastatic niche has proven to be another mechanism by which 
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organotropism is mediated. This introduces the concept that not only does the target 
organ impose demands on the colonizing tumor cells, but that the tumor cells 
themselves can shape target organs through tropic-factors. 
a. For example, injection of fluorescently-tagged exosomes from melanoma cell 
lines into mice resulted in rapid localization to target organs, which, in the 
lung, promoted vascular permeability more than exosomes from non-
metastatic cell line (Peinado et al. 2012). Additionally, pretreatment of mice 
with exosomes from different cell lines followed by subcutaneous injection of 
melanoma cells resulted in differential metastatic patterns, strongly 
suggesting different exosomes prime different organs for metastasis.  
b. Fortunately, for our purposes, the role of exosomes in pancreatic cancer 
metastasis has been investigated. Liver Kupffer cells preferentially absorb 
exosomes from PDAC, which, in turn, results in TGF-β-dependent stellate 
cell fibronectin production (Costa-Silva et al. 2015). Macrophages then 
preferentially bind to fibronectin, creating an inflammatory environment. The 
authors additionally showed, through macrophage depletion, that the 
increased liver metastasis mediated by these exosomes is dependent on 
their ability to promote macrophage recruitment. Exosomes, therefore, can 
have preferential binding to organ-specific cell types, which in turn can create 
a pro-metastatic environment in that organ.  
c. Exosome organotropism seems to be regulated by distinct integrin 
expression. Exosomes with integrins α6β4 and α6β1 drive lung tropism for both 
the exosome and cancer, while integrin αVβ5 drives liver tropism. (Hoshino et 
al. 2015). Interestingly, pancreatic cancer patients with recurrent liver 
metastasis after resection had significantly elevated amounts of integrin αV 
per µg of circulating exosomes. Cancer cell organotropism is therefore 
mediated, at least in part, by the organotropism of the exosomes they 
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release. This exosome organotropism, in turn, is controlled by integrin 
expression patterns.  
 
To summarize the answer to the second question in Figure 3-1, metastatic organotropism 
appears to be a real phenomenon even outside of the most well-studied context of breast cancer, 
and may be mediated by common mechanisms related to vasculature modeling; metabolic 
requirements; and shaping of the metastatic niche by organotropic exosomes (Kall 2013; Nguyen, 
Bos, and Massagué 2009; Peinado et al. 2017; Smith and Kang 2017).  
Is organotropism defined by similar signatures across cancers? 
 Colonized organs appear to impose certain demand on colonizing tumor cells through 
multiple mechanisms. Colonizing tumor cells, regardless of origin, therefore have to converge on 
similar adaptations. As Kall and Koblinski (2013) point out, bone metastases have similar profiles 
whether they come from lung cancer or breast cancer, and breast cancer brain-tropism genes 
overlap with lung and melanoma brain-tropism genes. The conclusion to this third questions, 
therefore, appears to be that organotropic signatures are in fact similar across cancers. 
 Final Assessment 
To conclude, we can make the following summary observations: 
1) Primary tumor growth can be thought of as a distinct program from metastasis, but this 
distinction is not easily detectable through sequencing of primary tumors and paired 
metastases. Additionally, even if there is a distinct metastatic program, large portions of 
the primary tumor may harbor it.  
2) Metastasis is “superimposed” (Kang et al. 2003) on the primary tumor growth program 
but is not necessarily part of it. 
3) We can speculate that metastasis has general, non-organotropic programs that drive 
general motility/survival phenotypes and then specific organotropic adaptations that drive 
the unique organotropic patterns of different cancers. 
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4) The organotropic metastatic program is likely enriched for genes that drive interaction 
with and shaping of the metastatic environment and, in particular, the endothelial-
adhesion step may be of particular importance for endowing organotropic phenotypes. 
5) Different cancers, when metastasizing to the same site, may use similar mechanisms, 
suggesting that the metastasis program depends more on the organ being colonized and 
less on the tumor origin. These common mechanisms may be mediated by vascular-
tumor cell interactions; resident-cell interactions; organ-specific metabolic requirements; 
and exosome-mediated organotropism that leads to shaping of the metastatic niche. 
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Pancreatic Cancer 
Normal Pancreas Biology 
 The pancreas is a part-exocrine, part-endocrine organ that develops from foregut 
endoderm starting at mouse embryonic day 8.5 (Gittes 2009; Reichert and Rustgi 2011). Both the 
ventral and dorsal buds merge on E13 followed by lineage differentiation into acinar, ductal, and 
multiple endocrine subtypes. While the acinar compartment is responsible for enzymatic 
secretion, the ductal compartment releases bicarbonate and traffics the secreted enzymes to the 
duodenum. The endocrine compartment contains five cell subtypes – α, β, δ, e, and polypeptide - 
responsible for glucose homeostasis and regulation of digestion. An intermediate type of cell, the 
centroacinar cells, exists at the meeting point of acinar cells and duct cells and is thought to have 
an important role as progenitor cells for other pancreatic lineages (Cleveland et al. 2012). 
 The transcriptional networks that define pancreatic differentiation are well-characterized. 
For our purposes, these lineage-transcription factor relationships provide us with the invaluable 
ability to target Cre recombinase and transgenes to specific cell compartments. These mouse 
models will be discussed in the last part of this section. Here, however, are the key transcription 
factors in pancreatic development, their lineage specification, and their temporal regulation. 
Transcription 
Factor 
Lineage 
Specification 
Day Turned On Notes 
Pdx1 Present in the 
initial multipotent 
pancreatic 
progenitor but 
restricted to 
endocrine 
compartment in 
adults. 
E8.5 (Guz et al. 
1995) 
Absolutely required for normal 
pancreas formation and is thought to 
be a master regulator of initial 
pancreas specification. 
 
Homozygous deletion in mice results 
in pancreatic agenesis (Jonsson et al. 
1994). 
 
Humans with pancreatic agenesis 
have been reported to have a frame-
shift mutation in Pdx1 (Stoffers et al. 
1997). 
 
All pancreatic tissue in a Pdx1-
lineage labeled mouse is derived 
exclusively from the Pdx1-positive 
progenitor population (Gu, 
Dubauskaite, and Melton 2002).  
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Sox9 Like Pdx1, Sox9 
is thought to 
label the initial 
multipotent 
progenitor pool. 
In the adult, it is 
restricted to duct 
cells and can be 
used for duct-
specific 
recombination. 
E9 (Seymour et al. 
2007) 
Sox9 appears to co-label the same 
initial pancreatic progenitor 
population Pdx1 does and co-
localizes up to day E12.5. Sox9 
deletion in mice results in small 
pancreata due to “depletion of the 
progenitor cell pool” (Seymour et al. 
2007). 
 
Sox9-positive cells in the adult mouse 
are limited to the ductal tree and may 
serve as a progenitor pool for acinar 
tissue (Furuyama et al. 2011); others, 
however, have shown that acinar 
cells themselves are responsible for 
acinar compartment replenishment 
(Desai et al. 2007).  
Ptf1α (p48) Ptf1α labels the 
acinar 
compartment in 
the adult, 
though it 
appears to have 
broader 
embryological 
importance to 
the other 
lineages. 
Masui et al. (2008) 
report a model of 
Ptf1α where low 
levels are 
maintained from the 
early pancreatic bud 
to E13, when the 
start of acinar fate 
differentiation 
requires significantly 
increased levels.  
Homozygous Ptf1α deletion leads to 
absent exocrine pancreas but 
retained endocrine cells (Krapp et al. 
1998).  
 
While Ptf1α labels the adult acinar 
compartment, its appearance before 
acinar fate differentiation suggests it 
has roles in general pancreatic 
organogenesis. Most cells across all 
lineages in newborn pups exhibit 
Ptf1α promoter activity (Kawaguchi et 
al. 2002).  
Hnf1β Hnf1β appears 
to be required 
for normal 
development of 
all lineages but 
is restricted to 
duct cells in the 
adult. 
Expressed in the 
initial pancreatic 
progenitors, but 
retained only in duct 
cell precursors and 
duct cells from 
E14.5 (summarized 
in introduction of De 
Vas et al. (2015)). 
Hnf1β homozygous loss results in 
pancreatic agenesis (Haumaitre et al. 
2005). 
 
Hnf1β labels a pool of early 
pancreatic progenitors and controls 
endocrine-specific transcription. Loss 
of Hnf1β prevents appearance of 
NGN3+ endocrine precursors and 
results in an abnormal acinar and 
ductal compartment (De Vas et al. 
2015).    
Ngn3 Ngn3 specifies 
the multipotent 
progenitor of all 
endocrine cells 
but is negative 
in all exocrine 
precursors. 
E9.5 (Gradwohl et 
al. 2000) 
NGN3 is necessary for specification 
of all endocrine compartment cells. 
 
NGN3 knockout results in normal 
exocrine pancreas but absent Islets, 
and duct cell progenitors are not 
NGN3+, thereby suggesting that 
NGN3+ is a decision point between 
exocrine and endocrine pancreas 
(Gradwohl et al. 2000).  
Table 1-3: Transcriptional Regulation of Pancreatic Development 
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Genetics of Pancreatic Cancer 
 Pancreatic cancer is the 3th leading cause of cancer mortality (American Cancer Society 
2017) and is projected to rise to the 2nd leading cause by 2020 (Rahib et al. 2014) despite the 
significantly lower incidence relative to, for example, breast, colon, and lung. The lower incidence 
and higher mortality indicates the dire clinical prognoses for most patients, which is dependent on 
stage of disease at diagnosis. The overall 5-year survival rate is 8%, rising to 29% for patients 
diagnosed with local disease and dropping to 3% for patients diagnosed with distant metastases 
(American Cancer Society 2017). Even the mild increase is survival for patients with local disease 
is poor consolation, as only 9% of patients are diagnosed at that stage whereas 52% are 
diagnosed with distant dissemination. 
 Our current understanding of pancreatic cancer is based on a dual genetics-morphology 
progression model that links the slow accumulation of genetic lesions to associated 
morphological changes (Hruban, Wilentz, and Kern 2000; Kern et al. 2001; Yachida et al. 2010), 
These preneoplastic lesions, termed pancreatic intraepithelial neoplasia (PanIN), are defined by a 
switch from cuboidal to columnar epithelium; the acquisition of a mucinous component; nuclear 
atypia; papillary protrusions; and epithelial depolarization (Hingorani et al. 2003; Hruban et al. 
2004). Each stage – PanIN1A, PanIN1B, PanIN2, and PanIN3 – is defined by the presence or 
exclusion of these characteristics. 
1) PanIA1A: The earliest stage, PanIN1As are defined by a mucinous columnar 
epithelial differentiating it from normal cuboidal acinar tissue. Nuclear atypia, papillary 
protrusions, and epithelial depolarization are absent.  
2) PanIN1B: PanIN1Bs are defined by the acquisition of papillary protrusions.  
3) PanIN2: PanIN2s demonstrate the first signs of nuclear atypia and epithelial 
depolarization, though they remain mild. 
4) PanIN3: PanIN3s demonstrate all the previous hallmarks with the addition of 
significant nuclear atypia and loss of epithelial polarity. 
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This histological progression is associated with an underlying genetic progression model. 
The first report of a major genetic mutation in pancreatic cancer was in 1988, when PCR of 
autopsy tissue revealed the presence of activating mutations in codon 12 of the proto-oncogene 
KRAS in 21 out of 22 patients as well as paired metastatic tissue in 7 cases (Almoguera et al. 
1988). Since that initial finding, the genetic landscape of pancreatic cancer has been richly 
described through studies that report individual new mutations or, more recently, from next-
generation sequencing studies (Dreyer et al. 2017; Hezel et al. 2006; J. P. Morris, Wang, and 
Hebrok 2010).  
In addition to KRAS, which has been reproducibly shown to be mutated in over 90% of all 
pancreatic cancers in multiple studies (Bailey et al. 2016; Biankin et al. 2012; Jones et al. 2008; 
Waddell et al. 2015; Witkiewicz et al. 2015), other common sites of mutations include p53 
(Redston et al. 1994; Ruggeri et al. 1992; Scarpa et al. 1993), SMAD4 (Hahn et al. 1996), and 
p16 (Caldas et al. 1994). As pointed out by Dreyer et al. (2017), genomic studies routinely reveal 
similar patterns: ubiquitous KRAS mutations; prevalent p53, p16, and SMAD4 mutations; and 
then low levels of other mutations. To take one example, whole genome sequencing by Waddell 
et al. (2015) revealed a nearly 100% mutation rate for KRAS, 74% for p53, 35% p16, and 31% 
SMAD4.  
The genetic data available has been used to make sense of possible PDAC classification 
systems. For example, Bailey et al. (2016) organized the genetic heterogeneity of PDAC by 
sequencing 456 patients and classifying 32 commonly mutated genes into 10 signaling pathways 
as well as by defining 4 PDAC subtypes. Collisson et al. (2011), meanwhile, defined 3 subtypes 
and demonstrated the clinical relevance for them, and Campbell et al. (2010), crucially for us, 
interrogated pancreatic cancer metastases and demonstrated organotropic signatures.   
Importantly for our purposes, KRAS mutations appear at the very earliest stage of PanIN 
development. Kanda et al. (2012) microdissected 169 PanIN1A-3 lesions from 89 patients and 
revealed codon 12 mutations in 92% of PanIN1As, the lowest grade. In total, across all PanIN 
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stages, 163/169 harbored KRAS mutations. Oncogenic KRAS, therefore, is the sine qua non of 
not only pancreatic cancer but also preneoplastic lesions. 
KRAS Signaling in Pancreatic Cancer 
 KRAS is a 21 kDA GTPase whose signaling is activated by GTP binding and inactivated 
by GDP binding (Eser et al. 2014). The switch between these two states is promoted by, 
respectively, guanine nucleotide exchange factors (GEFs) and GTPase-activting proteins (GAPs). 
Oncogenic mutations in KRAS, such as the common single residue change at codon 12, 
negatively regulate KRAS hydrolysis of GTP to GDP and thereby keep KRAS in the “on,” GTP-
bound position. 
  As Eser et al. (2014) point out, oncogenic KRAS in PDAC functions through three main 
downstream pathways: mitogen-associated protein kinase (MAPK) pathway, phosphoinositide 3-
kinase (PI3K), and the GEF Ral. 
1) Collisson et al. (2012) demonstrate that constitutive activation of BRAF, a 
downstream signaling element in the RAK-MAPK pathway, is sufficient alone induce 
widespread PanIN formation. The addition of a p53R172H mutation leads to 
widespread metastatic PDAC. Pharmacologic MEK inhibition, meanwhile, blunts 
tumorigenesis in an orthotopic transplantation model. Since oncogenic KRAS feeds 
into non-MAPK pathways, this demonstrates the importance of MAPK signaling 
specifically. 
2) Eser et al. (2013) illustrated the importance of PI3K signaling by targeting a 
constitutively-active PI3K to the pancreas, which gives rise to PanIN lesions. 
Additionally, pharmacologic PI3K inhibition reduces tumor burden in genetic PDAC 
models. 
3) The GEF RalA, downstream of KRAS, is activated in human pancreatic cancer cell 
lines (Lim et al. 2005), and knockdown of RalA in subcutaneously transplanted 
human cancer cell lines inhibits tumorigenesis (Lim et al. 2006). RalB, while 
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apparently dispensable for primary tumor formation, is critical for metastasis as 
assayed by tail vein injection (Lim et al. 2006). 
In addition to the above three pathways downstream of RAS, EGFR signaling upstream 
of RAS is likely a crucial potentiator. As Siveke and Crawford (2012) say, this appears 
counterintuitive – if RAS is constitutively active already, why would upstream signaling be 
needed? The answer may be that oncogenic KRAS alone does not push its downstream 
signaling activity to the levels needed to drive tumorigenesis. This is supported by evidence 
demonstrating that temporary RAS activation through exogenous insults, such as inflammation, 
does not induce pathology (Daniluk et al. 2012) and that mutant RAS-mediated PanIN formation 
is abrogated by EGFR knockout (Navas et al. 2012).  
Whatever the relative importance of upstream input into KRAS or downstream output 
from KRAS, the KRAS signaling node is not only crucial for initiation of pancreatic cancer but is 
necessary for maintenance. Using an inducible mutant KRAS that can be toggled on and off, two 
separate groups have in fact shown that KRAS-driven tumorigenesis is addicted to mutant RAS 
(Collins et al. 2012; Kapoor et al. 2014).  
Genetic Models of Pancreatic Cancer 
 With our understanding of the transcription factors that drive pancreas development; 
some of the core KRAS signaling pathways and their fundamental role in PDAC initiation and 
maintenance; and the genetics of PDAC, we can now begin to trace the development of genetic 
mouse models (GEMMs) of pancreatic cancer. The most important step in this process was 
generation of the KRASG12D mutant, which introduces a constitutively-activating glycine to 
aspartic acid residue at codon 12 of exon 1. This happens to be the single most mutated codon in 
human pancreatic cancer (Westphalen and Olive 2012), and it was first functionally proven to 
drive adenocarcinoma in the lung (Jackson et al. 2001; Johnson et al. 2001). 
 The development of this allele occurred in parallel to the codification of a dual genetics-
morphology progression model in which the progression from less to more dysplastic PanINs is 
associated with particular genetic lesions (Hruban et al. 2000; Kern et al. 2001). As KRAS 
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mutations are the most common genetic lesion in PDAC and routinely found at the PanIN stage, 
KRASG12D introduction into mice under the control of the pan-pancreas Pdx1 driver allowed proof-
of-principle that oncogenic KRAS along could induce PanIN formation up to and including the 
most advanced stage, PanIN3 (Hingorani et al. 2003). These mouse lesions recapitulated the 
hallmarks of human PanINs. In rare instances, these mice even exhibited metastatic PDAC.  
 Because this mouse model is so key to this dissertation and almost all other pancreatic 
cancer research, it is worth delineating certain contributions it made as well as advantages and 
disadvantages to its use. First, it functionally proved the correlation between KRAS mutations and 
PanIN/PDAC development. Second, it was the first functional evidence that PanIN lesions both 
progress in the hypothesized PanIN sequence and are the precursor lesions for PDAC. Third, 
even though its low penetrance levels for metastatic PDAC may appear as a complete drawback, 
this is actually a benefit as the slow temporal progression makes it easy to determine if added 
mutations cause more rapid progression. Fourth, because of this slow progression, KRASG12D has 
become the standard mutation on which virtually all other accelerated PDAC GEMMs are built. 
 There are, however, drawbacks. First, while the slow progression is an advantage if one 
wants to test whether certain additions accelerate PDAC, it is a disadvantage if one wants to 
decelerate PDAC, study PDAC itself, or perform mouse clinical trials. Second, the Pdx1 promoter 
is a pan-lineage driver that affects the ducts, acinar cells, and endocrine compartment. This 
prevents asking cell-of-origin questions. 
 All future PDAC models, in some way or another, modify one of these disadvantages or 
leverage one of the advantages to make an advance in our understanding of PDAC. While I have 
listed many of the most important GEMMS in Table 1-4, here I will outline five of what I believe 
are the most biologically-revealing and useful PDAC GEMMs that build on the Pdx1-cre; 
KRASG12D mouse (KC). 
First, the Pdx1-cre; KRASG12D; p53R172H mouse (KPR172HC) leverages the slow 
progression of the KC mouse by adding a gain-of-function p53 mutation (Hingorani et al. 2005). 
Importantly, this is relevant to human disease, as p53 mutations are the second most common 
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genetic lesion in PDAC after KRAS mutations. The hallmarks of this mouse include a metastatic 
profile consistent with human disease, with the liver being the most common site of 
dissemination; a desmoplastic reaction that is reminiscent of human PDAC fibrosis; poor 
vascularization; immune infiltrates; rapid progress to morbidity; and chromosomal abnormality 
consistent with human PDAC. Its fidelity to human disease makes this mouse a powerful model 
for preclinical trials, and many successful studies have already been done. 
 For example, the marked desmoplastic reaction has been used to study whether this 
fibrotic capsule prevents effective chemotherapy delivery to the tumor (Aiello et al. 2016; Olive et 
al. 2009; Provenzano et al. 2012), and inhibitors of this stromal reaction were effective in 
promoting gemcitabine delivery either through enzymatic degradation of hyaluronic acid 
(Provenzano et al. 2012) or Hedgehog signaling inhibition (Provenzano et al. 2012). Similarly, the 
model has proven amenable to immunotherapy studies, with macrophage activating CD40 
agonists proving effective (Beatty et al. 2011). The KPR172HC mouse, therefore, has proven to be 
a valuable tool for both modeling PDAC progression and for studying therapy. 
Second, the Pdx1-cre; KRASG12D; p53wt/fl; Rosa26YFP mouse (KPwt/flCY) successfully uses 
the metastatic properties of combined KRAS and p53 perturbations to track dissemination of 
pancreatic cancer (Rhim et al. 2012). While not a new model in terms of genetic perturbations 
(though this mouse uses p53wt/fl alleles as opposed to a p53R172H gain-of-function mutation), this 
was the first time a lineage labeling approach was used in a PDAC GEMM. This has allowed the 
study of micrometastatic dissemination and the insight that cells at the PanIN stage are able to 
delaminate and metastasize.  
Third, the cell-of-origin of PDAC is a controversial topic (Kong et al. 2011). Models, 
therefore, that identify lineage-specific differences in potential for oncogenic transformation 
deserve consideration. Here, the Sox9-CreER; KRASG12D and Ptf1-CreER; KRASG12D models stand 
out for their role in answering cell-of-origin questions (Kopp et al. 2012). These models take the 
original KC mouse and replace the pan-pancreatic Pdx1 driver with either an acinar-specific Ptf1α 
or duct-specific Sox9. By using lineage-specific Cre drivers, the authors are able to show that the 
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acinar compartment is far more susceptible to oncogenic transformation than the ductal 
compartment. This work is supported by other models, including an Ink4A/ARF loss model under 
the control of Ptf1α (Bardeesy, Cheng, et al. 2006) and TGF-α overexpression model under the 
control of either Ptf1α or Elastase (Siveke et al. 2007). In both these systems, the acinar-specific 
drivers were able to generate PanIN-PDAC lesions. 
Fourth, while the KRASG12D models as a group predominantly follow the PanIN-PDAC 
sequence, there are a handful of models that demonstrate cystic lesion development. For the 
purposes of this dissertation, mouse models of cystic lesions are relevant background, as our 
work on p120ctn reveals a role for it in intraductal papillary mucinous neoplasm (IPMN) and 
mucinous cystic neoplasm (MCN) pathology. Here, it suffices to say that there are published 
IPMN and MCN models (Bardeesy, Cheng, et al. 2006; von Figura et al. 2014; Izeradjene et al. 
2007; Siveke et al. 2007). Additionally, they all depend on KRASG12D as well, suggesting that the 
decision point between the PanIN versus cystic lesion pathway is not determined by KRAS. Of 
particular note is the Ptf1α or Elastase-driven TGF-α overexpression model (Siveke et al. 2007). 
Both drivers are acinar-specific and demonstrate the capacity of acinar cells to give rise to IPMN 
lesions. In addition to IPMN lesions, some mice demonstrate the PanIN-PDAC sequence, 
showing that, within the same mouse model, there exists the PanIN-PDAC and IPMN/MCN-
PDAC sequence. This will be relevant for us, as our model demonstrates a similar dual nature 
between PanIN and cystic lesions.  
Fifth, by using a Sleeping Beauty-transposon approach, different groups have discovered 
genes that cooperate with oncogenic KRAS to accelerate PDAC (Mann et al. 2012; Pérez-
Mancera et al. 2012). Sleeping Beauty-transposon mutagenesis depends on the use of 
transposons, mobile pieces of DNA that integrate at random sites through the help of 
transposases. These insertions, when they break up coding sequences, act as random 
mutations. Since the sequence of the transposon is known, its location can be determined. And 
when bred into the KC mouse, these random insertions will sometimes accelerate the slow 
latency of PanIN-PDAC development and thereby allow discovery of a new accelerator of PDAC. 
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This approach yielded USP9X (Pérez-Mancera et al. 2012), a deubiquitinase, as a novel 
accelerator of PDAC, and another yielded a list of several hundred cancer candidate genes that 
included p120ctn (Mann et al. 2012).  
These, then, are five of the most relevant PDAC GEMM types or classes, each of which, 
in its own way, leverages one of the advantages of the KC mouse to advance our understanding 
of PDAC. In addition to these, other relevant GEMMS are summarized in Table 1-4. 
Mutations Driver Description Phenotype and Importance Reference 
KRASG12D Pdx1 Constitutively 
active KRAS 
Early PanINs with rare progression 
to late PanINs or PDAC. The very 
first genetic model developed. 
(Hingorani et 
al. 2003) 
KRASG12D; 
p53R172H 
Pdx1 Constitutively 
active KRAS with 
gain-of-function 
p53 
Rapid progress to PDAC and 
widespread metastasis. Possesses 
hallmarks of human PDAC including 
desmoplasia, poor survival, and 
chromosomal instability. 
(Hingorani et 
al. 2005) 
KRASG12D; 
p53wt/fl; 
Rosa26YFP 
Pdx1 Constitutively 
active KRAS with 
heterozygous p53 
loss (LOH in vivo) 
PDAC and widespread metastasis, 
though the loss of p53 as opposed 
to a gain-of-function mutation is less 
metastatic. 
The key insight derived from this 
mouse depends on its lineage 
labeling, which allows tracking of 
PanIN/PDAC cells.  
(Rhim et al. 
2012) 
KRASG12D; 
TGFα 
Ptf1α, 
Elastase 
Constitutively 
active KRAS 
(driven by Ptf1α) 
with TGFα 
overexpression 
(driven by 
Elastase) 
PDAC and widespread metastasis 
Cystic lesions that resemble IPMNs 
Both drivers are acinar specific, 
demonstrating the capacity of the 
acinar compartment to give rise to 
both the PanIN-PDAC sequence 
and the cystic sequence 
(Siveke et al. 
2007) 
KRASG12D; 
Ink4a/Arffl/fl 
 
Pdx1 Constitutively 
active KRAS and  
homozygous 
Ink4a/Arf deletion 
PDAC and widespread metastasis 
 
(Aguirre et al. 
2003) 
KRASG12D; 
Smad4fl/fl 
KRASG12D; 
Ink4a/Arfwt/fl; 
Pdx1, 
Ptf1α 
Constitutively 
active KRAS and 
homozygous 
Smad4 loss with 
our without 
heterozygous 
Smad4 loss pushes mice towards 
IPMN lesions and accelerates 
lesion formation. 
Addition of heterozygous Ink4a/Arf 
loss restores predominance of 
(Bardeesy, 
Cheng, et al. 
2006) 
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Smad4f/fl Ink4a/Arf deletion. PanIN-PDAC sequence and 
accelerates formation. 
Phenotype appears unaffected by 
Pdx1 versus Ptf1α driver – 
suggests acinar compartment is 
effective at transition to either IPMN 
or PanIN-PDAC sequence. 
KRASG12D; 
Ink4a/Arfwtlfl 
or fl/fl 
KRASG12D; 
p53fl/fl 
Ink4a/Arfwt/fl 
or fl/fl 
Pdx1 Oncogenic KRAS 
and Ink4a/Arf loss 
with p53 deletion. 
Ink4A/Arf loss dramatically 
accelerates KRAS-mediated PDAC 
development in a dose-dependent 
manner. 
Compared to KPC controls, the 
addition of Ink4A/Arf loss shifts 
tumor morphology from 
adenocarcinoma to sarcomatoid or 
anaplastic. 
(Bardeesy, 
Aguirre, et al. 
2006) 
KRASG12D; 
Brg1fl/fl 
Ptf1a Constitutively 
active KRAS with 
homozygous Brg1 
knockout. 
Brg1 loss, in the context of an 
oncogenic KRAS, drives cystic 
lesion formation down the IPMN, 
but not MCN, path. 
Despite rapid progression to IPMN, 
prognosis is significantly better than 
in PDAC KPC group. 
In two different inducible (Ptf1α-
CreER or Hnf1β-CreER) models, Brg1 
loss prevented PanIN development 
in the acinar compartment but 
promoted IPMN lesions in the duct 
compartment. Suggests that Brg1 is 
a switch that regulates decision-
making between PanIN and cystic 
lesion pathways. 
(von Figura 
et al. 2014) 
KRASG12D; 
p53wt/fl; 
Egfrfl/fl 
KRASG12D; 
p53wt/fl; 
Adam17fl/fl 
Ptf1α Constitutively 
active KRAS, p53 
loss, and either 
EGFR or Adam17 
knockout. 
PDAC driven by oncogenic KRAS 
and p53 loss abrogated by either 
EGFR or Adam17 loss. 
In KRASG12D only mice, 
caeureulein-driven PDAC is blocked 
by loss of either EGFR or Adam17. 
This study provides rationale for 
erlotinib therapy in PDAC. 
(Ardito et al. 
2012) 
KRASG12V Elastase-
tTa/tetO-
Cre 
An oncogenic 
KRAS under the 
control of a tet-
inducible system 
using an acinar-
Adult acinar cells are refractory to 
oncogenic transformation by KRAS 
unless paired with an added 
stimulus – in this case, caereulein-
mediated pancreatitis. This is 
(Guerra et al. 
2007) 
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specific Elastase 
driver. 
consistent with Hingorani et al. 
(2003), which demonstrated that 
oncogenic KRAS alone, activated in 
the mouse embryo using a pan-
lineage driver, leads to low PDAC 
penetrance. 
KRASG12D; 
Tgfbr2wt/fl or 
fl/fl 
Ptf1α Oncogenic KRAS 
with either 
heterozygous or 
homozygous loss 
of TGF-β receptor 
II. 
Very rapid advance to metastatic 
PDAC – significantly faster than 
KPC model (Hingorani et al. 2005). 
Homozygous knockout mice dead 
by approximately 6 months of age 
with dose-dependent effect (i.e., 
heterozygous knockout mice do 
better).  
TGF-β may be an inhibitor of 
epithelial cell proliferation, and 
removing its receptor may promote 
malignancy. 
(Ijichi et al. 
2006) 
KRASG12D; 
Sox9fl/fl 
Sox9-
CreER, 
Ptf1α-
CreER, 
Ptf1α 
 Sox9 loss in the acinar 
compartment abrogates KRAS-
mediated PanIN formation. 
Ptf1α-CreER-driven oncogenic 
KRAS is an effective mediator of 
PanIN formation, but Sox9-CreER is 
not. Consistent with previous work 
that shows the acinar compartment 
as the compartment from which 
PanINs arise. Additionally shows 
the duct compartment is ineffective. 
(Kopp et al. 
2012) 
KRASG12D; 
Stat3fl/fl 
KRASG12D; 
p53wt/fl; 
MMP7fl/fl 
Ptf1α 
Pdx1 
Oncogenic KRAS 
with Stat3 loss. 
 
Oncogenic KRAS 
with p53 and 
MMP7 loss. 
Stat3 loss lowers PanIN formation 
in both an oncogenic KRAS 
background and an oncogenic 
KRAS with pancreatitis context. 
MMP7, which is downstream of 
Stat3 activation, is required for 
efficient PDAC development in a 
KRASG12D; p53wt/fl background.  
(Fukuda et 
al. 2011) 
KRASG12D; 
Tg(Muc1) 
Ptf1α Oncogenic KRAS 
with Mucin1 
overexpression. 
Mucin1 overexpression in an 
oncogenic background dramatically 
accelerates PanIN formation and 
PDAC-associated metastasis. 
(Tinder et al. 
2008) 
KRASG12D 
with 
Sleeping 
Beauty 
elements 
Pdx1 Oncogenic KRAS 
with Sleeping 
Beauty 
transposon 
Sleeping Beauty insertional 
mutagenesis revealed hundreds of 
new possible drivers of PDAC, 
including p120ctn. 
(Mann et al. 
2012) 
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KRASG12D 
with 
Sleeping 
Beauty 
elements 
Pdx1 Oncogenic KRAS 
with Sleeping 
Beauty 
transposon 
Sleeping Beauty insertional 
mutagenesis revealed that USP9X 
cooperates with KRAS to accelerate 
PDAC. 
(Pérez-
Mancera et 
al. 2012) 
iKRASG12D; 
p53wt/fl; 
Rosa-rtTA 
Ptf1α Oncogenic KRAS 
under the control 
of doxycycline 
responsive tet-on. 
Heterozygous 
p53. 
PDAC spontaneously regresses 
upon withdrawal of mutant KRAS. 
Bypassing of this KRAS addiction is 
observed in YAP1 amplified tumors. 
(Kapoor et al. 
2014) 
iKRASG12D; 
Rosa-rtTA 
 
iKRASG12D; 
p53wt/fl; 
Rosa-rtTA 
Ptf1α Oncogenic KRAS 
under the control 
of doxycycline 
responsive tet-on 
with or without 
heterozygous 
p53. 
PanIN and PDAC spontaneously 
regresses upon withdrawal of 
mutant KRAS. 
(Collins et al. 
2012) 
Review - - - (Gopinathan 
et al. 2015) 
Review - - - (Guerra and 
Barbacid 
2013) 
Review - - - (Westphalen 
and Olive 
2012) 
Table 1-4: Genetic Mouse Models of Pancreatic Neoplasia 
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p120ctn and E-cadherin: Structure and Function at 
the Adherens Junction 
p120ctn Origins and Interactions with E-cadherin 
p120-catenin, from here on p120ctn, was first described in 1989 as a substrate of the tyrosine 
kinase v-src (Reynolds et al. 1989) and named simply as p120. As a foreshadowing of where 
p120ctn biology would lead, it was observed that p120ctn was preferentially bound to the cell 
membrane in chicken embryo cells and that the role of p120ctn phosphorylation in transformation 
would need to be investigated. Three years later, murine p120ctn cDNA was isolated, and the 
resulting protein was observed to contain multiple repeats of a 42-amino acid motif found in the 
Drosophila armadillo protein and its human homolog plakoglobin, as well as β-catenin (Peifer, 
Berg, and Reynolds 1994; Reynolds et al. 1992). This led to the hypothesis that p120ctn may 
have similar functions and binding partners, which was confirmed when p120ctn was found to 
interact with E-cadherin (Reynolds et al. 1994; Shibamoto et al. 1995; Staddon et al. 1995). Upon 
this discovery, p120, the original name, was changed to p120 CAS for p120 cadherin-associated 
Src substrate (Reynolds 2007). This, in turn, was later changed to p120catenin, when, at the 
1994 Oncogene scientific conference, a poster for p130, also a Src substrate, appeared right next 
to the p120 CAS poster, a state of affairs deemed too confusing (Reynolds 2007).  
 After the discovery that p120ctn was a Src substrate, E-Cadherin partner, and structurally 
related to other ARM-containing proteins, p120ctn’s myriad biological roles began revealing 
themselves – particularly in regulation of E-cadherin. First came the observation that E-cadherin 
was capable of recruiting p120ctn to the cell membrane through a region (amino acids 758-773)  
highly-conserved in the cadherin family and that E-cadherin mutants decoupled from p120ctn 
were incapable of forming fully-functional cell junctions (Thoreson et al. 2000). Then, using 
p120ctn deficient SW480 colon carcinoma cells, it was revealed that p120ctn affects E-cadherin 
membrane stability through a post-translational mechanism that requires direct p120ctn-E-
cadherin interaction dependent on ARM repeat domains 1-5 and 7 (Ireton et al. 2002). p120ctn 
mutants with deletions of ARM domains 6 and 8-10 were capable of rescuing E-cadherin to 
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varying degrees suggesting these domains are less essential in p120ctn-mediated E-cadherin 
stabilization. Using vascular endothelium, the available p120ctn pool was found to be directly 
related to vascular E-Cadherin (VE-cadherin) stability (Xiao et al. 2003). VE-Cadherin constructs 
that preferentially drew away endogenous p120ctn led to endogenous VE-cadherin degradation, 
and knockdown of endogenous p120ctn led to VE-cadherin loss. Conversely, p120ctn 
overexpression stabilized VE-cadherin at the membrane. Consistent with the earlier observation 
(Thoreson et al. 2000) that E-cadherin is decoupled from p120ctn by mutating a region that is 
highly-conserved across the cadherin family, p120ctn loss leads to downregulation of not just E-
cadherin and VE-cadherin but also P-cadherin and N-cadherin (Davis, Ireton, and Reynolds 
2003). Additionally, by inhibiting lysosomal or proteosomal degradation pathways in p120ctn 
knockdown A431 human skin cancer cells, E-cadherin could levels could be rescued – crucially, 
however, localization could not be rescued. This illustrates that p120ctn is required for stability at 
the cell membrane. Without p120ctn, therefore, E-cadherin is fated to be internalized. 
 E-cadherin internalization is mediated by the E3 ubiquitin-ligase Hakai, which displaces 
p120ctn from E-cadherin and recruits both E1 and E2 (Fujita et al. 2002). This, then, is followed 
by E-cadherin internalization. The E-cadherin interaction with Hakai is dependent on tyrosine 
residues 755 and 756 of E-cadherin, and Hakai overexpression is capable of displacing p120ctn 
from wild-type E-cadherin.  
 The full p120ctn protein is composed of distinct domains with varying degrees of 
understanding as to their roles (Figure 1-3). Perhaps least understood is the coiled-coil domain 
unique to the full-length p120ctn protein. At least one unique binding partner is known (Markham 
et al. 2014), and others have suggested that this region endows a unique confirmation to the full-
length protein that prevents interactions with a transcription factor known as Kaiso, a regulator of 
WNT signaling (Jiang et al. 2012). In addition to the full-length protein, there are 3 alternative start 
sites that give truncated isoforms. This is regulated at least in part by epithelial splicing regulatory 
protein, which switches from the long isoform to the shorter ones (Warzecha et al. 2009).  
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Figure 1-3: p120ctn 
Structure. A schematic 
of the full-length 
p120ctn protein with 
important domains 
outlined. 
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p120ctn and Small G Proteins 
As p120ctn’s role as an adherens junction protein was being discovered, Albert Reynolds 
observed that p120ctn overexpression in mouse fibroblasts results in an obvious branching 
patterns described as “dendritic” (Reynolds et al. 1996). These dendritic processes were unique 
to p120ctn, as other catenin proteins could not reproduce it. This was an initial clue that p120ctn 
has an important role in regulating cell motility.  
Since then, p120ctn’s effects on branching and motility have been found to be mediated 
by its regulation of the small G proteins RhoA, Rac1, and Cdc42, which themselves are effectors 
of cytoskeletal organization and motility (Pieters, van Roy, and van Hengel 2012; Reynolds and 
Roczniak-Ferguson 2004). The first connection was described with RhoA (Anastasiadis et al. 
2000), where p120ctn-mediated inhibition of RhoA was found to be required for the branching 
phenotype observed in mouse fibroblasts. p120ctn mutants with amino acid 622-28 deletion fail to 
induce a branching phenotype, suggesting that p120ctn-mediated inhibition of RhoA is regulated 
by that domain. This region is described as a nuclear localization signal due to its ability to cause 
nuclear translocation and may therefore have dual roles. Crucially, when the authors expressed 
partial E-cadherin peptides in the cytoplasm, they were able to draw p120ctn away from RhoA. 
Therefore, the cadherin-stabilization functions of RhoA may be exclusive with its RhoA-regulation, 
and signaling events which shuttle p120ctn away from the membrane, such as phosphorylation 
(Calautti et al. 1998; Kinch et al. 1995), may result in altered motility. In fact, multiple residues 
which, when phosphorylated, alter p120ctn modulation of RhoA have been identified (Castaño et 
al. 2007). Tyrosine residues 227/228, for example, upon phosphorylation, drive p120ctn-RhoA 
interactions, which results in lower RhoA activity and enhanced stress fiber formation. 
At the same time that p120ctn regulation of RhoA was being identified, interactions with 
Rac1 and Cdc42 were described (Noren et al. 2000). Unlike RhoA, whose inhibition by p120ctn 
drives branching, p120ctn-mediated activation of Rac1 and Cdc42 are required for branching. 
This regulation of RhoA, Rac1, and Cdc42 is dependent on Vav2, a guanine nucleotide exchange 
factor that stimulates small G proteins to release GDP and bind GTP. 
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The branching phenotypes induced by p120ctn also appear to be linked to its nuclear 
localization and not just small G protein activity (Pieters et al. 2012). Exon B, which contains a 
nuclear export signal with the requisite hydrophobic residues, abrogates the branching phenotype 
(van Hengel et al. 1999). Exon C, which disrupts a nuclear localization domain, also abrogates 
branching (Pieters et al. 2012). Interestingly, p120ctn ARM domains may have their own intrinsic 
nuclear signaling capacity. Deletion of ARM repeats 3 and 5 leads to impaired nuclear entry even 
if both other nuclear localization signals are present (Roczniak-Ferguson and Reynolds 2003). 
The authors point out that these two domains are also necessary for E-cadherin binding, 
suggesting they have a critical role in mediating localization between membrane and nucleus.  
p120ctn in Human Carcinomas 
 A broad range of human carcinomas have been interrogated for p120ctn status 
(Thoreson and Reynolds 2002). At least nine separate human carcinomas - colorectal, bladder, 
gastric, breast, prostate, lung, pancreatic, melanoma, and endometrial – have abnormal p120ctn 
status, whether that is loss, decrease, or mislocalization. Additionally, an isoform switch in clear 
cell renal cell cancer in which p120ctn1A expression increases relative to p120ctn3A is correlated 
with higher incidence of metastasis (Yanagisawa et al. 2008).  
p120ctn Conditional Knockout Mouse Models 
Our study of p120ctn has been informed by multiple previous p120ctn conditional 
knockout models. p120ctn knockouts have targeted the salivary gland and breast (Davis and 
Reynolds 2006), skin (Perez-Moreno et al. 2006, 2008), neuron (Elia et al. 2006), colon (Smalley-
Freed et al. 2010, 2011), esophagus (Stairs et al. 2011), and prostate (data unpublished, lack of 
phenotype reported in a single sentence of Smalley-Freed et al. [2010]). Each model has yielded 
important insights into p120ctn function. 
Salivary Gland and Breast 
 The first p120ctn conditional knockout targeted mammary tissue with a MMTV-Cre driver 
(Davis and Reynolds 2006). Pups were born at expected Mendelian ratios, but most animals died 
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soon after birth due to unknown reasons. Mammary gland development was reported to have 
entirely failed upon p120ctn ablation from unpunished results (Smalley-Freed et al. 2010).   
Further study of the MMTV-Cre; p120ctnfl/fl mouse indicated that p120ctn ablation was also found 
in salivary tissue, which became the basis for their study. For our purposes, this is extremely 
fortuitous, as the acinar-ductal architecture of the salivary gland mimics that of the pancreas.  
Upon homozygous p120ctn ablation, the salivary gland lost its normal acinar-ductal 
appearance and was characterized by poorly-organized ductal structures with lumens filled with 
cell debris. The loss of acinar structures and their replacement with disorganized ductal structures 
is highly-reminiscent of acinar-to-ductal metaplasia, a regenerative process seen in the pancreas 
upon injury in mouse models of pancreatitis (Reichert and Rustgi 2011). The replacement of 
acinar tissue with this ductal phenotype suggests that p120ctn maintains acinar fate in the normal 
mouse salivary gland and perhaps in other similarly-organized tissues. In particular, as far as I 
have been able to determine, this is the very first time the in vivo role of p120ctn-mediated 
stabilization of E-Cadherin was demonstrated.  
Prostate 
 Unlike the breast, where p120ctn loss is a catastrophic event, p120ctn loss in the 
prostate has “little or no effect” (data unpublished, phenotype mentioned in Smalley-Freed et al. 
[2010]). 
Neuron 
 Neuronal postsynaptic densities are characterized by numerous finger-like extensions 
that are thought to be sites of abnormal synaptic signaling in disease. Because changes in 
cadherins and Rho GTPases have been implicated in this abnormal signaling, Elia et al. (2006) 
used the forebrain specific-promoter emx1 to knockout p120ctn and determine what effects this 
would have dendritic morphology. Compared to wild-type mice, p120ctn knockouts exhibit 
decreased protrusion density and cadherin levels, as well as decreased Rac1 and increased 
RhoA activity. 
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Skin 
 p120ctn ablation in mouse skin leads to hyperplasia as well as cell-intrinsic NFκB 
activation (Perez-Moreno et al. 2006), and p120ctn loss and NFκB activation is common in 
human squamous cell carcinoma  (Perez-Moreno et al. 2006). Interestingly, the hyperproliferative 
effect of p120ctn loss in skin cells does not endow increased proliferation in vitro, only in vivo. 
The in vivo hyperproliferation appears to be driven by p120ctn-mediated inflammation and mitotic 
instability driving genomic instability, whereas in vitro, p120ctn null keratinocytes do not have the 
benefit of pro-proliferative inflammation.  
Colon 
 Using the Villin-Cre driver, which targets recombination to the small and large intestines, 
p120ctn loss in these organs was found to be incompatible with life, as mice die within 3 weeks of 
birth (Smalley-Freed et al. 2010).  The loss of p120ctn, which resulted in downregulation of E-
Cadherin, led to a severe barrier defect that undermined the integrity of the gut epithelium and to 
an overwhelming inflammatory response.  
 To bypass this early lethality and establish p120ctn’s role in cancer formation, this same 
group used an inducible Villin-CreER (Smalley-Freed et al. 2011) with imperfect recombination 
efficiency. 18 months post-Cre induction, p120ctn ablation led to tumors without evidence of 
metastasis; however, none of the tumors observed were p120ctn deficient, suggesting that the 
cancer was indirectly the result of a barrier defect-driven inflammatory response in the 
recombined part of the epithelium. Taken together, the work on p120ctn in the colon further 
reinforces the crucial role of p120ctn in maintaining luminal integrity and stabilizing E-Cadherin, 
but it does not reveal a direct role for p120ctn loss as a tumor promoter.  
Esophagus 
 Using the foregut-specific L2-Cre driver, homozygous p120ctn ablation has been shown 
to give rise to esophageal squamous cell carcinoma (ESCC) (Stairs et al. 2011). In addition to 
ESCC and consistent with the inflammatory response seen in the colon p120ctn knockout 
models, a significant inflammatory response was observed along with increased release of 
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multiple inflammatory cytokines by tumor cells. This is the first instance in which p120ctn loss 
alone has been shown to have the capacity to drive cancer.   
Pancreas 
 There are two published knockout models of p120ctn in the pancreas. The first uses a 
pan-lineage Pdx1 driver to delete both p120ctn alleles (Hendley et al. 2015), whereas the second 
uses an acinar specific, tamoxifen-inducible Mist1CreER to drive both p120ctn and oncogenic 
KRASG12D (Hendley et al. 2016). In non-KRASG12D mice, biallelic p120ctn loss results in 
phenotypes associated with barrier defects and inflammation, the hallmarks of p120ctn loss in 
other organs. The authors report mucinous lesions that resemble PanIN1A, but no invasive 
cancer. This is consistent with all non-esophageal models that p120ctn loss alone cannot drive 
cancer. Additionally, inflammation upon p120ctn loss again demonstrates p120ctn’s role in 
mediating epithelial barrier integrity.   
 The combination of an oncogenic KRAS with biallelic p120ctn loss in the acinar 
compartments drives both high-grade PanIN formation and delamination of cells but not cancer. 
Despite the absence of cancer, animal mortality is affected. In a cohort of KRAS mutant mice with 
wild-type p120ctn compared to monoallelic or biallelic loss, mortality post-tamxoifen induction was 
worse with biallelic loss. This mortality appeared to be secondary to cachexia. Remarkably, the 
authors claim that p120ctn deficient cells can stabilize E-cadherin through other mechanisms in 
cells with oncogenic KRAS. Their immunofluorescence is convincing in this regard, though they 
provide no possible mechanism for such a proposition. 
Lessons 
 These mouse models teach us five general principles related to p120ctn biology.  
1) GI tissue lumens, such as that of the esophagus and colon, are susceptible to barrier 
defects that result from p120ctn loss and adherens junction instability. This, however, 
is not always due to cell-intrinsic effects – in the colon, for example, the tumors that 
develop are not p120ctn deficient, suggesting that it is the inflammation downstream 
of barrier defects that is the immediate cause of tumor formation. 
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2) Tissues with acinar-ductal architecture, such as mammary and salivary tissue, are 
susceptible to catastrophic morphologic collapse from p120ctn loss. Exocrine 
compartments, therefore, have a strong need for p120ctn-mediated epithelial 
stability. 
3) p120ctn loss alone is not sufficient to induce cancer in most instances. No tissue 
other than the esophagus shows cell-intrinsic tumor development (i.e., the tumors 
themselves are p120ctn-deficient) upon p120ctn loss. The colon, for example, does 
develop tumors upon p120ctn deletion, but the tumors are p120ctn-positive. 
4) The most important cell-intrinsic effects that drive the in vivo phenotypes in p120ctn 
deficient tissue appear to be mediated through cadherins, Rho GTPases, and NFκB. 
5) Not all tissues require p120ctn for homeostasis. The prostate, for example, appears 
normal even without p120ctn. 
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CHAPTER 2: Regulation of epithelial 
plasticity determines metastatic 
organotropism in pancreatic cancer 
 
 
 
 
 
 
 
 
 
 
This chapter published in Developmental Cell (Reichert et al. 2018). 
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Abstract 
Pancreatic cancer is the third leading cause of cancer mortality, the overwhelming majority of 
which is due to metastasis. The mechanisms of dissemination have been intensively studied, but 
questions remain as to how epithelial properties are regulated between the primary tumor site 
and destination as well as to how organotropic patterns of metastasis are determined. We 
demonstrate, using multiple complementary mouse models, that liver and lung metastatic 
organotropism in pancreatic cancer is dependent on p120catenin (p120ctn)-mediated epithelial 
identity. Monoallelic p120ctn loss accelerates KrasG12D-driven PanIN/PDAC formation and 
metastasis to the liver as well as being sufficient for E-CADHERIN-mediated cell adhesion. In 
contrast, cells with biallelic p120ctn loss demonstrate marked lung organotropism, although 
rescue with p120ctn restores liver metastasis. In a p120ctn-independent PDAC model, mosaic E-
cadherin knockout shows selective pressure for E-cadherin-positive liver metastasis and E-
cadherin-negative lung metastasis. Furthermore, human PDAC and liver metastases support the 
premise that liver metastases exhibit predominantly epithelial characteristics. RNA-seq 
demonstrates differential induction of pathways associated with metastasis and epithelial-to-
mesenchymal transition in p120ctn-deficient versus p120ctn-wild-type cells. Taken together, 
p120ctn-mediated epithelial plasticity may be added to the list of emerging concepts underlying 
metastatic organotropism. 
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Introduction 
Pancreatic cancer, chiefly pancreatic ductal adenocarcinoma (PDAC), is responsible for a large 
disease burden (American Cancer Society 2017)and is projected to be the second leading cause 
of cancer mortality by 2020 (Rahib et al. 2014). The overwhelming majority of patients are 
diagnosed after metastasis and nearly all will succumb to disease within 6-12 months of clinical 
presentation (Hidalgo 2010).  
One of the primary bottlenecks to progress is in understanding the metastatic cascade, especially 
how tumor cells colonize distant organs and features underlying metastatic organotropism. To 
that end, we have utilized the main component of the adherens junction, Cdh1 (E-CADHERIN), 
and its binding partner responsible for stabilizing it, Ctnnd1 (P120CATENIN, P120CTN), to study 
the role of epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions (EMT and MET, 
respectively) in mediating metastatic colonization and metastatic organotropism.  P120CTN is 
known to stabilize E-CADHERIN at the adherens junctions (Ireton et al. 2002; Ishiyama et al. 
2010; Thoreson et al. 2000), and our group has demonstrated that conditional p120ctn loss in the 
esophagus leads to invasive squamous cell carcinoma (Stairs et al. 2011).  Strikingly, p120ctn 
was identified as a “cancer candidate gene” by analyzing the transposon insertion sites of 
sleeping beauty mutagenesis-induced pancreatic cancers (Mann et al. 2012). Interestingly, this 
study also demonstrated that P120CTN loss or mislocalization is associated with worse outcomes 
(Mann et al. 2012).   
Genetic studies in mice have demonstrated that the absence of p120ctn has variable adverse 
consequences in other tissues, such as skin, salivary gland, and colon by modulating signals that 
promote tissue proliferation, migration, and inflammation, which may predispose the tissue to 
dysplasia or cancer (Davis and Reynolds 2006; Perez-Moreno et al. 2006, 2008; Short et al. 
2017; Smalley-Freed et al. 2010). The salivary gland is particularly interesting since its 
morphology is very similar to that of the exocrine pancreas where acinar cells secrete digestive 
enzymes into ductal conduits (Reichert and Rustgi 2011). p120ctn loss in the salivary gland 
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displays a phenotype reminiscent of acinar-to-ductal metaplasia (ADM), a transient phenomenon 
during pancreatitis and a precursor to pancreatic intraepithelial neoplasia (PanIN) and PDAC 
(Davis and Reynolds 2006; Kopp et al. 2012). 
EMT appears to be important for tumor initiation (Craene and Berx 2013). At the same time, 
some have advocated that it is dispensable in PDAC (Zheng et al. 2015), lung cancer (Fischer et 
al. 2015), breast cancer (Ocaña et al. 2012), and skin cancer (Tsai et al. 2012), although this 
premise has garnered divergent viewpoints (Aiello et al. 2017; Ye et al. 2017). The reverse 
process, MET, may foster metastatic colonization and outgrowth (Aiello et al. 2016; Takano et al. 
2016). The role of P120CTN in mediating epithelial identity makes it a powerful tool to study the 
role of EMT-MET in pancreatic cancer dissemination, and, in particular, whether EMT and MET 
may play roles in mediating metastatic organotropism.  
Herein, we demonstrate that monoallelic p120ctn loss accelerates KrasG12D-driven PDAC 
formation and liver metastasis. By contrast, bi-allelic p120ctn loss prevents pancreatic cancer 
cells from acquiring a MET-phenotype required for liver metastases; however, bi-allelic p120ctn 
loss is permissive for lung metastases. An independent genetic approach utilizing mosaic 
Cdh1/E-cadherin loss in a KrasG12D background results in predominantly E-CADHERIN-negative, 
mesenchymal lung metastasis but E-CADHERIN-positive, epithelial liver metastasis. 
Furthermore, restoration of the p120ctn1A isoform in a p120ctn null background restores liver 
metastatic tropism. Finally, human liver metastases show increased membranous E-CADHERIN 
relative to paired primary PDAC, providing a new prism through which to view metastatic 
organotropism in PDAC. 
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Results 
 
Monoalleic p120ctn loss accelerates KRASG12D-driven PDAC 
formation and metastatic dissemination 
Given the fact that chronic pancreatitis is a major risk factor of PDAC (Guerra et al. 2007), we first 
investigated the effects of p120ctn under homeostatic conditions and injury using the Pdx1-cre; 
p120ctnfl/fl; Rosa26YFP mouse (Figure S1A). We confirmed mosaic recombination in ducts as well 
as loss in the exocrine compartment (Figure S1B) and observed a significant impairment of 
exocrine compartment maintenance over a period of one year (Figure S1C). However, in a cohort 
of 31 Pdx1-cre;p120ctnwt/fl;Rosa26YFP and 20 Pdx1-cre;p120ctnfl/fl;Rosa26YFP mice that were aged 
to a maximum of 74 weeks and 65 weeks of age, respectively, we detected no cancer. In 
addition, while the exocrine compartment was compromised by p120ctn loss, the endocrine 
compartment was not affected (Figure S1D and S1E). In a cerulein model of acute pancreatitis, 
p120ctn loss led to impaired regeneration and a prolonged ADM phenotype (Figures S1F, S1G 
and S1H). 
We next introduced the mutant LSL-KrasG12D allele in to Pdx1-cre; p120ctnfl/fl; R26YFP mice (Figure 
1A). Pdx1cre;LSL-KrasG12D/wt;p120ctnfl/fl;Rosa26YFP mice were not viable. Timed matings indicated 
that embryos died between E8.5 and E14.5 (data not shown). Pdx1-cre; LSL-KrasG12D/wt; 
p120ctnwt/fl; Rosa26YFP mice (from here on referred to as KCYp120ctnwt/fl) were born according to 
Mendelian ratios. Across an age-matched cohort ranging from 3 to 58 weeks of age (Tables S1 
and S2), KCYp120ctnwt/fl mice (n = 38) show a significant acceleration of KrasG12D-driven 
pathology compared to control KCYp120ctnwt/wt animals (n = 32) (Figures 1B, 1C, and S1A). 
Remarkably, KCYp120ctnwt/fl mice harbor the entire spectrum of PDAC-precursor lesions, 
including PanINs 1-3, mucinous cystic neoplasm (MCNs)-like lesions, and intraductal papillary 
mucinous neoplasm (IPMN)-like lesions. MCN-like and IPMN-like lesions are significantly more 
frequent in KCYp120ctnwt/fl (9/38) compared to controls (1/32) (Figure 1D) and, in 4/9 cases, mice 
exhibited simultaneous PanIN1A or 1B lesions. Mono-allelic p120ctn loss results in twice as many 
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PanIN lesions compared to controls (14.67 ± 4.71 vs 6.1 ± 2.15, mean ± SD, respectively) (Figure 
1E).  Interestingly, it has been demonstrated that PDAC arising from cystic neoplasms might 
harbor a distinct cell-of-origin than that in the PanIN–PDAC sequence (von Figura et al. 2014; 
Kopp et al. 2012). Specifically, the ductal compartment may serve as the cellular origin of IPMN. 
Moreover, 2/38 KCYp120ctnwt/fl mice presented with frank invasive PDAC with evidence of 
metastasis in one mouse (the liver of the other mouse was not available for analysis). The 
phenotype in control KCYp120ctnwt/wt mice was restricted almost entirely to ductalization, acinar-
to-ductal metaplasia (ADM) and PanIN 1A/B lesions with a single mouse exhibiting MCN-like 
lesions.  
Given the remarkably accelerated phenotype of KCYp120ctnwt/fl mice (Figure S2A), we next 
asked whether the second allele of p120ctn might be lost during the progression from 
preneoplastic lesions to primary PDAC formation to metastasis. Surprisingly, we were able to 
demonstrate that the remaining wild-type p120ctn allele is retained in all stages of PanIN to 
PDAC metastases by immunohistochemistry (Figure 1F) and immunofluorescence (co-staining of 
YFP/E-CADHERIN/P120CTN) (Figure S2B), indicating that p120ctn loss-of-heterozygosity (LOH) 
did not occur. This was also true of the epithelial lining of MCN/IPMN lesions (Figure 1G). In all all 
pathological states, including liver metastasis, P120CTN co-localizes with E-CADHERIN at the 
cell membrane, thereby indicating that a single p120ctn allele is sufficient to stabilize E-
CADHERIN.  
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p120ctn impacts metastatic organotropism in a mouse model of 
accelerated PDAC 
In order to investigate the effect of p120ctn loss on metastatic colonization, we utilized a mouse 
model of accelerated PDAC by additionally deleting one allele of Trp53 (Pdx1-cre; KrasG12D/wt; 
p120ctnwt/fl; p53wt/fl; Rosa26YFP, KPCYp120ctnwt/fl) (Figure 2A). The KPCYp120ctnwt/fl mice exhibit a 
marked propensity lung metastasis relative to liver metastasis (Figure 2B). Mono-allelic p120ctn 
loss significantly shifted metastatic burden from the liver to the lung (4/5 lung in the 
KPCYp120ctnwt/fl group versus 9/11 liver in the PCYp120ctnwt/wt group) (Figure 2C).  Additionally, 
the absolute number of metastases in liver and lungs shows a much higher burden in liver for 
KPCYp120ctnwt/wt and lung for KPCYp120ctnwt/fl mice (Figure 2D). The primary tumors in 
KPCYp120ctnwt/fl mice express P120CTN to a varying degree. Differentiated (ductal/tubular) 
regions express membranous P120CTN that co-localizes with E-CADHERIN. By contrast, 
delaminated and invading tumor cells undergoing EMT are devoid of both P120CTN and E-
CADHERIN (Figure 2E).  Lung metastases in KPCYp120ctnwt/fl mice do not express P120CTN or 
E-CADHERIN, thereby suggesting that pancreatic cancer cells maintain their mesenchymal 
phenotype and fail to undergo MET in the lung (Figure 2E). This was confirmed by 
immunofluorescence, which revealed that YFP+ lung metastases do not express P120CTN or E-
CADHERIN (Figure 2F). A total of 169 liver metastatic lesions were analyzed for P120CTN and 
183 liver metastatic lesions for E-CADHERIN, with both showing robust membranous staining in 
almost all lesions (148/169 for P120CTN and 146/183 for E-CADHERIN) (Figure 2G). P120CTN 
and E-CADHERIN staining frequently tracked with each other, with non-membranous P120CTN 
staining correlating with absent or low E-CADHERIN staining (Figure 2H), which underscores the 
crucial role for P120CTN in fostering the MET phenotype in liver metastasis.  
We next utilized another independent genetic model, which uses an inducible KRASG12V under 
the control of the elastase promoter (Guerra et al. 2007). These mice had either mono-allelic or 
bi-allelic Trp53 loss under the control of either a FLP-FRT or CRE-LOXP Elastase-tTA/tetO (Elas-
tTA/tetO-cre; KrasG12V/wt; p53wt/fl or fl/fl or Elas-tTA/tetO-flp; KrasG12V/wt; p53wt/frt or frt/frt). A total of 29 
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liver lesions (n = 4 mice) were analyzed for both P120CTN and E-CADHERIN, with metastases 
demonstrating overwhelming membranous staining (26/29 for P120CTN and 25/29 for E-
CADHERIN) (Figure 2I). Analysis of 20 lung lesions across the same 4 mice for P120CTN and E-
CADHERIN demonstrated a shift from membranous expression (7/20 for P120CTN and 4/20 for 
E-CADHERIN). These data support the notion that the lung organotropism observed in the 
KPCYp120ctnwt/fl mouse is not dependent upon MET.  
Single circulating tumor cells exhibit differing epithelial properties 
compared to clusters of cells 
We next asked whether the profile of circulating tumor cells mimics that of metastases, insofar as 
they exhibit a spectrum of epithelial and mesenchymal properties. Both single cells and clusters 
of circulating tumor cells were isolated from KPCY mice and stained for E-CADHERIN and 
additional markers, including P120CTN (Figure S3A) and β-CATENIN (Figure S3B). Additionally, 
clusters were stained for CYTOKERATIN-19 (Figure S3C). Clusters of tumor cells exhibited 
membranous localization of the markers, whereas individual tumor cells did not. 
Sequential genetic manipulation of E-cadherin in pancreas 
cancer reveals the requirement of epithelial integrity to establish 
liver metastases in vivo 
In order to verify that the metastatic shift caused by p120ctn loss is due to the functional role of 
P120CTN in stabilizing E-CADHERIN, we next utilized an inducible, conditional dual-
recombination system in which E-cadherin (Cdh1) can be manipulated independently from the 
PDAC-initiating KrasG12D mutation (Pdx1-Flp; FSF-KrasG12D/wt; FSF-R26GAG-CreERT2;CDH1fl/fl) 
(Figure 3A) (Schönhuber et al. 2014). Mice were induced with tamoxifen at 3 months of age and 
maintained until moribund.  We did not observe a survival difference between mice with wild-type 
CDH1 and heterozygous CDH1 knockout (data not shown). Tumors show heterogeneous E-
CADHERIN expression by immunofluorescence, thus indicating a variable degree of E-
CADHERIN loss (Figure 3B).  Well-differentiated tumor regions display high E-CADHERIN 
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expression levels and membranous E-CADHERIN and P120CTN. Poorly-differentiated areas 
within the same tumor lack E-CADHERIN and P120CTN.  
We employed the genetic heterogeneity regarding the recombination of the Cdh1 locus to 
investigate the role of E-CADHERIN in PDAC metastasis evolution within each individual mouse. 
A given cancer cell that lacks E-CADHERIN would only be able to establish E-CADHERIN-
negative metastases. By contrast, cancer cells with retained E-CADHERIN expression can 
establish E-CADHHERIN-positive or -negative metastases. We next analyzed the number and 
distribution of metastases in these mice. There was no statistical difference between Cdh1 
heterozygous animals; however, when liver and lung metastases were stained for E-CADHERIN, 
liver metastases uniformly expressed membranous E-CADHERIN (n = 30/32) (Figures 3C and 
3D). Only a negligible number of micro-metastases present within the liver lacked E-CADHERIN 
expression indicating that E-CADHERIN loss leads to a negative selection pressure restricting the 
capability of PDAC cells to establish liver metastases. Conversely, lung metastases demonstrate 
mixed E-CADHERIN expression, thereby suggesting E-CADHERIN-mediated epithelial integrity 
is dispensable for lung metastasis (Figures 3C and 3D).  
Taken together, the results obtained in an entirely independent genetic mouse model of PDAC 
emphasize that epithelial integrity mediated by P120CTN, and its role regulating E-CADHERIN 
turnover, determines metastatic outgrowth in the liver. 
One p120ctn allele is sufficient to maintain epithelial integrity in 
vitro and in vivo 
Our in vivo data suggest one p120ctn allele is required to re-establish epithelial integrity or MET 
in the liver. In order to address this mechanistically, we performed 3D organoid culture with 
primary pancreatic cells isolated from LSL-KrasG12D/wt;p120ctnwt/wt;Rosa26YFP (wild-type p120ctn, 
KYp120ctnwt/wt) (cell line ID: 611, 793, 801), LSL-KrasG12D/wt; p120ctnwt/fl; Rosa26YFP 
(heterozygous floxed p120ctn, KYp120ctnfl/wt) (cell line ID: 363, 732, 866) and LSL-KrasG12D/wt; 
p120ctnfl/fl; Rosa26YFP pancreata (homozygous floxed p120ctn, KYp120ctnfl/fl) (cell line ID: 288, 
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690, 791) (Deramaudt et al. 2006; Reichert, Takano, Heeg, et al. 2013). Lentiviral-mediated, Cre 
recombinase in vitro followed by FACS for YFP positive (YFP+) cells was utilized to establish 
stable, recombined cell lines (Figure 4A). The in vitro recombination approach was necessary 
since bi-allelic p120ctn loss in combination with KrasG12D is lethal in utero.  
We confirmed the recombination efficiency in YFP+ cells by FACS (Figure S4A) and western blot 
(Figure 4B), which indicated a gene dose-dependent reduction of P120CTN levels that correlated 
with E-CADHERIN levels. 3D culture reveals that wild-type p120ctn cells form multicellular 
organoids with hollow lumens (Figure 4C). Mono-allelic p120ctn loss disrupts the symmetry of 
these structures with a loss of hollow lumens; and leads to invadopodia-like protrusions. Bi-allelic 
loss of p120ctn completely prevents cells from forming organized structures (Figure 4C). To 
characterize these 3D structures, we used the established markers of invadapodia Tks5 (Blouw 
et al. 2015; Seals et al. 2005) and cortactin (Clark et al. 2007), in addition to α-smooth muscle 
actin (α-SMA). We observed higher expression of these invadapodia markers and αSMA with 
p120ctn loss (Figure 4D). To validate this phenotype in vivo, we next injected these cell lines 
orthotopically into the pancreata of athymic nude mice (Figure 4E). KYp120ctnwt/wt cells form 
PanIN-like structures within 3 weeks (21 days). Surprisingly, KYp120ctnwt/fl cells establish large 
cystic structures reminiscent of IPMN/MCN lesions with highly organized regions, especially at 
the epithelial lining of the cyst, as well as more invasive areas (Figure 4E, middle upper panel and 
two lower panels). The epithelial lining of the cysts displayed membranous expression of 
P120CTN and E-CADHERIN whereas the invasive parts of the tumor showed varying localization 
of P120CTN and E-CADHERIN. Finally, KYp120ctnfl/fl cells, characterized by a spindle shape and 
lack of membranous E-CADHERIN, generate invasive undifferentiated tumors.  
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MET is required for metastatic outgrowth in the liver but not in 
the lung 
The liver is the most common site of metastasis in PDAC (Yachida and Iacobuzio-Donahue 
2009). Thus, we next asked the question whether the remaining p120ctn allele is required for 
metastatic outgrowth in the liver. In order to focus on steps within the metastatic cascade that do 
not require primary tumor growth, invasion and intravasation, we employed intraportal vein 
injections. We again used the cell lines described above harboring mutant KrasG12D, a YFP 
reporter and one of three p120ctn genotypes: p120ctnwt/wt, p120ctnwt/fl, or p120ctnfl/fl. Fourteen 
days post-injection, no macroscopic liver metastases were observed. Histologically, 
KYp120ctnwt/wt cells show sparse metastases in the livers (2.05 ± 0.32 lesions per HPF, mean ± 
SD) (Figure 4F). KYp120ctnwt/fl cells colonize the liver significantly more frequently (4.33 ± 1.03 
lesions per HPF, mean ± SD). KYp120ctnfl/fl cells demonstrated the least capacity to form liver 
metastases (0.3 ± 0.09 lesions per HPF, mean ± SD). Additionally, immunofluorescence 
confirmed that P120CTN and E-CADHERIN expression track with each other (Figure 4G). These 
data suggest that bi-allelic p120ctn loss abrogates the ability of pancreatic cancer cells to 
establish liver metastases. 
To test whether p120ctn levels alter the frequency of lung metastasis, we utilized the retro-orbital 
injection model. Due to transpulmonary passage, this model system preferentially metastasizes to 
the lung (Galaup et al. 2006; Hollern et al. 2014). Interestingly, KrasG12D cells form lung 
metastases irrespective of their p120ctn status (Figure S4B). As expected, p120ctn wild-type 
cells establish metastases with high E-CADHERIN levels. Cells with mono-allelic p120ctn loss 
show intermediate E-CADHERIN expression whereas E-CADHERIN is absent in metastases 
formed by cells with bi-allelic p120ctn loss (Figure S4B).  
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Long-term orthotopic transplantation of KYp120ctnwt/fl cells 
results in both macroscopic solid tumors and fluid-filled cystic 
structures 
We next orthotopically injected 5 x 105 KYp120ctnwt/fl cells into 12 nude mice and aged them for 
up to 180 days. Intriguingly, we saw two distinct paths reminiscent of the PanIN versus 
IPMN/MCN phenotype in the KCYp120ctnwt/fl model. Specifically, 3 mice exhibited macroscopic 
solid tumors whereas 4 harbored macroscopic cystic lesions. 1 mouse showed a mixed 
solid/cystic phenotype, and 4 showed no evidence of tumor (Figure S5A). The difference between 
these two pathways is evident both macroscopically and histologically (Figure S5B) where 
immunohistochemistry was used to confirm YFP+ expression in solid tumor cells and the 
epithelial lining of the cysts. Retention of P120CTN and E-CADHERIN was seen in the ductal 
structures of the solid tumor and in the epithelial lining of the cysts (Figure S5B). 
Restoration of MET shifts metastatic organotropism from the 
lung back to the liver 
We next tested whether we could restore liver metastatic ability in KYp120ctnfl/fl cells by 
reintroducting p120ctn. To investigate this, we rescued our KYp120ctnfl/fl cells with the full-length 
p120ctn isoform p120ctn1A. KYp120ctnfl/fl cells were stably transfected with either an empty 
control construct or p120ctn1A and validated by western blot (Figure 5A). 5 x 105 cells were 
orthotopically injected into the pancreata of athymic nude mice and aged for between 10-14 
weeks. Parental KrasG12D/wt; p120ctnfl/fl; Rosa26YFP cells formed macroscopic lung metastases in a 
higher number of mice than macroscopic liver metastases (Figures 5B and 5C). Cells without the 
ability to modulate E-cadherin and undergo MET bypass the liver altogether and preferentially go 
to the lung.  We were able to restore macroscopic liver metastasis in 8/17 mice orthotopically 
injected with p120ctn1A-rescued cells (Figures 5B and 5D). These mice demonstrated significant 
macroscopic liver and lung metastatic burden; however, metastatic lesions derived from the same 
primary tumor in the p120ctn1A-recused orthotopics showed a distinct appearance based upon 
site of metastasis. Specifically, lesions in the liver demonstrated an almost entirely epithelial 
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phenotype characterized by membranous E-CADHERIN and well-organized ductal structures 
(Figure 5D and 5F). Conversely, lung metastases were disorganized and de-differentiated. 12/18 
liver lesions were well-whereas 27/30 lesions were de-differentiated (Figure 5E).  It is interesting 
to note that the invasive front of these metastatic liver lesions is characterized by well-
differentiated ductal structures and not individual cells (Figure 5E). We also noted that this 
difference was not entirely due to size, as even large lung lesions, comparable in size to some 
liver lesions, were de-differentiated. Additionally, even small liver lesions were well-differentiated. 
This supports our observation that P120CTN/E-CADHERIN expression levels are strongly 
membranous in KPCY liver metastasis (Figure 2G).  
Epithelial integrity mediated by P120CTN and E-CADHERIN is 
critical in human PDAC-derived liver metastases 
We next determined the expression pattern of P120CTN and E-CADHERIN in human PDAC and 
associated liver metastasis using a human tumor microarray. In total, we analyzed 21 and 20 
primary tumors for E-CADHERIN and P120CTN, respectively (Figure 6A). All primary and 
metastatic PDAC tissues with artifacts or necrosis were excluded. For matched liver metastases, 
we analyzed 14 patients for E-CADHERIN and 13 for P120CTN. Each sample was assigned to 
one of four groups for staining pattern: membranous (M), membranous and cytoplasmic (M+C), 
cytoplasmic (C), or negative (N). Remarkably, liver metastases were significantly more epithelial 
than paired primary tumors based upon E-CADHERIN localization: only 9 out of 21 primary 
tumors (42.9%) demonstrated membranous or membranous and cytoplasmic staining whereas 
11 out of 14 liver metastases (78.6%) did so (Figure 6A).  When we examined only these liver 
metastases with paired primary tumors, we found that of 8 out 12 paired samples showed a shift 
from cytoplasmic E-CADHERIN staining at the primary site to membranous and cytoplasmic 
staining in the liver. Of the other 4 patients, 2 exhibited membranous E-CADHERIN in both the 
primary and metastatic site; 1 was predominantly cytoplasmic in both locations; and only 1 
showed a shift from membranous to cytoplasmic E-CADHERIN from primary tumor to liver 
metastasis. These results support the premise that MET is important in liver colonization and 
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outgrowth. Analysis of P120CTN revealed that, while there was no significant difference between 
P120CTN at the primary and metastatic site in terms of localization (Figure 6A), there was a 
significant increase in membranous staining intensity from primary tumor to liver metastasis 
(Figure 6B). 17/20 primary tumors showed a maximum of weak staining whereas 6/12 liver 
metastases expressed moderate or higher membranous staining intensity. This trend is 
consistent with the observed increase in membranous E-CADHERIN localization observed in liver 
metastases.  
p120ctn is associated with epithelial-to-mesenchymal transition 
in human and mouse PDAC 
To evaluate the possible correlation of P120CTN and E-CADHERIN expression in human PDAC 
(n=47), we utilized publicly available databases (www.broadinstitute.org). In addition, we have 
generated a unique library of gene expression profiles of 53 primary mouse PDAC cell lines 
isolated from several different mouse models of PDAC and a variety of PDAC phenotypes. 
Interestingly, both human (Pearson r = 0.4805) (Collisson et al. 2011) and mouse (Pearson r = 
0.4601) PDAC cell lines show a significant correlation of p120ctn (CTNND1/ctnnd1) and E-
cadherin (cdh1) expression (Figure 6C). We analyzed gene sets that are enriched in mouse and 
humans depending upon their p120ctn expression levels (p120ctn “low” and “high” PDAC). 
Indeed, p120ctn “low” genes are enriched in gene sets that are associated with a mesenchymal 
signature whereas p120ctn “high” PDAC genes are found in gene sets with an epithelial signature 
(Figure 6C). These data suggest that p120ctn in human and mouse PDAC influences the 
epithelial or mesenchymal signature.  
P120CTN and E-CADHERIN status in human IPMN 
We analyzed a cohort of IPMN patients from across a range of subtypes for P120CTN (Figure 
S6A and S6B). Overall, human IPMN demonstrated robust epithelial staining with some subtype 
specific differences. We next looked at E-CADHERIN intensity levels in IPMN patients, also 
across multiple subtypes (Figure S6C and S6D). While we did not observe statistical differences 
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in overall localization, we did observe statistically significant greater E-CADHERIN intensity in the 
membranous than in the cytoplasmic compartment. 
P120CTN and E-CADHERIN status in human pancreatic 
neuroendocrine tumors 
We evaluated NET samples along with normal adjacent tissue from 2 patients. As we showed in 
Figure S1, the endocrine compartment is not affected by p120ctn loss in the Pdx1-cre; p120ctnfl/fl 
mouse. Interestingly, no PNET samples showed membranous P120CTN (Figure S6E). Although 
6 samples showed both membranous and cytoplasmic E-CADHERIN localization, no samples 
showed only membranous staining, and, the intensity of membranous E-CADHERIN staining was 
less than that in the cytoplasmic compartment (Figure S6F). Lastly, we confirmed that the normal 
human pancreas expresses both P120CTN and E-CAHDERIN at the cell membrane (Figure 
S6G), in contrast to PNET (Figure S6H). Therefore, PNET demonstrates dispensability of 
epithelial properties, which is consistent with the ability of islet cells to retain normal architecture 
in Pdx1-cre; p120ctnfl/fl mice. 
Unbiased analysis of KRASG12D-transformed pancreatic epithelial 
cells with varying p120ctn status reveals a differential EMT and 
metastasis signature 
We next performed RNA-Seq on KYp120ctnwt/wt, KYp120ctnwt/fl, and KYp120ctnfl/fl primary cell 
lines. Homozygous deletion of p120ctn significantly altered 608 genes (Figure 7A; P<0.05 and 
fold-change>2). Cells with wild-type p120ctn and bi-allelic p120ctn loss showed the largest 
difference, with 225 differentially expressed genes. Additionally, there was significant overlap 
between lists of differentially expressed genes – 191 genes were common in the comparison 
between mono-allelic or bi-allelic loss and wild-type p120ctn (Figure 7B).  Gene Set Enrichment 
Analysis (GSEA) of these data validated our in vivo results by showing that cells lacking p120ctn 
are enriched for EMT and metastasis gene sets (Figure 7C). Of note, EMT and metastasis gene 
sets that were enriched in comparisons of KYp120ctnwt/wt and KYp120ctnfl/fl cells were not 
enriched in comparisons of KYp120ctnwt/wt and KYp120ctnwt/fl cells, suggesting that one allele of 
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p120ctn is sufficient to restrain EMT programs. In addition to restrained EMT, certain genes 
exhibit a biphasic response to mono-allelic p120ctn loss, with both KYp120ctnwt/wt and 
KYp120ctnfl/fl cells having a statistically significant difference in the same direction compared to 
KYp120ctnwt/fl cells. It is possible that the phenotypes described are mediated by some of the 
genes upregulated (Figure 7D) and downregulated (Figure 7E) in KYp120ctnwt/fl cells compared to 
both p120ctn wild-type and p120ctn null states.   Interestingly, we noted by GSEA that 
KYp120ctnfl/fl cells were enriched for a positive-prognosis gene signature seen in breast cancer. 
This observation was consistent with interrogation of TCGA, which revealed that higher p120ctn 
and Cdh1 levels correlate with worse survival (Figure 7F). Patients with p120ctn and Cdh1 
expression below the 50th percentile have median survival of 518 days compared to 684 days for 
patients with expression above the 50th percentile. Our work may provide a biological rationale for 
why TCGA data demonstrates a worse outcome with higher epithelial markers as they are 
conducive for liver colonization and outgrowth. However, tumor cells in a fixed mesenchymal 
state form undifferentiated tumors but fewer liver metastases. 
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Discussion 
P120CTN and E-CADHERIN mediate epithelial plasticity and 
PDAC metastatic organotropism 
The ability of epithelial cells to shift between epithelial and mesenchymal identities is critical to 
fundamental biological processes, such as embryonic development, differentiation, regeneration 
and carcinogenesis (Thiery et al. 2009). Epithelial cells acquire a mesenchymal phenotype in a 
gene dose-dependent manner in vitro and in vivo based upon our findings. We show that 
pancreatic cancer cells lacking both alleles of p120ctn fail to establish any sort of contact with 
neighboring epithelial cells in 3D culture.  
We use multiple independent genetic and transplantation mouse models to highlight the 
mechanistic basis underlying metastatic organotropism. We demonstrate that liver metastasis is 
highly dependent upon P120CTN-mediated stabilization of membranous E-CADHERIN or MET, 
whereas the lung appears permissive to colonization by cells that are not MET-capable. Of note, 
PDAC patients with recurrent pulmonary metastases demonstrate significantly longer overall 
survival compared to patients with recurrence at other sites (40.3 vs. 20.9 months) (Yamashita et 
al. 2015). Along with our data it is tempting to speculate whether the aggressiveness of PDAC is 
dependent upon epithelial plasticity and not exclusively upon a mesenchymal/de-differentiated 
phenotype, although we certainly acknowledge the importance of this as well (Genovese et al. 
2017). 
Introduction of a mutant KrasG12D allele in combination with heterozygous p120ctn loss 
accelerates PanIN formation and PDAC progression. Importantly, in this PDAC progression 
model, we observed the classical PanIN-PDAC sequence as well as the IPMN/MCN-PDAC 
sequence when both mutations were targeted to all (acinar, ductal and endocrine) lineages with 
Pdx1-cre. However, in our orthotopic transplantation experiments in which we utilized purified 
pancreatic ductal cells harboring the same genetic mutations, the IPMN/MCN pathway to PDAC 
was also present, suggesting that the ductal compartment may represent the cell of origin of 
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cystic neoplasms (IPMNs, MCNs) as suggested previously (von Figura et al. 2014). During PDAC 
progression, in all our model systems (autochthonous and orthotopic mouse models) we 
observed that at least one p120ctn allele is expressed in liver metastasis. Interestingly, the 
retained expression of P120CTN is sufficient to stabilize E-CADHERIN at the cell membrane. 
Removing both alleles of p120ctn results in the absence of liver metastases while lung 
metastases prevail. This is also true in an E-CADHERIN-dependent mouse model of PDAC 
(Pdx1-Flp; FSF-KrasG12D/wt; FSF-R26GAG-CreERT2;CDH1fl/fl). These observations were confirmed 
by analysis of P120CTN and E-CADHERIN localization patterns in lung and liver metastases 
from two previously published PDAC models – the KPCY mouse (Rhim et al. 2012) and inducible 
tet-on Elastase-KRASG12V mouse (Guerra et al. 2007).  
The crucial role of P120CTN-mediated stabilization in driving liver metastasis was observed and 
underscored in two new genetic mouse models. First, we demonstrated that the metastatic switch 
from liver to lung in KPCYp120ctnwt/fl mice is characterized by P120CTN-deficient lung 
metastases arising from a mixed epithelial-mesenchymal primary tumor. Second, we 
demonstrated that in a mosaic E-CADHERIN knockout model of PDAC, the liver metastases are 
characterized by overwhelming E-CADHERIN -positivity whereas the lung metastases are 
overwhelmingly E-CADHERIN-negative. Third, analysis of human liver metastases shows a shift 
to membranous E-CADHERIN and stronger P120CTN membranous staining compared to 
primary PDAC. 
Epithelial identity and plasticity are important as a new principle 
in PDAC metastatic organotropism 
For a tumor cell to form a metastatic lesion, it must undergo several steps, including delamination 
from the primary epithelial layers, intravasation, survival in circulation, extravasation, survival at 
the metastatic site, and reactivation and outgrowth (Giancotti 2013; Massagué, Batlle, and Gomis 
2017; Massagué and Obenauf 2016). Our data show that cells with or without epithelial plasticity 
can accomplish all the steps up to and including survival in circulation since we observe lung 
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metastasis independent of membranous P120CTN or E-CADHERIN localization. We used an 
unbiased RNA-seq approach and demonstrated that p120ctn deletion in pancreatic tumor cells 
may lead to the induction of pathways associated with metastasis based upon GSEA. 
Furthermore, in comparing bi-allelic p120ctn loss and mono-allelic p120ctn loss, GSEA reveals 
induction of EMT in the former, but not in the latter. 
We and others have published on the paradoxical observation that metastasis may be enhanced 
by certain epithelial properties, including E-CADHERIN expression. Tail vein injection of breast 
cancer cells with knockdown of the EMT transcription factors PRRX1 and Twist1 showed 
increased lung metastatic burden (Ocaña et al. 2012). In a skin cancer model, persistent 
induction of Twist was seen to inhibit metastatic outgrowth, whereas turning off Twist expression 
promoted it (Tsai et al. 2012). In pancreatic cancer, liver metastatic outgrowth was associated 
with the acquisition of an epithelial phenotype (Aiello et al. 2016). Additionally, we have 
demonstrated that two isoforms of the transcription factor Prrx1 (Reichert, Takano, Burstin, et al. 
2013), Prrx1A and Prrx1B, promote MET and EMT, respectively (Takano et al. 2016). PRRX1A, 
the MET-promoting isoform, is significantly upregulated in human PDAC liver metastases 
compared to primary tumor. In addition, using orthotopic transplantation of Prrx1A- or Prrx1B-
inducible mouse pancreatic cancer cells, we found that either induction of Prrx1A (i.e., MET) or 
repression of Prrx1B (i.e., turning off EMT) promoted both the incidence of liver metastasis as 
well as the size of the lesions. The microenvironment of the liver may therefore demand 
acquisition of an epithelial phenotype for reasons that do not exist in the lung. It is possible that a 
proclivity towards acquiring an epithelial state in cancer cells occurs prior to actual metastatic 
colonization (del Pozo Martin et al. 2015; Korpal et al. 2011; Tsai et al. 2012). Intriguingly, 
pancreatic cancer cells can undergo either "classical" EMT or "partial" (p-EMT), with the latter 
being characterized by retained epithelial gene expression (Aiello et al. 2018). This p-EMT 
predisposes to invasion in a collective manner. In light of our observation that EMT-MET plasticity 
is involved in regulating metastatic organotropism, this work informs our understanding of how 
disseminated tumor cells regulate their position on the EMT-MET spectrum. 
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We believe that epithelial plasticity under the governance of P120CTN is critical to the 
establishment of pancreatic cancer cellular colonization in the liver or lung (Figure S7). 
Subsequent to initial colonization and further outgrowth, maintenance of epithelial identity is 
critical in the liver but not required in the lung.  Our delineation of this mechanism underlying 
pancreatic cancer metastatic organotropism provides a window of opportunity to tackle new 
perspectives in therapeutic innovation and customization. 
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Main Figures 
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Figure 1: Monoallelic p120ctn loss in a KrasG12D background leads to accelerated 
pancreatic pathology. A. Genetic schematic of Pdx1-cre; KrasG12D/wt; p120ctnwt/fl; Rosa26YFP 
(KCYp120wt/fl) mice. B. A comparison of PanIN, IPMN, and MCN lesion development in KCY and 
KCYp120wt/fl mice. From 32 KCY mice aged between 3 weeks and one year, 26 exhibited lesions 
equal to or less severe than PanIN1As, while 6 exhibited more severe lesions. In an age-matched 
cohort of 38 KCYp120wt/fl mice, 14 exhibited lesions less or equal to PanIN1As, while 24 harbored 
PanIN1B, PDAC, IPMN, or MCN lesions. Fisher’s Exact Test. C. Representative pathology from 
KCY and KCYp120wt/fl mice. D. When only IPMN or MCN lesions (with or without concomitant 
PanIN lesion presence) are considered, 1 out of 32 KCY mice harbored an IPMN/MCN-like 
lesion, while 9 KCYp120wt/fl mice harbored such lesions. Fisher’s Exact Test. E. Three high-
powered fields (10X) across a cohort of age-matched mice (n = 5 KCY, n = 6 KCYp120wt/fl) were 
quantified by two independent observers for the number of PanIN lesions. KCYp120wt/fl mice 
harbored more than two times as many PanIN lesions than KCY mice (14.67 ± 4.71 vs 6.1 ± 2.15, 
mean ± SD). Unpaired t-test. F. Membranous P120CTN and E-CADHERIN expression are 
present at all stages of disease: PanINs in KCY mice and PanINs, PDAC, and liver metastasis in 
KCYp120wt/fl mice. G. IPMN and MCN lesions also display membranous P120CTN and E-
CADHERIN. 50 µm scale bar. *, p < .05, ** < .01, *** < .001. See Supplemental Figures 1 and 2 
and Supplemental Tables 1 and 2. 
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Figure 2: Monoallelic p120ctn loss in a KrasG12D; p53wt/fl background leads to a metastatic 
shift characterized by P120CTN-deficient lung lesions.  A. Genetic schematic of Pdx1-cre; 
KrasG12D/wt; p53wt/fl; p120ctnwt/fl; Rosa26YFP (KPCYp120ctnwt/fl) mice. B. Gross brightfield and YFP 
images of primary PDAC, liver, and lung from a KPCYp120ctnwt/fl mice. C. One slide of liver and 
lung each from KPCYp120wt/fl (n = 5) and KPCY (n = 12) mice was quantified at 10X 
magnification. Each mouse was assigned to either lung or liver dominant category. One mouse of 
each genotype, which had a single lesion in both liver and lung, was excluded. Mice with no 
tumor burden in either organ were excluded. Fisher’s Exact Test. D. Stratification of mice by the 
burden of tumor metastasis shows an increase in lung metastasis and diminution of liver 
metastasis in KPCYp120ctnwt/fl versus KPCY mice. E. Primary tumors and lung metastasis from 
KPCYp120ctnwt/fl mice show retention of membranous P120CTN and E-CADHERIN staining at 
the primary site but loss in the lungs. F. Immunofluorescence of primary and lung metastasis in 
KPCYp120ctnwt/fl mice reveals absent P120CTN (red) in YFP-positive (green) lung metastasis 
with retained E-CADHERIN (lower panel) in P120CTN-positive primary tumor areas and absent in 
lung metastasis. P120CTN-deficient lung metastasis (arrowhead) is surrounded by P120CTN-
positive lung tissue (star). G. Quantification of P120CTN (n = 169) and E-CADHERIN (n = 183) 
localization in KPCY liver metastasis (n = 14 mice), which were analyzed by two independent 
observers. Binomial test. H. Examples from KPCY mice of a well-differentiated liver lesion with 
strongly membranous P120CTN/E-CADHERIN and a poorly-differentiated liver lesion with 
cytoplasmic P120CTN and absent E-CADHERIN. 1 mm scale bar for gross pathology. I. 
Quantification of P120CTN and E-CADHERIN localization in liver and lung metastases (n = 29 for 
liver, n = 20 for lung) (n = 4 mice) in a tet-on, Elastase KRASG12V PDAC model was done by two 
independent observers. Fisher’s Exact Test. *p < .05, **p < .01, ***p < .001, ****p < .0001. 50 µm 
scale bar for histology. See Supplemental Figure 3 and Supplemental Tables 3 and 4. 
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Figure 3: Sequential and mosaic Cdh1 deletion in a KrasG12D background demonstrates 
selective pressure for E-CADHERIN-positive liver metastasis and E-CADHERIN-deficient 
lung metastasis. A. Genetic schematic of the Pdx1-Flp;FSF-KrasG12D/wt;FSF-R26GAG-
CreERT2;CDH1fl/fl mouse. This dual-recombinase system allows FLP recombinase-mediated 
recombination of the FRT sites at the KRASG12D/wt and Rosa26YFP loci as well as independent 
manipulation of CDH1 through tamoxifen-mediated induction of CreERT2. B. Examples of well-, 
moderately-, and poorly-differentiated tumor regions in Pdx1-Flp;FSF-KrasG12D/wt;FSF-R26GAG-
CreERT2;CDH1fl/fl mice. Tumors show strong correlation between membranous co-localization of 
P120CTN and E-CADHERIN. These areas, in turns, are more highly differentiated. C. 
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Immunohistochemistry of representative metastatic lesions in liver and lung by E-CADHERIN 
status. D. Liver (n = 32) and lung (n = 38) metastatic lesions, quantified across 5 mice, were 
classified by E-CADHERIN status. Liver metastases showed a strong predisposition towards E-
CAHDERIN-positivity (n = 30/32), whereas lung metastases showed a strong predisposition 
towards E-CADHERIN-negativity (n = 30/38). Comparison between liver and lung showed a 
statistically significant switch in E-CADHERIN status. Binomial test for comparisons within each 
organ. Fisher’s Exact Test for comparison between organs. ***p < .001, ****p < .0001. 50 µm 
scale bar. 
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Figure 4: A single allele of p120ctn is sufficient to stabilize E-CADHERIN and to colonize 
the liver. A. Ex-vivo recombination of KrasG12D/wt; Rosa26YFP (KY) cells with either wild-type 
p120ctn or mono-/bi-allelic loss. B. Confirmation of efficiency of recombination with ex-vivo cre in 
three replicates per genotype. C. 3D organotypic culture demonstrates that normal cyst formation 
is dependent on P120CTN. Cells were plated in chamber slides in quadruplicate in bovine 
collagen. Cyst formation was quantified 5 days later. KYp120ctnwt/wt cells formed normal cysts a 
majority of the time (94 regular versus 47 irregular), whereas KYp120ctnwt/fl cells showed 
dramatically impaired regular cystogenesis (9 regular versus 70 irregular). KYp120ctnfl/fl cells 
formed no cysts in 4 technical replicates. Fisher’s Exact Test. D. 3D organotypic cultures were 
stained for Tks5, cortactin (CTTN), α-smooth muscle actin (α-SMA), actin (ACTN1), and DAPI. 
Arrowheads indicates protrusions reminiscent of invadopodia. E. Nude athymic mice were 
orthotopically injected with 500,000 cells and harvested three weeks post-injection (n = 3 per 
genotype). H&E on the left and immunofluorescence (P120CTN in red, YFP in green, E-
CADHERIN lower panel]. F. Athymic nude mice were injected with 750,000 cells and harvested 
two weeks post-injection. Ten high power fields were analyzed per mouse (n = 2 wildtype, n = 3 
heterozygous/null). Welch’s T-test. G.  Immunofluorescence of liver metastasis in intraportal vein 
injection model. (P120CTN in red, E-CADHERIN in green]. *p < .05,  ***p < .001, ****p < .0001. 
50 µm scale bar. See Supplemental Figure 4. 
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Figure 5: KrasG12D; p120ctnfl/fl; Rosa26YFP (KYp120ctnfl/fl) cells readily colonize the lung, but 
not the liver, unless rescued with p120ctn1A isoform. A. Western blot demonstrates 
p120ctn1A restoration in KYp120ctnfl/fl cells. B. Nude mice orthotopically injected with 500,000 
KYp120ctnfl/fl cells (n = 10) show lung (n = 6/10), but not liver (n = 0/10), metastasis. p120ctn1A 
rescue (n = 17) restores liver metastasis (n = 8/17) to the liver while still permitting lung 
metastasis (n = 9/14 [3 lungs excluded from this analysis due to lack of gross fluorescence 
images]). Fisher’s Exact Test. C and D. Representative gross pathology and histology from nude 
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mice orthotopically injected with KYp120ctnfl/fl cells stably transfected with an empty vector (C) or 
p120ctn1A-expressing vector (D) and aged out for up to 102 days post-injection. The examples 
represented here were aged for 70- (D) and 98-days (E) post-implantation. E. 18 liver and 30 lung 
metastatic lesions in mice injected with p120ctn1A-rescue cells were classified as either well-
differentiated or moderately/poorly-differentiated on the basis of the presence or absence of 
ductal structures. 12/18 liver lesions were well-differentiated compared to only 3/30 lung lesions 
classified as well-differentiated. Fisher’s Exact Test. F. Immunofluorescence for P120CTN, E-
CADHERIN, and YFP in p120ctn1A-rescued liver metastasis. 1 mm scale bar for gross 
pathology. 50 µm scale bar for histology. *p < .05, ****p < .0001. See Supplemental Figure 5 and 
Supplemental Tables 5 and 6. 
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Figure 6: P120CTN and E-CADHERIN expression in human PDAC. A.  Primary PDAC (n = 20 
for P120CTN, n = 21 for E-CADHERIN) and paired liver metastases (n = 13 for P120CTN, n = 14 
for E-CADHERIN) were analyzed for localization patterns. Whereas 9/21 primary tumors 
demonstrated M or M+C E-CADHERIN, 11/14 liver metastases demonstrated M or M+C staining. 
Fisher’s Exact Test for comparison between organs. Binomial Test for comparison within organs. 
B. Comparison of P120CTN staining intensity between primary PDAC and liver metastases. 
Whereas 17/20 primary tumors showed, at most, weak membranous staining, 6/12 liver 
metastases showed moderate staining or higher. Fisher’s Exact Test for comparison between 
organs. Binomial Test for comparison within organs. C. Correlation of P120CTN (CTNND1) and 
E-CADHERIN (CDH1) expression in human PDAC (n=47) (www.broadinstitute.org) (Pearson r = 
0.4805). Correlation of p120ctn (Ctnnd1) and E-cadherin (Cdh1) expression in murine PDAC 
(n=53) (Pearson r = 0.4601). Gene expression profiles were divided according to p120ctn 
expression levels. Genes associated with a p120 high status (> 90 percentile) and a p120 low 
status (< 10 percentile) shared in human and mouse are enriched in gene sets associated with an 
88 
 
epithelial or mesenchymal signature, respectively. Scale bar: 50 µm. *p < .05. See Supplemental 
Table 7. 
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Figure 7: A single allele of p120ctn restrains EMT programs, and p120ctn and E-cadherin 
are negative predictors of outcomes. A. Heatmap depicting 608 significantly altered genes 
(P<0.05 and fold-change>2) identified through RNA-Seq analysis comparing KYp120ctnfl/wt and 
KYp120ctnfl/fl cells. B. There is significant overlap in differentially induced genes between 
comparisons of KYp120ctnwt/wt cells with KYp120ctnfl/wt and KYp120ctnfl/fl cells. C. GSEA plots 
EMT and metastasis pathways significantly enriched in KYp120ctnfl/fl cells compared to either 
KYp120ctnwt/wt or KYp120ctnfl/wt cells. Note that mono-allelic p120ctn loss restrains transcriptional 
programs associated with EMT. D. Genes that are significantly upregulated in KYp120ctnwt/fl cells 
compared to both KYp120ctnwt/wt and KYp120ctnfl/fl cells. E. Genes that are significantly 
downregulated in KYp120ctnwt/fl cells compared to both KYp120ctnwt/wt and KYp120ctnfl/fl cells. F. 
Interrogation of TCGA reveals that P120CTN and E-CADHERIN are negative predictors of 
outcomes together (shown) or independently (not shown). See Supplemental Figure 7. 
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Supplemental Figures and Tables 
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Figure S1, related to Figure 1: p120ctn is required for both exocrine compartment 
homeostasis and regeneration after pancreatitis. A. Genetic schematic of Pdx1-cre; 
p120ctnfl/fl; Rosa26YFP mice. B. P120CTN (green) is lost in a mosaic fashion in the ductal 
compartment as well as acinar compartment. C. Relative amylase levels are significantly 
decreased in three independent age-matched cohorts (n = 3 per genotype per time interval). T-
test. D. Representative histology of Pdx1-cre; p120ctnwt/wt, Pdx1-cre; p120ctnwt/fl, and Pdx1-cre; 
p120ctnfl/fl mice (60-, 74-, and 55-weeks of age, respectively) and P120CTN/E-CADHERIN 
staining of the acinar and endocrine compartments. Note that whereas P120CTN and E-
CADHERIN are localized at the membrane in mice with either wild-type or heterozygous p120ctn, 
homozygous p120ctn loss results in fatty degeneration surrounding solitary islets. E. Unlike the 
exocrine compartment of Pdx1-cre; p120ctnfl/fl mice, recombined islets (as indicated by YFP+ 
staining) appear to not require P120CTN for normal architecture. F. Pancreata of Pdx1-cre; 
p120ctnfl/fl mice are atrophic 7 days post-pancreatitis induction. G. Whereas wild-type have 
recovered 7 days post-pancreatitis induction, Pdx1-cre; p120ctnfl/fl mice show persistent edema, 
inflammation, and acinar-to-ductal metaplasia (as shown by DBA staining). Pdx1-cre; p120ctnwt/fl 
mice show an intermediate phenotype. H. 3 mice per genotype per time point (with the exception 
of day 1 and 3 of mice with bi-allelic p120ctn loss, where only 2 mice were analyzed) were 
analyzed for edema, inflammation, vacuolization, and necrosis based upon a published 
pancreatitis scoring system (Rongione et al. 1997). Three high-powered fields per mouse. Mice 
with bi-allelic p120ctn loss showed significantly impaired regenerative capability 7-days post-
induction. Multiple t-tests with Holm-Sidak Correction and assumed equivalent scatter. *p < .05. 
50 µm scale bar for histology. 10 mm for gross pathology. 
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Figure S2, related to Figure 1: P120CTN and E-CADHERIN remain co-localized at the 
membrane in PanIN lesions and PDAC. A. Spectrum of pancreatic lesions in Pdx1-cre; 
KrasG12D/wt; Rosa26YFP (KCY) (n = 32) and Pdx1-cre; KrasG12D; p120ctnwt/fl; Rosa26YFP 
(KCYp120wt/fl) (n = 38) mice expressed as a percentage of total mice in each cohort. B. 
P120CTN, E-CADHERIN, and YFP staining of KCY and KCYp120wt/fl mice show co-localization of 
P120CTN and E-CADHERIN at all stages of disease. 50 µm scale bar. (1:50 ECad; 1:250 p120; 
1:250 YFP) 
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Figure S3, related to Figure 2: Circulating tumor cells from KPCY mice differ in their 
epithelial characteristics based on whether they are single cells or clusters. A. Single cells 
or clusters of circulating tumor cells were stained for E-CADHERIN, P120CTN, and YFP. B. 
Single cells or clusters of circulating tumor cells were stained for E-CADHERIN, β-CATENIN, and 
YFP. C. Clusters of circulating tumor cells were stained for CYTOKERATIN-19. 10 µm scale bar. 
 
97 
 
 
98 
 
Figure S4, related to Figure 4: KrasG12D; Rosa26YFP (KY) cells demonstrate the ability to 
colonize the lung regardless of p120ctn status. A. Representative FACS plots (x=GFP/YFP; 
y=FSC) of PDCs with indicated genotypes. YFP positive (YFP+) PDC lines (n=9) were derived 
from age-matched mice (6-15 weeks). In vitro lentiviral Cre-recombination was performed after a 
given PDC line was established. Phase-contrast photographs of 9 independently derived KY lines 
with different p120ctn status: p120ctnwt/wt, p120ctnwt/fl, p120ctnfl/fl. B. Athymic nude mice were 
retro-orbitally injected with 750,000 cells from these genotypes and harvested 21 days post-
injection. 50 µm scale bar for histology. 
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Figure S5, related to Figure 5: KrasG12D/wt; p120ctnwt/fl; Rosa26YFP (KYp120wt/fl) cells give rise 
to both solid and cystic lesions. A. Athymic nude mice were orthotopically injected with 
KYp120ctnwt/fl cells and harvested 101 to 180 days post-implantation. Lesions were classified, 
based on both gross pathology and histology, as to whether they were solid, cystic, or mixed. 
4/12 mice had no tumor penetrance. B. Athymic nude mice were orthotopically injected with 
KYp120ctnwt/fl cells and harvested 180 days post-implantation. Gross pathology was markedly 
different, with either solid tumors or clear fluid-filled cystic lesions. 1 mm scale bar for gross 
pathology. 50 µm scale bar for histology. 
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Figure S6, related to Figure 6: P120CTN and E-CADHERIN expression in human IPMN and 
pancreatic neuroendocrine tumors. A. P120CTN expression in human IPMN. Multiple 
histological subtypes of human IPMN, including gastric-type, intestinal-type, and pancreatobiliary 
(PB)-type, and unspecified IPMN were stained for P120CTN. Binomial test. B. P120CTN 
expression in human IPMN. C. E-CADHERIN intensity is higher in the membranous compartment 
compared to the cytoplasmic compartment in human IPMN. Wilcoxon Test.  D. E-CADHERIN 
expression in human IPMN.   E. Comparison of localization in human PNET (n = 9) for P120CTN 
and E-CADHERIN. P120CTN was membranous (M) in 0/9 samples, whereas it was cytoplasmic 
(C) in 7/9 with or without nuclear (N) staining. E-CADHERIN was demonstrated an absence of 
any purely membranous samples. Binomial Test. F. E-CADHERIN intensity is higher in the 
cytoplasmic compartment than at the membrane in human PNET. Wilcoxon Test. G. Normal 
human pancreas (n = 2), taken from non-affected tissue adjacent to PNET, shows robust 
membranous P120CTN and E-CADHERIN localization in both acini and ducts. Interestingly, islets 
appear to have less membranous staining than the exocrine pancreas. H. PNET demonstrates 
minimal membranous staining for either P120CTN or E-CADHERIN. Scale bar: 50 µm. *p < .05, 
**p < .01, ***p < .001. 
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Figure S7, related to Figure 7: Metastatic organotropism is dependent on epithelial-
mesenchymal plasticity in multiple genetic and implantation models of pancreatic cancer.  
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Pdx1-cre; KRASG12D/+ Age  (weeks) Classification Additional Notes 
614 4.5 Normal  
616 4.5 Normal  
1328 6 Acinar Atrophy Focal Necrosis 
703 7 Normal  
799 8.2 Normal  
540 8.3 Normal  
1349 9.4 PanIN1A   
1346 9.4 Normal  
658 10 Normal  
981 11 Normal  
1099 11 PanIN1A  
702 13.2 Normal  
313 15 PanIN1A/IPMN-like 
dilation 
IPMN-like dilatation of 
pancreatic duct 
414 16 Normal  
1304 16.6 Normal  
390 18 Normal  
633 19.1 Ductalization  
1274 20 PanIN1A    
335 22.9 ADM  
1258 23.7 PanIN1B   
1257 23.7 Focal Duct Dilation  
1252 23.7 ADM  
316 23.9 PanIN1A  
1210 32.8 PanIn1A  
1179 35.7 Normal  
1178 35.7 PanIN1A    
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1177 35.7 PanIN1A    
1176 35.7 PanIN1A/1B  
1175 35.7 PanIN1A/1B  
1103 40-50 PanIN1A  
1101 40-50 PanIN1A/1B  
7548 58 PanIN1A/1B  
 
Table S1, related to Figure 1: Delineation of 32 Pdx1-cre; KrasG12D/wt; Rosa26YFP mice 
characteristics 
Mouse ID, age, pathological state, and notes for all 32 Pdx1-cre; KrasG12D/wt; Rosa26YFP analyzed. 
PanIN, Pancreatic Intraepithelial Neoplasia. IPMN, Intraductal Papillary Mucinous Neoplasm. 
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Pdx1-cre; 
KRASG12D/+; 
p120ctn+/fl 
Age  (weeks) Classification Additional Note 
238 3 Ductalization  
607 5 Ductalization  
696 5 Normal  
243 6 PanIN3 associated 
with cystic changes 
 
1125 7.9 Normal  
648 8 Normal  
995 8 PanIN1A  
869 9.4 PanIN1B  
520 9.5 PanIN1B/IPMN-like 
change 
Branch duct IPMN-like 
multilocular cystic 
lesion with low grade 
mucinous lining.  
1023 10 Normal  
516 10.7 Ductalization  
515 11 Normal  
334 14 PanIN1B/IPMN-like 
change 
Branch duct IPMN-like 
multilocular cystic 
lesion with low grade 
mucinous lining.  
1040 14 PanIN1A/IPMN-like 
change 
 
597 17 Normal  
346 20 PanIN1A  
248 20 PDAC Liver metastasis 
present. 
354 20 PDAC  
685 21.1 PanIN1B  
680 21.1 PanIN1B  
686 21.1 PanIN1B/MCN  
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369 21.6 PanIn1B  
366 22 Normal  
340 23.9 PanIN1B  
322 25.4 Normal  
327 25.7 PanIN1B  
557 30 Normal  
244 33.5 MCN  
1074 34.1 MCN possible MCN? 
Periepithelial stroma + 
and epithelium mostly 
nonmucinous 
1063 34.6 PanIN1A & 1B/MCN possible MCN, focal 
sarcomatoid tumour 
753 35 IPMN-like change   
1187 35.4 PanIN1B Pseudoneoplastic islet 
cell hyperplasia 
1183 35.4 PanIN1B Pseudoneoplastic islet 
cell hyperplasia 
1035 39.1 PanIN1B  
1104 42.3 PanIN1B  
1067 44.1 PanIN1B possible sarcoma, 
small focus; 
Pseudoneoplastic islet 
cell hyperplasia 
1038 40-50 PanIN1B  
990 55.7 PanIN1B/IPMN-like 
change 
marked dilatation of 
main duct the head 
(ipmn like changes?); 
Pseudoneoplastic islet 
cell hyperplasia 
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Table S2, related to Figure 1: Delineation of 38 Pdx1-cre; KrasG12D/wt; p120ctnwt/fl; Rosa26YFP 
mice characteristics 
Mouse ID, age, pathological state, and notes for all 38 Pdx1-cre; KrasG12D/wt; p120ctnwt/fl; 
Rosa26YFP analyzed. PanIN, Pancreatic Intraepithelial Neoplasia. MCN, Mucinous Cystic 
Neoplasm. IPMN, Intraductal Papillary Mucinous Neoplasm. 
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Pdx1-cre; 
KRASG12D/+; p53+/fl  
Age (weeks) Lung Liver 
1087 16 0 7 
1096 13.3 2 14 
1353 9.7 0 0 
1344 0-10 0 19 
1276 13.1 Infarcted Infarcted 
1236 17.7 Infarcted Infarcted 
1303 16.9 0 0 
2032 25 0 0 
2061 23 1 1 
2041 38.7 2 0 
PD 437 Unknown 0 1 
PD 9238 15.8 0 18 
PD 8078 27.1 564 1 
PD 8963 Unknown 3 72 
PD 9402 13.8 0 1 
PD 422 34.2 0 7 
PD 431 31.1 0 6 
PD 635 23 1 8 
 
Table S3, related to Figure 2: Quantification of metastatic lesions in 18 Pdx1-cre; 
KrasG12D/wt; p53wt/fl; Rosa26YFP mice  
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Pdx1-cre; 
KRASG12D/+; p53+/fl; 
p120ctn+/fl;  
Age (weeks) Lung Liver 
958 6 0 0 
1037 17 3 0 
1072 17 Saturated - 
Unquantifiable 
0 
1355 9.7 0 0 
2113 11.5 0 0 
2126 23.9 2 (including one large 
macroscopic 
metastasis) 
0 
2143 22.7 0 3 
2173 11.3 0 0 
2187 14.9 1 1 
2278 19 1 (including one large 
macroscopic 
metastasis) 
0 
 
Table S4, related to Figure 2: Quantification of metastatic lesions in 10 Pdx1-cre; 
KrasG12D/wt; p53wt/fl; p120ctnwt/fl; Rosa26YFP mice 
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Cell 
Line 
Transplantation 
Set 
Mouse ID Days 
post-
injection 
Tumor 
Penetrance 
Liver 
Metastasis 
Lung 
Metastasis 
791Y B 20 70 Yes No No 
791Y B 23 70 Yes No Yes 
791Y B 26 57 No N/A N/A 
791Y L 14 95 Yes No Yes 
791Y L 16 76 Yes No Yes 
288Y C 1 84 Yes No Yes 
288Y C 2 75 Yes No Yes 
288Y C 4 102 No N/A N/A 
288Y C 5 102 Yes No No 
288Y C 6 99 Yes No No 
288Y C 7 99 Yes No No 
288Y C 44 98 Yes No Yes 
 
Table S5, related to Figure 5: Delineation of characteristics of long-term orthotopic 
transplantation with KrasG12D/wt; p120ctnfl/fl; Rosa26YFP cells 
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Cell 
Line 
Transplantation 
Set 
Mouse 
ID 
Days 
post-
injection 
Tumor 
Penetrance 
Liver 
Metastasis 
Lung 
Metastasis 
791Y A 8 84 Yes No 
fluorescence 
available, 
but no 
No 
fluorescence, 
excluded 
791Y A 10 62 Yes No 
fluorescence 
available, 
but no 
No 
fluorescence, 
excluded 
791Y A 11 79 Yes Yes No 
fluorescence, 
excluded 
791Y B 24 70 Yes Yes Yes 
791Y B 24 70 Yes Yes Yes 
791Y B 27 67 Yes Yes Yes 
791Y G 30 93 Yes Yes Yes 
791Y G 31 52 Yes Yes Yes 
791Y G 33 49 Yes Yes Yes 
791Y G 34 46 Yes Yes Yes 
288Y C 8 88 Yes No No 
288Y C 9 88 Yes No No 
288Y C 10 88 Yes No Yes 
288Y C 11 80 Yes No No 
288Y C 13 70 Yes No Yes 
288Y C 45 82 Yes No No 
288Y C 46 82 Yes No No 
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Table S6, related to Figure 5: Delineation of characteristics of long-term orthotopic 
transplantation with KrasG12D/wt; p120ctnfl/fl; Rosa26YFP cells rescued with the p120ctn1A 
isoform 
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ID Metastasis ID Primary 
tumor 
Date of birth age Gender 
(0=female, 
1= male) 
CTX (0=no, 
1=yes) 
E/2014/10393 E/2014/10393 2/22/1971 46 0 0 
E/2014/794 E/2014/794 9/1/1968 49 1 1 
E/2014/13508 E/2014/13508 11/17/1957 60 1 0 
E/2013/34659 E/2013/34659 4/25/1939 78 0 0 
E/2013/33897 E/2013/33897 1/4/1948 69 1 0 
E/2013/31750 E/2013/31750 11/26/1941 75 1 0 
E/2013/31749 E/2013/31749 12/28/1965 51 1 1 
E/2013/31457 E/2012/016585 4/20/1963 54 0 0 
E/2013/28594 E/2013/28594 11/12/1934 83 0 0 
E/2013/18357 E/2013/035750 2/4/1951 66 0 1 
E/2013/028825 E/2008/007691 12/1/1938 78 0 0 
E/2013/002879 E/2013/002879 6/8/1956 61 0 0 
E/2012/37959 E/2011/46424 2/1/1941 76 1 0 
E/2012/13235 E/2011/28673 10/2/1949 68 1 0 
E/2012/6665 E/2012/6665 12/14/1957 59 0 1 
E/2012/002947 E/2012/3115 3/24/1961 56 0 0 
E/2011/046143 E/2011/008097 10/14/1950 67 1 0 
 
Table S7, related to Figure 6: Characteristics of Human Tumor Microarray 
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Methods 
Experimental Model and Subject Details 
General Animal Surgery 
All animal work was approved by the University of Pennsylvania Institutional Animal Care and 
Use Committee under protocol #804959. For all procedures, animals are anesthetized using 
isoflurane (1-4%) delivered through an isoflurane vaporizer and face mask. Adequate anesthesia 
is determined by loss of hind limb retraction to stimulation. Buprenorphine was provided for 
analgesia. Athymic female nude mice between the ages of 8-12 weeks were used for all 
transplantation studies (Taconic Cat#NCRNU-F). 
Orthotopic Transplantation 
After anesthesia and proper sterile preparation of the abdomen, a small (5-10mm) incision was 
made over the left upper quadrant of the abdomen. After exposure of the peritoneal cavity, the 
spleen was located and exteriorized onto a sterile field surrounding the incision site. 500,000 cells 
suspended in 50 µl DMEM (10 or 20% FBS) were then injected into the tail of the pancreas via an 
insulin syringe. A cotton can be held over the injection site for 1 min to ensure that no cancer cells 
leak into the peritoneal cavity, though this is not necessary with the cells used in this study. 
Successful injection of the tail of the pancreas was be confirmed by the appearance of a liquid 
bleb in the pancreas, without leakage of contents into the peritoneum. Afterwards, the spleen and 
pancreas as be placed back into the peritoneal cavity and ventral incision closed with 4-0 sterile 
absorbable suture in a double layer closure. A useful published protocol can be found in Aiello, 
Rhim, and Stanger (2016). 
Intraportal Vein Injection 
After anesthesia and proper sterile preparation of the abdomen, a small (10-15mm) incision will 
be made on the upper median of the abdomen, and followed by mobilization of the duodenum to 
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liberate the portal vein. Tumor cells suspended in 200 µl 20% FBS DMEM will then be injected 
into the portal vein using a needle. After removal of the needle, a cotton swab will then be held 
over the injection site for 3 min to stop bleeding. The injection procedure will be considered 
successful if there is no post-injection bleeding from the puncture site or recoil of tumor cells 
within the injection canal or tumor cell spread into the abdominal cavity. After tumor cell injection 
the intestine will be repositioned and the ventral incision will then be closed with 4-0 absorbable 
suture in a double layer closure using a running suture technique. 
Retroorbital Injection 
Generally anesthetized mice are given local ophthalmic anesthesia (0.5% proparacaine 
hydrochloride) on the eye that will receive the bolus of cells. Cells are injected at a 30° angle on 
the medial side and the needle is slowly and smoothly retracted. 7.5 x 105 tumor cells suspended 
in 200 µl 20% FBS DMEM were injected into the retro-orbital sinus of 10 weeks old athymic nude 
mice. Lungs were harvested 21 days after injection.   
Pancreatitis 
Acute pancreatitis was induced as described previously (Reichert, Takano, Burstin, et al. 2013). 
Mice were starved starting 18 hours prior to induction while given access to water ad libitum. On 
days -1 and day 0, mice were intraperitoneally injected once an hour for eight hours with either 
200 µl of sterile PBS (control group) or 200 µl of 10 µg/mL cerulein (Sigma Cat#C9026) 
(experimental group). On days 1, 3, and 7, pancreata were harvested and fixed.  
Human Tissues 
De-identified and IRB-exempt human pancreatic tissue was obtained from the Technical 
University of Munich Institute of Pathology. In detail, 26 cases of resected pancreatic 
adenocarcinomas and matched liver metastases were included in the cohort. Mean patient age 
was 68.4 years (range: 46 to 82). 13 patients were female 11 were male. According to the 7th 
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TNM classification, one tumor was pT1, 24 were pT3 and one was pT4. 6 patients were pN0, 18 
were pN1, per definition all cases were pM1. 5 patients received neoadjuvant chemotherapy. For 
the creation of tissue microarrays, tumor cores (2 cores of 1.5mm diameter) were punched out of 
formalin-fixed paraffin embedded (FFPE) tissue blocks and arranged in two newly generated 
paraffin block using a tissue microarrayer (Beecher Instruments, Sun Praierie, USA) after tumor 
areas were marked by a board certified pathologist. Use of the tissue was approved by the 
institutional review board of the Technical University Munich (No 403/17 S). 
De-identified and IRB-exempt human IPMN slides were obtained from Dr. Volkan Adsay at Emory 
University. Deidentified and IRB-exempt human PNET slides were obtained from Dr. Andrea 
Califano at Columbia University. 
 
Method Details 
Primary Pancreatic Cell Line Generation and Culture 
Primary pancreatic mouse cells were generated as follows: pancreata were harvested from mice 
and placed in G solution (1 L HBSS [Invitrogen Cat#14175079] + 10 mL penicillin-streptomycin 
[Invitrogen Cat#15140122] + 10 mL Fungizone [Invitrogen Cat#15290018] + 400 µl 0.11M CaCl2]. 
Pancreata were physically dissociated with scissors and then underwent three washes (allow 
cells to settle, aspirate G solution and floating tissues, and the resuspend in 25 mL G solution). In 
the last wash, all G solution was aspirated save for a small amount with cells and remaining 
tissue was resuspended in 25 mL of a 1 mg/mL solution of collagenase type V (Sigma Aldrich 
Cat#9263) diluted in DMEM/F12 (Gibco Cat#11330-032). This mixture was incubated in a bottle 
with a magnet on a stir plate at 37 C for 20-30 minutes. Following digestion, the mixture was 
centrifuged, trypsinzed, resuspended, filtered through a 40 um mesh, and plated on collagen gels 
(type I rat tail collagen [Corning Cat#354236] mixed with 10X PBS and 1 N NaOH) in primary 
pancreatic cell media (see below). All tools, bottles, and magnets were autoclaved prior to use, 
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and the G solution and collagenase mix were filter sterilized. 
Primary pancreatic cells were grown in a 12-component special media composed of (amounts are 
for a 500 mL bottle) 500 mL DMEM/F12 (Gibco Cat#11330-032), 25 mL Nu-Serum (BD 
Biosciences Cat#355104), 2.5 g D-Glucose (Sigma-Aldrich  Cat#G5400), 0.66 g Nicotinamide 
(Sigma-Aldrich Cat#N3376), 5 mL penicillin-streptomycin (Invitrogen Cat#15140122), 2.5 mL 
ITS+ Premix (BD Biosciences Cat#354352), 100 ng/mL cholera toxin (Sigma-Aldrich 
Cat#C8052), 20 ng/mL mouse recombinant EGF (Gibco Cat#PMG8043), 1 µM dexamethasone 
(Sigma-Aldrich Cat#1756), 5nM T3 (Sigma-Aldrich Cat#T6397), 900 µl bovine pituitary extract 
(Gemini BioProducts Cat#500-102), and 0.5 g STI (Gibco Cat#17075029).  
Passage of primary pancreatic cells cultured on collagen plates was performed by digestion of 
collagen gels in Collagenase Type IV (Worthington Biochemical Cat#LS004189) diluted in 
DMEM/F12 (Gibco Cat#11330-032). 
A useful methods paper for the generation and culture of primary pancreatic cells can be found in 
Reichert, Takano, Heeg et al. (2013). 
Cells were infected with lentiviral-Cre-SD (see “Lentiviral Virus Generation and Transduction” 
below) and sorted for YFP. All nine lines used in this paper (KrasG12D/wt; p120ctnwt/wt; Rosa26YFP: 
611, 793, 801; KrasG12D/wt; p120ctnwt/fl; Rosa26YFP: 363, 732, 866; KrasG12D/wt; p120ctnfl/fl; 
Rosa26YFP: 288, 690, 791) are detailed in reagent table. 
Lentiviral Virus Generation and Transduction 
LV-Cre-SD (Addgene #12105, gift from Inder Verma) (Pfeifer et al. 2001) was made using 
pCMVR8.74 (Addgene #22036, gift from Didier Trono) and pMD2.G (Addgene #12259, gift from 
Didier Trono) packaging. HEK293T cells were plated at 6x106 in a 10 cm plate in 10% FBS 
(Sigma-Aldrich Cat#F2442) in DMEM (Corning #MT10013CV) the day prior to transfection. For 
transfection, two cocktails were made (quantities are per 10 cm plate). First, 10 µg of LV-Cre-SD 
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was mixed with 6.5 µg pCMV dR8.74 and 3.5 µg pMD2 VSVG in 1 mL of Opti-MEM-I (Gibco 
#31985070). Second, 1 mL of Opti-MEM-I with 30 µl of Lipofectamine LTX (Invitrogen 
Cat#15338100). After 5 minutes of incubation at room temperature, the latter was added to the 
former and left at room temperature for 30 minutes. 2 mL of the mix was then added to each 10 
cm plate. After either a 3-6 hour incubation or overnight incubation, media was replaced and 
harvested 24 or 48 hours later with a second 72-hour incubation. For transduction, 400 µl of viral 
supernatant was placed on each collagen-coated well of a 6-well plate of PDCs in two sequential 
spin infections. YFP sorted cells were continued to be cultured on collagen. 
3D Culture and Immunofluorescence 
Primary pancreatic epithelium was seeded into 4-well chamber slides (Fisher Scientific Cat#12-
565-21) and allowed to grow for 5 days. First, a collagen solution was prepared as follows 
(amounts are for a full 4-well chamber slide): 294 µl L-Glutamine (Gibco Cat#25030) + 77 µl 
sodium bicarbonate (Gibco Cat#25080) + 245 µl MEM (Invitrogen Cat#11430030) + 816 µl 
bovine collagen (Advanced BioMatrix Cat#5010-50ML) + 49 µl HEPES (Sigma-Aldrich 
Cat#H0887) + 1020 µl water. Second, 225 µl of this solution was allowed to solidify on the bottom 
the chamber slides at 37°C for 30-60 minutes in an oven at atmospheric conditions. Third, a 
mixture of 350 µl of collagen solution was mixed with 5000 cells in 50 µl of primary pancreatic 
media and placed on top of the acellular collagen layer with another 30-60 minutes of 
solidification in a 37°C oven at atmospheric conditions. Fourth, 500 µl primary pancreatic media 
was placed on top and replaced every 2-3 days.  
For 3D culture immunofluorescence, samples were fixed with 4% PFA (room temperature for 30 
minutes) and permeabilized (gently rocking at 30 minutes room temperature or 4 C overnight) 
with a solution composed of 0.35 g fish skin gelatin (Sigma Cat#G7765) and 250 µl Triton X-100 
diluted in 50 mL of PBS with Ca2+ and Mg2+ (PBS+) (Invitrogen Cat#14040). Primary antibodies 
were diluted in permeabilization solution and incubated for 3 hours at room temperature of 4 C 
overnight. Wash samples with permeabilization solution 3 times for 10 minutes and incubate in 
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secondary antibodies/DAPI diluted in permeabilization solution (3 hours at room temperature of 4 
C overnight). Following additional permeabilization solution and PBS+ washes, incubate for 30 
minutes in 4% PFS. Wash with PBS+; remove chambers that surround samples; mount coverslip; 
and image. 
A useful, step-by-step protocol can be found in Reichert, Takano, Heeg, et al. (2013) for both 3D 
culture growth and immunofluorescence staining.  
Antibodies used can be found in “Primary and Secondary Antibody Dilutions.” 
CTC Isolation and Immunofluorescence 
1 ml of blood from KPCY mice was obtained using a heparinized insulin syringe. Blood was 
transferred immediately to a 10 cm plate containing PBS. Single and clustered CTCs were 
identified under fluorescent microscopy and handpicked using a 10ul pipette and tip. Each cell 
was placed into 25 µl of a 1:1 Matrigel:PBS solution on glass coverslip bottom plate. After 
allowing Matrigel/PBS mix to harden for 1 hour at 37 C, cells were fixed with 4% PFA and then 
washed 3 times with PBS. 
Staining of these Matrigel-embedded CTCs was done as follows. First, 0.5% Triton (diluted in 
PBS) was used to permeabilize for 10 minutes at 4 C followed by 3 PBS washes. Second, 10% 
donkey serum was used to block. Third, primary antibodies were diluted in 10% donkey serum 
and incubated overnight at 4 C. On day 2, following further washes in 10% donkey serum, 
secondary antibodies were incubated overnight. On day 3, two further washes in 10% donkey 
serum and two further PBS washes were done before DAPI staining. 
Antibodies used can be found in “Primary and Secondary Antibody Dilutions.” 
Cloning 
p120ctn1A was PCR amplified from of a Mammalian Gene Collection clone (Cat# MMM1013-
202859190) with primers having NHEI and EcoRI enzyme restriction sites and then ligated into 
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PiggyBac plasmid EF1α-MCS-IRES-Neo (Systems Bioscience Cat#PB533A-2). The sequence 
was validated through the University of Pennsylvania Genomics Analysis Core. 
PiggyBac Transfection 
Transfections were performed using Lipofectamine 3000 (Invitrogen Cat#L3000008) per 
manufacturer's instruction with changes to ratio of DNA to transfection components. Briefly, cells 
were plated to 70-90% confluency.  On day of transfection, media was replenished and 125 µl of 
mixture A (3 µg PiggyBac [Systems Bioscience Cat#PB533A-2] vector [either empty control 
vector or p120ctn1A rescue vector], 0.6 µg Hyperactive Piggybac Transposase, and 7.2 µl P3000 
Reagent [part of Invitrogen Cat#L3000008] diluted in 125 µl Opti-MEM) was added to mixture B 
(16.2 µl Lipofectamine 3000 diluted in 125 µl Opti-MEM [Gibco #31985070]) and allowed to 
incubate for 5 minutes. Fresh media was placed on each well and transfection solution added. 
Media was replaced 24 hours later, and G-418 antibiotic selection (Gold Biotechnology Cat#G-
418-5]) started 48 hours post-transfection at 100 µg/mL. Cells were propagated indefinitely in 
G418 at 70 µg/mL. 
Primary and Secondary Antibody Dilutions 
For western blots, primary antibody dilutions were as follows: 1:1000 P120CTN (BD Biosciences 
Cat#610134), 1:1000 E-CADHERIN (Cell Signaling Cat#3195), 1:5000 β-actin (Sigma 
Cat#A5316). Secondary antibody dilutions were 1:5000-1:15000 for anti-mouse (LiCor Cat#925-
68070) and anti-rabbit (LiCor Cat#926-32211).  
For tissue immunohistochemistry, primary antibody dilutions were as follows: 1:400 P120CTN 
(BD Biosciences Cat#610134), 1:400 E-CADHERIN (Cell Signaling Cat#3195), and 1:2500 GFP 
(Abcam Cat#13970). Secondary antibody dilutions were 1:200 for biotin-conjugated anti-mouse 
(Vector Labs Cat#BA-2001), anti-rabbit (Vector Labs Cat#BA1000), and anti-chicken (Vector 
Labs Cat#BA-9010). 
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For tissue immunofluorescence, primary antibody dilutions were as follows: 1:250 to 1:500 
P120CTN (BD Biosciences Cat#610134), 1:50 to 1:500 E-CADHERIN (Cell Signaling Cat#3195), 
1:250 GFP (Abcam Cat#13970), 1:100 amylase (Santa Cruz Cat#12821). Secondary antibody 
dilutions were 1:600 for Cy-2 (usually anti-chicken, Jackson ImmunoResearch Cat#703-225-155) 
and Cy-3 (usually anti-mouse, Jackson ImmunoResearch Cat#715-165-150) conjugated 
secondary antibodies and 1:300 for Cy-5 (usually anti-rabbit, Jackson ImmunoResearch 
Cat#711-175-152) conjugated secondary antibodies. 
For 3D culture immunofluorescence, primary antibody dilutions were as follows: 1:200 CTTN 
(Abcam Cat#81208), 1:100 TKS5 (Merck Cat#09-268), 1:200 αSMA (Sigma Cat#A2547), and 
1:100 ACTIN-1 (Thermo-Fisher Cat#A22287). 
For CTC immunofluorescence, primary antibody dilutions were as follows: 1:200 P120CTN (BD 
Biosciences Cat#610134), 1:250 E-CADHERIN (Clonetech Cat#M108), 1:200 β-CATENIN (Cell 
Signaling Cat#8480), 1:1000 CK-19 synthesized as described (Ito et al. 2000; Tanimizu et al. 
2003; Zong et al. 2009), and 1:250 YFP (Abcam Cat#6673). All secondary antibody dilutions 
used for CTC immunofluorescence were 1:200. 
Western Blot 
Equal amounts of protein were run in reducing conditions on SDS-Page gels and transferred on 
Immobilon-FL PVDF membrane (Millipore Cat#IPFL00010). After blocking in Odyssey Blocking 
Buffer (Li-Cor Biosciences Cat#927-40003), membranes were incubated overnight at 4° in 
antibody diluted in Odyssey Blocking Buffer. After PBS-Tween washes, membranes were 
incubated in the dark at room temperature in the appropriate secondary antibody conjugated to 
an infrared fluorophore. Following another round of PBS-Tween washes and then PBS washes, 
membranes were imaged on Li-Cor Odyssey.  
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Tissue Immunohistochemistry 
Tissue was fixed in zinc formalin followed by 70% ethanol dehydration. Following paraffin 
embedding, sectioning, and mounting, slides were incubated at 60 degrees for 30 minutes 
followed by xylene and ethanol washes. For antigen retrieval, slides were placed in pH 6 citrate 
buffer and microwaved for 15 minutes followed by 15 minutes cool down. Washes were 
performed as follows: 5 minutes PBS; 15 minutes 3% hydrogen peroxide; 5 minutes water; 15 
minutes avidin D blocking; fast PBS wash; 15 minutes biotin blocking; fast PBS wash; 15 minutes 
in T-20 blocking agent (Fisher Cat#PI-37539); incubation overnight at 4°C in antibody diluted in 
PBT [43.5 mL water + 5 mL 10X PBS + 1 mL 10% TritonX-100 + 500 µl 10% BSA]. On day 2, 
slides were processed as follows: two 5-minute washes in PBS; 30 minutes in biotin-conjugated 
secondary antibody (anti-mouse [Vector Labs Cat#BA-2001], anti-rabbit [Vector Labs Cat#BA-
1000], anti-mouse [Vector Labs Cat#BA-2001]) at 37°C; 2 5-minute washes in PBS; 30 minutes 
in ABC Solution (Vector Labs Cat#PK-6100) at 37°C; 5 minute PBS wash; 5 minute water wash; 
DAB exposure (Vector Labs Cat#SK-4100); 5 minutes under running tap water; hematoxylin 
counterstaining; ethanol dehydration and xylene washes followed by cover slipping. 
Tissue Immunofluorescence 
Tissue was fixed in zinc formalin followed by 70% ethanol dehydration. Following paraffin 
embedding, sectioning, and mounting, slides were incubated at 60 degrees for 15-30 minutes 
followed by xylene and ethanol washes. For antigen retrieval, slides were placed in ph 6 citrate 
buffer and either microwaved for 15 minutes (followed by 15 minutes cool down) or put in a 
pressure cooker for 2 hours. Following antigen retrieval, slides were washed in water and blocked 
at room temperature for 1 hour with 0.3% TritonX-100 PBS w/ 5% donkey serum (Jackson 
ImmunoResearch Laboratories Cat#017-000-121). Antibodies were diluted in 0.3% TritonX-
100PBS w/5% donkey serum and incubated overnight a 4°C. On day 2, slides were washed with 
.05% TBS-Tween 3 times for 10 minutes and then incubated at room temperature for 2 hours in 
secondary antibody (1:600 for Cy2- and Cy3-conjugated antibodies, 1:300 for Cy-5 conjugated). 
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After a final set of 3 10 minute washes in .05% TBS-Tween and TBS once for 5 minutes,  
Relative Amylase Area 
Relative amylase area was scored on a similar basis to a previously-published study (J. Morris et 
al. 2010).  Immunofluorescence staining was performed using anti-amylase antibody (sc-12821) 
and DAPI (Life Technologies). The intensity of amylase staining and DAPI positive nuclei across 
all specimen was measured by iVision-Mac software (BioVision Technologies, Exton, PA, USA). 
A ratio of amylase intensity and DAPI intensity was calculated. Overall, 3 high power fields per 
mouse were used across 3 mice per genotype (Pdx1-cre; p120ctnwt/wt, Pdx1-cre; p120ctnwt/fl, 
Pdx1-cre; p120ctnfl/fl) per age group (10-20, 30-40, 50-60 weeks of age). 
Pancreatitis Scoring 
Pancreatitis was scored on the basis of a previously-published criteria covering edema, 
inflammation, vacuolization, and necrosis (Rongione et al. 1997). Three mice per genotype 
(Pdx1-cre; p120ctnwt/wt, Pdx1-cre; p120ctnwt/fl, Pdx1-cre; p120ctnfl/fl) were randomized to 4 groups: 
a control group that received sterile PBS and three experimental groups that were harvested at 
days 1, 3, and 7 post-induction (see “Pancreatitis” in Experimental Model and Subject Details). 3 
high-powered fields were analyzed per mouse per condition and averaged. One mouse in the day 
1 and day 3 group of the Pdx1-cre; p120ctnfl/fl genotype were excluded from final analysis. 
Statistical comparison was performed using multiple T-tests per row with a Holm-Sidak correction 
and assumed same standard deviation.  
Human Tissue Scoring 
Stained microarrays were scanned on an Aperio ScanScope slide scanner. Images were 
transferred to the Institute of General Pathology and Pathological Anatomy (Technical University 
of Munich, Munich, Germany) for analysis. Each specimen was graded for localization status. For 
P120CTN, samples were classified as very weak, weak, weak/moderate, moderate/strong, or 
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strong. A specimen was classified in the highest group it fell in. 
RNA-Sequencing Differential Expression Analysis 
RNA was isolated using the Qiagen RNEasy Mini Kit (Cat#74104) from in vitro lentiviral-Cre 
recombined KrasG12D; p120ctnwt/wt , KrasG12D; p120ctnwt/fl, and KrasG12D; p120ctnfl/fl cell lines and 
analyzed by RNA-sequencing analysis at Hudson BioAlpha (Birmingham, Alabama). The FastQC 
software was applied on raw fastq files to examine the sequence quality.  Paired-end reads were 
aligned to the mouse genome NCBIM37 using Tophat software. Alignments were performed 
using default parameters. Transcript expression quantification was performed using cufflinks. 
Differential gene expression analysis was performed using cuffdiff 6. Counts for each gene were 
computed by means of HTSeq Python package, using the annotation of the Ensembl 66 mouse 
genes and only reads that mapped to exons. Gene set enrichment analysis (GSEA) was 
performed on RNA-seq data using Broad Institute guidelines as previously established. 
Significantly associated gene sets had nominal p-values≤0.05 and false discovery rates 
(FDR)≤0.25 with 1000 permutations and weighted enrichment scoring (Subramanian et al. 2005). 
The RNA-seq data have been deposited at Gene Expression Omnibus accession number 
GSE96729: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96729. 
Quantification and Statistical Analysis 
Replicates, statistical tests, and experimental results (quantification, mean, standard deviation) 
are indicated in figure legends for the respective experiments.  
Data and Software Availability 
Statistical tests were performed in Graphpad Prism. Immunofluorescence and 
immunohistochemical images were adjusted for contrast, color, and tone in Adobe Creative Cloud 
Photoshop. Western blots were imaged on the Odyssey Li-Cor software and manipulated using 
the built-in image processing software. Relative amylase area quantification was performed on 
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iVision. No specific portion of any given image for immunofluorescence, immunohistochemistry, 
H&E’s, or Western blot was ever manipulated differently than other portions of the same image. 
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Table S8: Key Resource Table 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Mouse monoclonal p120ctn BD Biosciences Cat#BD 610134; 
RRID: AB_397537 
Rabbit monoclonal E-cadherin Cell Signaling 
Technology 
Cat#CS 3195; RRID: 
AB_2291471 
Chicken polyclonal GFP Abcam Cat#AB 13970; 
RRID: AB_300978 
Rabbit monoclonal Cortactin Abcam Cat#AB81208; 
RRID:AB_1640383 
Rabbit polyclonal Tks5 Merck Cat#09-268; 
RRID:AB_1587225 
Mouse monoclonal α-smooth muscle actin Sigma Cat#A2547; 
RRID:AB_476701 
Alexa-Fluor 647 conjugated actin-1 Thermo-Fisher  Cat#A22287; 
RRID:AB_2620155 
Rat monoclonal E-cadherin Clonetech Cat#M108 
Rabbit monoclonal β-catenin Cell Signaling 
Technology 
Cat#8480; 
RRID:AB_11127855 
Rabbit cytokeratin-19 Synthesized (Ito et al. 2000; 
Tanimizu et al. 2003; 
Zong et al. 2009) 
Goat polyclonal GFP Abcam Cat#6673; 
RRID:AB_305643 
Mouse monoclonal β-actin Sigma Cat#A5316; RRID: 
AB_476743 
Goat polyclonal amylase Santa Cruz Cat#SC 12821; 
RRID: AB_633871 
Biotinylated anti-mouse Vector Labs Cat#BA-2001 
Biotinylated anti-rabbit Vector Labs Cat#BA-1000 
Biotinylated anti-chicken Vector Labs Cat#BA-9010 
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Cy-2-conjugated anti-chicken Jackson 
ImmunoResearch  
Cat#703-225-155 
Cy-3-conjugated anti-mouse Jackson 
ImmunoResearch 
Cat#715-165-150 
Cy-5-conjugated anti-rabbit Jackson 
ImmunoResearch 
Cat#711-175-152 
Goat anti-mouse, 680RD Li-Cor Cat#925-68070 
Goat anti-rabbit, 800CW Li-Cor Cat#926-32211 
Bacterial and Virus Strains  
LV-Cre-SD (Pfeifer et al. 2001), 
Gift from Inder Verma 
Addgene Plasmid 
12105 
Biological Samples   
Human pancreatic neuroendocrine tumors Dr. Andrea Califano, 
Columbia University 
califano.c2b2.colum
bia.edu/ 
Human intrapapillary mucinous neoplasm Dr. Volkan Adsay, 
Emory University 
http://pathology.emo
ry.edu/AdsayResear
ch/AdsayResearch.h
tml 
Human pancreatic cancer and matched metastasis 
microarray 
Technical University of 
Munich 
https://www.path.me
d.tum.de/index.php?i
d=5&L=1 
Chemicals, Peptides, and Recombinant Proteins 
Rat Tail Type I Collagen Corning Cat#354236 
Fetal Bovine Serum Sigma-Aldrich Cat#F2442 
DMEM Corning MT10013CV 
Opti-MEM I Reduced Serum Medium Gibco Cat#31985070 
Lipofectamine LTX Invitrogen Cat#15338100 
Lipofectamine 3000 Invitrogen Cat#L3000008 
G-418 Sulfate (Geneticin) Gold Biotechnology G-418-5 
T-20 Blocking Reagent Fisher Cat#PI-37539 
VECTASTAIN Elite ABC HRP Kit Vector Labs Cat#PK-6100 
DAB Peroxidase HRP Substrate Kit Vector Labs Cat#SK-4100 
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Caerulein Sigma Cat#C9026 
DMEM/F12 Gibco Cat#11330-032 
Nicotinamide Sigma-Aldrich Cat#N3376 
D-Glucose Sigma-Aldrich Cat#G5400 
Nu-Serum BD Biosciences Cat#355104 
Penicillin-Streptomycin Invitrogen 15140122 
ITS+ Premix BD Biosciences Cat#354352 
Cholera Toxin Sigma-Aldrich Cat#C8052 
Mouse recombinant EGF Gibco Cat#PMG8043 
Dexamethasone Sigma-Aldrich Cat#1756 
T3 Sigma-Aldrich Cat#T6397 
Bovine Pituitary Extract Gemini Bioproducts Cat#500-102 
STI Gibco Cat#17075029 
Fungizone Invitrogen Cat#15290018 
HBSS Invitrogen 14175079 
Collagenase Type V Sigma-Aldrich C9263 
Collagenase Type IV Worthington 
Biochemical 
LS004189 
DAKO Target Retrieval Solution Dako Cat#S1699 
DAKO Serum-free Protein Block Dako Cat#X0909 
DAKO Antibody Diluent Dako Cat#S3022 
Donkey Serum Jackson 
ImmunoResearch  
Cat#017-000-121 
Bovina Collagen Solution, Type I, 6 mg/ml Advanced BioMatrix Cat#5010-50ML 
L-Glutamine Gibco Cat#25030 
Sodium Bicarbonate Gibco Cat#25080 
Minimum essential medium without glutamine Invitrogen Cat#11430030 
HEPES, 1M, pH 7.6 Sigma-Aldrich Cat#H0887 
Permanox Plastic Chamber Slides Fisher Scientific Cat#12-565-21 
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Critical Commercial Assays 
Odyssey Blocking Buffer Li-Cor Biosciences Cat#927-40003 
Qiagen RNeasy Mini Kit Qiagen Cat#74104 
Immobilon-FL PVDF Membrane Millipore Cat#IPFL00010 
Fish Skin Gelatin Sigma Cat#G7765 
PBS with Ca2+ and Mg2+ Invitrogen Cat#14040 
Deposited Data 
RNA-Seq on primary pancreatic epithelium This paper GEO #GSE96729: 
http://www.ncbi.nlm.
nih.gov/geo/query/ac
c.cgi?acc=GSE9672
9 
Experimental Models: Cell Lines 
611 – Primary cells from female mouse This paper N/A 
793 – Primary cells from male mouse This paper N/A 
801 – Primary cells from male mouse This paper N/A 
363 – Primary cells from male mouse This paper N/A 
732 – Primary cells from male mouse This paper N/A 
866 – Primary cells from female mouse This paper N/A 
288 – Primary cells from female mouse This paper N/A 
690 – Primary cells from female mouse This paper N/A 
791 – Primary cells from female mouse This paper N/A 
Experimental Models: Organisms/Strains 
Foxn1nu/Foxn1nu(athymic nude mice) Taconic Cat#NCRNU-F 
p120ctnfl/fl Dr. Albert Reynolds (Davis and Reynolds 
2006) 
Pdx1-Flp;FSF-KrasG12D/wt;FSF-R26GAG-
CreERT2;CDH1fl/fl 
Dr. Dieter Saur (Schönhuber et al. 
2014) 
Oligonucleotides 
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Forward Primer for p120ctn1A cloning into PiggyBac: 
AATATAATAAATGCTAGCGCCACCATGGACGACTCA
GA 
This paper N/A 
Reverse Primer for p120ctn1A cloning into PiggyBac: 
AATAGGTAATAAATGAATTCCTAAATCTTCTGCATCA
AGGGTGC 
This paper N/A 
Recombinant DNA 
Source DNA for p120ctn1A cloning Mammalian Gene 
Collection 
Cat#MMM1013-
202859190 
pCMVR8.74 Unpublished, Gift from 
Didier Trono 
Addgene Plasmid 
22036 
pMD2.G Unpublished, Gift from 
Didier Trono 
Addgene Plasmid 
12259 
PiggyBac plasmid EF1α-MCS-IRES-Neo Systems Bioscience Cat#PB533A-2 
   
Software and Algorithms 
Graphpad Prism Graphpad https://www.graphpa
d.com/scientific-
software/prism/ 
Li-Cor Odyssey Infrared Imager Li-Cor https://www.licor.co
m/bio/products/imagi
ng_systems/odyssey
/ 
Adobe Creative Cloud Adobe http://www.adobe.co
m/creativecloud.html 
FastQC Babraham 
Bioinformatics 
http://www.bioinform
atics.babraham.ac.u
k/projects/fastqc/ 
iVision BioVision 
Technologies 
http://www.biovis.co
m/ivision.html 
HTSeq Python Package EMBL Heidelberg http://www-
huber.embl.de/HTSe
q/doc/overview.html 
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Chapter 3: Conclusion 
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Solid Tumor Metastasis 
Contributions 
 The theme of solid tumor metastasis, as discussed in the introduction, focused on the 
breakdown of the metastatic cascade into discrete steps. One example of this is the work on 
reactivation from dormancy (H. Gao et al. 2012), which has yielded specific effectors that control 
that very particular step in the metastatic cascade. Because of the nature of our experiments, we 
never interrogated the role of p120ctn in the individual steps of the metastatic cascade and only 
ever looked at gross phenotypes after long-term aging of mice. With this limitation fully conceded, 
let me try to glean some possible insights in this area from our work. 
 First, one of the most obvious phenotypic differences we observed was that of 
differences in tumor penetrance between orthotopically transplanted KY cells depending upon 
their p120ctn status. While KYp120ctnfl/fl cells formed tumors at high penetrance, there was lower 
tumor penetrance in KYp120ctnwt/fl cells as well as longer latency. KYp120ctnwt/wt cells never 
formed gross tumors upon orthotopic transplantation. Even though we could not determine what 
homozygous p120ctn loss does in the KCY model due to embryonic lethality, we did see that 
partial destabilization of the adherens junction through heterozygous p120ctn loss does 
accelerate neoplasia. While not unexpected, loss of adherens junction structure does, in fact, 
promote primary tumor growth. Therefore, we can conclude that p120ctn-mediated stabilization of 
the adherens junction is a restraint on the very first steps of the metastatic cascade: the 
establishment of a primary tumor and its subsequent growth. 
 Second, even though KYp120ctnfl/fl cells virtually never formed gross liver metastases in 
our orthotopic model, they routinely did so in the lung, diaphragm, and lymph nodes. While we did 
not quantify to CTCs in these models, the remarkably increased metastatic burden outside the 
liver suggests that KYp120ctnfl/fl are more competent at intravasating, surviving in circulation, 
extravasating and then growing out in non-hepatic parenchyma than KYp120ctnwt/fl  cells.  We can 
therefore conclude that the abrogation of MET is not an impediment to completion of all discrete 
steps in the metastatic cascade, at least when the target organ is not the liver. 
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 Third, as a general principle, we can conclude that what promotes primary tumor growth 
is not necessarily always pro-metastatic. The role of the adherens junction in restraining primary 
tumor growth but fostering metastatic liver outgrowth is an example of this. 
Limitations and Future Directions 
 The limitations to this work in this theme all stem from the lack of any temporal 
manipulation and characterization of the adherens junction. For example, we may have 
demonstrated a propensity for primary PDAC and their paired liver metastases to be defined by 
E-cadherin, but do tumor cells circulate in an E-cadherin-positive state or is E-cadherin toggled 
on and off? Additionally, liver metastases may require E-cadherin to grow, but is E-cadherin 
required for their maintenance? Unanswered questions such as these, related to the kinetics of 
the adherens junction and its effects at discrete metastatic steps and not just the effect on gross 
phenotypes, represent one of the primary limitations of our work. Examples of recent papers that 
dissect the metastatic cascade into discrete steps include the work on lineage-labeling of tumor 
cells in spontaneously metastatic GEMMs (Fischer et al. 2015; Rhim et al. 2012); the toggling on 
and off of EMT-TFs (Takano et al. 2016; Tsai et al. 2012); the molecular effectors that control 
reactivation from dormancy (H. Gao et al. 2012); and the role of oncogenic RAS in maintaining 
PDAC in an inducible KRAS model (Collins et al. 2012). With papers such as these as models, let 
me pose three questions related to this theme that our work leaves unanswered and offer 
solutions.  
First, are the cells that give rise to E-cadherin-positive liver metastases ever E-cadherin 
negative? In section 2 of the introduction, I introduced a breast cancer model that irreversibly 
labels EMT cells green using a Fsp1-Cre and a RFP-LSL-GFP cassette (Fischer et al. 2015). 
One could use a similar approach in either our KCYp120ctnwt/fl model or the standard KPCY 
model. In either case, we would be able to determine if the overwhelmingly epithelial liver 
metastases are derived from cells that ever expressed FSP1, which is known to be one of the 
earliest events in EMT (Okada et al. 1997).  
136 
 
Rhim et al. (2012) have already demonstrated that circulating CTCs in KPCY mice are 
overwhelmingly E-cadherin-negative (though they are EpCAM-positive), and Aiello et al. (2016) 
showed that E-cadherin expression increases as metastases grow out in the liver. It is therefore 
very likely that E-cadherin-positive liver metastases are derived from initially E-cadherin-negative 
CTCs. Irreversibly labeling cells that have undergone EMT would, however, permit us to decide 
whether E-cadherin-positive liver metastases in our model are derived from cells that have 
undergone EMT at some point. 
Second, if E-cadherin is required for the outgrowth of liver metastasis, is it required for 
the maintenance of already established lesions? We know, for example, that oncogenic KRAS is 
both required for the initiation and maintenance of PDAC (Collins et al. 2012). We could 
determine the role of the adherens junction in the maintenance of liver metastasis through the 
same inducible systems Takano et al. (2016) and (Tsai et al. 2012) used to toggle Prrx1 and 
Twist1 on and off and thereby show at what discrete steps these EMT-TFs acted. In our case, 
one could CRISPR either p120ctn or E-cadherin in a KPCY tumor line, reintroduce an inducible 
construct of either, and orthotopically transplant into mice. The first cohort would not be induced; 
the second would be continuously induced; and the last would be induced, and after time was 
allowed to for liver metastasis formation, induction would be withdrawn. This would allow us to 
determine if E-cadherin at the metastatic site is required for only the initial outgrowth or whether it 
has a role in maintaining the metastatic lesions, a conclusion our data does not permit us to 
make. 
Third, the portal vein injection model we used bypasses all early steps in the metastatic 
cascade and instead interrogates later steps, including: survival in circulation, extravasation, 
survival in the liver parenchyma, and outgrowth. Using this model, we showed that KYp120ctnwt/fl 
cells are more competent at forming liver metastases than cells with either wild-type p120ctn or 
homozygous p120ctn loss. However, even with this experimental model, we cannot precisely say 
when the adherens junction acts to endow cells with this metastatic capacity. 
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 It is highly unlikely that survival in circulation is the difference, as KYp120ctnfl/fl cells are 
floridly metastatic to non-hepatic tissue in orthotopic models. Liver endothelium may be a 
particularly attractive target for KYp120ctnwt/fl cells, and, if so, extravasation may be the key step, 
though this is only speculation based on the work showing tumor cell-endothelial interactions as 
crucial. Additionally, based on the work that demonstrates a role for MET in fostering metastatic 
outgrowth, KYp120ctnwt/fl cells may simply be superior at proliferating in that environment.  
 Our experiments also had two technical limitations. First, portal vein injections are 
challenging technically, and leakage during injections may be a confounding factor. Second, we 
relied on H&E slides, not YFP staining, to quantify metastasis, which means we likely missed 
isolated tumor cells during quantification. 
 A mixing experiment, in which Kp120ctnwt/fl cells are labeled with YFP and Kp120ctnfl/fl 
labeled with RFP and then co-injected intravenously, would allow us to determine, in the same 
mouse, whether the EMT/RFP cells are present in the liver parenchyma as isolated cells next to 
proliferating MET/YFP cells. Furthermore, if MET/YFP cells are uniquely capable of creating a 
pro-metastatic niche, we can ask whether EMT/RFP cells situated near MET/YFP cells are more 
proliferative than those isolated in other parts of the liver. Such a mixing experiment, therefore, 
would permit us to make more specific conclusions about what discrete steps in the metastatic 
cascade EMT and MET cells differ in with regards to liver colonization. 
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Epithelial-to-mesenchymal and Mesenchymal-to-
epithelial Transition 
Contributions  
 The second theme in the introduction focused on EMT-MET plasticity during metastasis, 
with a particular focus on whether there is a requirement for MET. I believe we have made 
contributions to this theme that are consistent with recent findings from other groups. 
 First, our work reinforces the notion that whether or not EMT is required at the initial 
stages of dissemination, metastatic outgrowth is enhanced by epithelial properties in certain 
contexts. We demonstrate this phenomenon in 4 separate genetic mouse models.  To briefly 
review, the rare metastatic events in the KCYp120ctnwt/fl show no evidence of LOH; second, in 
the KPCY model, we observed overwhelming membranous E-cadherin/p120ctn in liver 
metastasis; third, in the KPCYp120ctnwt/fl model, absence of p120ctn by staining correlates with a 
shift to lung tropism away from the liver tropism observed in the KPCY model; and fourth, in the 
mosaic KCYE-cadherinfl/fl model, E-cadherin-positive escapers colonize the liver whereas lung 
metastases are E-cadherin-negative. We additionally demonstrate in transplantation models that 
p120ctn loss promotes florid metastasis except to the liver and that p120ctn1A restoration in a 
p120ctn null background restores liver metastasis.  
 Our data therefore confirm the work done on MET in pancreatic cancer. Aiello et al. 
(2016) show that epithelial properties correlate with liver metastatic outgrowth in KPCY mice, 
while Takano et al. (2016) illustrate the role of an MET-promoting transcription factor, Prrx1b, in 
enhancing liver metastasis in orthotopic transplantation models. Additionally, the importance of 
MET in promoting liver outgrowth supports work by Zheng et al. (2015) showing that Snail or 
Twist1 knockout in KPCY mice does not change tumor and metastasis kinetics, though Krebs et 
al. (2017) showed that this dispensability for EMT does not extend to Zeb1.  
 Second, a recurring theme in the study of EMT is the connection between EMT, 
stemness, and chemoresistance. To provide just a few examples, knockout of Snail/Twist1 in 
KPCY mice induces chemoresistance (Zheng et al. 2015), and chemotherapy induces EMT in 
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disseminating breast cancer cells in a spontaneously metastatic model (Fischer et al. 2015). 
Additionally, radiation and chemotherapy upregulate stemness genes such as Sox2 and promote 
spheroid formation (Ghisolfi et al. 2012; Hu et al. 2012).  Using geneset enrichment analysis, we 
were able to detect both an EMT signature and chemoresistance signature in KYp120ctnfl/fl cells. 
Even though our work is certainly not focused on chemoresistance, we show that p120ctn 
perturbations lead to genetic profiles that fit in coherently with what is known about EMT and 
chemotherapy.  
Third, in the introduction, I laid out the evidence that while some work suggests EMT 
endows stemness properties that assist in self-renewal and proliferation, other work shows that it 
is MET that provides a growth advantage. In our model, MET clearly provides a competitive 
advantage to cells in the liver.  
 Both del Pozo Martin et al. (2015) and D. Gao et al. (2012), discussed in the introduction 
and above, demonstrate that microenvironment-mediated suppression of EMT in disseminated 
cancer cells leads to increased proliferation at the metastatic site. Additionally, Tsai et al. (2012) 
showed that Twist1 suppression promoted metastatic colonization, and Takano et al. (2016) 
demonstrate that an MET-promoting Prrx1 isoform enhances PDAC liver metastasis. As del Pozo 
Martin et al. (2015) say in the introduction of their paper, “The outgrowth of metastases requires 
cancer cell self-renewal and growth ability. Therefore, in the context of metastatic growth, 
‘stemness’ is not strictly coupled to the mesenchymal features of cancer cells.” Our work, then, 
supports the possibility stemness/self-renewal properties are decoupled from EMT. 
Limitations and Future Directions 
First, while we confirmed the role of MET in PDAC outgrowth in the liver, a theme others 
have reported (Aiello et al. 2016; Takano et al. 2016; Zheng et al. 2015), our results are 
inconsistent with other reports regarding lung metastasis and EMT. The withdrawal of doxycycline 
in a tet-on Twist1-inducible skin cancer model promotes lung metastasis (Tsai et al. 2012), as 
does Prrx1 knockdown in a tail-vein injection model (Ocaña et al. 2012). Our hypothesis, which is 
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that the lung is permissive to cells in both an EMT and MET state, does not fit in coherently with 
that work.  
There may be several reasons for this, though none are completely convincing. For 
example, one could argue that cancers originating from separate tissue have differing 
requirements for EMT and MET across organs. Whereas pancreatic cancer cells can colonize the 
lung in either an EMT or MET state, skin cancer cells benefit from MET. This is not especially 
satisfying, as one idea I tried to emphasize in the introduction is that it is the organ being 
colonized that sets the requirements for successful colonization. If the lung is permissive to 
pancreatic cancer cells in an EMT or MET state, the “seed-and-soil” hypothesis suggests it 
should be the same for skin cancer cells.  
One other way of reconciling the data is through refining our conclusion that the lung is 
equally permissive to EMT and MET cells. Perhaps, despite the capacity of our KYp120ctnfl/fl cells 
to give rise to florid lung metastasis, they would be even more capable had they been forced to 
undergo a non-E-cadherin-mediated MET. We have already seen in other work that some forms 
of what we can call MET are not mediated by E-cadherin – specifically, mIR-200, which 
suppresses Zeb1 and therefore restores E-cadherin expression, promotes lung colonization by 
breast cancer cells in an E-cadherin-independent mechanism (Korpal et al. 2011). Our 
KYp120ctnfl/fl cells could exhibit similar properties – if we were to knockout certain EMT-TFs, we 
might see increased lung colonization without E-cadherin re-expression, which is, by definition, 
impossible in a p120ctn null background. This, therefore is a major limitation of our work that 
deserves to be emphasized: in the context of EMT-MET plasticity, one can move towards the 
MET part of the spectrum in ways other than E-cadherin expression, but our work only defines 
MET by E-cadherin.  
 One limitation of our work, therefore, is that the conclusion of lung permissiveness to 
colonization by either EMT or MET cells is not supported by data that suggests MET promotes 
lung colonization and that our strict definition of MET likely leads to missed nuances. 
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Second, I made the case above that EMT and stemness/self-renewal may be decoupled 
on the basis of our data showing that MET is required for liver metastasis; however, I have also 
stated that we saw a chemoresistance GSEA signature in our KYp120ctnfl/fl cells. It is difficult to 
accept that both of these are true, as stemness/self-renewal capacity should correlate with 
chemoresistance. Additionally, we know from experience culturing our cells that KYp120ctnfl/fl 
cells are highly proliferative and have very high penetrance in orthotopic models. A limitation of 
this work, therefore, is that we have not characterized the connection between EMT/MET, 
stemness, and chemosresistance. 
We know that disseminating breast cancer cells in a spontaneous breast cancer 
metastasis model do not show evidence of EMT at any point unless they are given systemic 
chemotherapy (Fischer et al. 2015), leaving open the possibility that our KYp120ctnwt/fl cells only 
remain in their epithelial state under untreated conditions. One informative experiment would be 
to treat either the KCYp120wt/fl GEMM or mice orthotopically transplanted with KYp120ctnwt/fl cells 
and determine the effect of chemotherapy on cells primed at the middle ground between normal 
adherens junction stability (p120ctn wildtype) and no adherens junction stability (p120ctn null). If 
these cells were to lose their membranous p120ctn/E-cadherin under treatment but still colonize 
the liver successfully, it might suggest that epithelial properties are dispensable for liver 
colonization under conditions in which you select for a subpopulation of stem-like EMT cells. 
Third, if one starts with the premise that CTCs in pancreatic cancer have undergone 
EMT and express no E-cadherin (Rhim et al. 2012), it leads to the question of what induces 
KPCY liver micrometastases to undergo MET (Aiello et al. 2016). We know from work on prostate 
cancer cells (Yates et al. 2007) and breast cancer cells (Chao et al. 2010) that co-culture with 
hepatocytes induces E-cadherin expression. Additionally, breast cancer cells seeded in a laminin-
1 matrix undergo E-cadherin promoter demethylation. (Benton, Crooke, and George 2009). While 
the mechanisms by which hepatocytes induce E-cadherin re-expression are not understood, they 
likely converge on demethylation, as that is the most common mechanism of E-cadherin 
expression loss. 
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Mouse models, additionally, support the hypothesis that MET is an induced process. 
del Pozo Martin et al. (2015) show that fibroblasts in the lung inhibit EMT in disseminated breast 
cancer cells, and lung myeloid cells induce MET through deposition of versican, which 
downregulates pSMAD2 (D. Gao et al. 2012).  These studies demonstrate that MET can be 
induced by environmental clues, and it possible, therefore, that MET is a process that hepatic 
tissue elicits, though it certainly does not explain why it is unique to the liver when the above 
mentioned mouse models show that lung tissue induces MET (Figure 3-1). 
Fourth, as I discussed in theme number 1 in the conclusion section, one of the 
fundamental limitations of this study is the lack of longitudinal tracking of cell phenotypes – we do 
not know whether E-cadherin-positive cells in the liver came from E-cadherin-negative cells or 
whether they did not undergo EMT in the first place. Therefore, if, instead of accepting that EMT 
occurs (Krebs et al. 2017; Rhim et al. 2012), one accepts that it is dispensable in pancreatic and 
breast cancer (Fischer et al. 2015; Zheng et al. 2015), we are relieved of the responsibility of 
explaining MET since the tumor cells never lose E-cadherin in the first place (Figure 3-2).This is 
supported by work demonstrating that breast and prostate cancer tumor cell circulate as clusters; 
express epithelial markers such as plakoglobin and E-cadherin; and that CTC clusters are 
superior to isolated tumor cells at forming metastases (Aceto et al. 2014).  
Our experiments, however, do not permit us to answer whether E-cadherin-positive liver 
metastases are derived from E-cadherin-negative CTCs or whether the CTCs arrive as E-
cadherin-positive clusters. It is possible both models are in effect within the same tumor, as there 
is no reason to necessarily think they are mutually exclusive (Figure 3-3). 
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Figure 3-1: Model of dynamic E-cadherin changes. Temporally-regulated changes in 
E-cadherin function to maximize tumor cell invasiveness at the primary site and 
promote metastatic outgrowth in the colonized organ. 
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Figure 3-2: Model of EMT bypass. The retention of E-cadherin at the metastatic site can possibly 
be explained by relying on the dispensability of EMT at the primary site; the existence of CTC 
clusters in circulation; and the metastatic outgrowth advantage these CTC clusters possess. 
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Figure 3-3: Model of EMT and non-EMT Dissemination. The primary site is characterized by both 
EMT and non-EMT cells. While EMT cells have an advantage in invasiveness and predominate in 
circulation, only the non-EMT cells and EMT-to-MET cells reactivate from dormancy and grow. 
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Primary Tumor Growth, Metastasis, and 
Organotropism 
Contributions  
 The third theme in the introduction tried to explain the conceptual relationship between 
primary tumor and metastatic genetics as well as the evidence for organotropism in metastasis. 
We demonstrate that less proliferative Kp120ctnwt/fl cells, which develop tumors with delayed 
latency and lower penetrance in orthotopic models, have a metastatic advantage to the liver over 
more proliferative, more tumorigenic Kp120ctnfl/fl cells. In principle, this demonstrates a 
decoupling of properties that promote primary tumor growth and metastasis and is one small data 
point in favor of the idea that primary tumor growth and metastasis are distinct properties. 
Limitations and Future Directions 
 First, by using mouse cells that are p53 wild-type for our RNA-Seq, we have perhaps 
moved away from physiologic and clinical relevance. Previous attempts to discover mediators of 
metastatic organotropism used human cancer cells, such as Minn, Gupta, et al. (2005) and Kang 
et al. (2003), who used human breast cancer cells in serial transplantation models. Furthermore, 
our cells were not in-vivo educated, meaning we would not pick up any effects mediated by 
environmental cues. A limitation of this study is that we did not perform an unbiased, serial 
transplantation experiment to generate in vivo educated organotropic clones. 
 Second, a linked limitation the above is that our human data showed a significant portion 
of mesenchymal liver metastasis and epithelial lung metastasis. Interestingly, KPCY mice, the 
standard in the field, showed overwhelmingly epithelial liver metastasis as well. There is therefore 
a discrepancy between the overwhelming epithelial liver metastasis seen in our models (and the 
KPCY mouse) versus the seemingly greater propensity for mesenchymal liver metastasis in 
human patients. This strongly suggests that a serial transplantation approach with human PDAC 
cell lines may be a better way to discover metastasis mediators.  
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One reason for the higher levels of mesenchymal liver metastasis may be that patients 
have undergone chemotherapy, which we know selects for EMT-like cells (Fischer et al. 2015). 
This, however, does not explain why the lung metastases are epithelial – or the primary tumors 
for that matter. Another possible reason is that perhaps KPCY mice recapitulate one or only a few 
of the PDAC subtypes that happen to be more epithelial identified by sequencing studies 
(Collisson et al. 2011). 
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Pancreatic Cancer 
Contributions  
 By generating multiple new pancreatic cancer mouse models, as well as by phenotyping 
the metastatic ability of KRASG12D cells with differing epithelial properties in transplantation 
models, we have made meaningful contributions to our understanding of pancreas biology. 
 First, in the context of normal pancreas biology, we demonstrate that exocrine, but not 
endocrine, homeostasis requires p120ctn. In a cohort of age-matched mice up to a year of age, 
amylase levels decrease significantly more with p120ctn loss in a dose-dependent fashion. This 
is consistent with Hendley et al. (2015), who used a pan-lineage Pdx1-cre to delete p120ctn in 
the pancreas and reported both acinar and duct cell defects. Though, like us, they do not 
interrogate the endocrine compartment in any detail, it appears Islets were less affected than the 
exocrine cells, which is consistent with our results. Additionally, like us, p120ctn recombination 
was not entirely effective with significant mosaicism. In particular, they report that whereas the 
embryonic pancreas of Pdx1-cre; p120ctnfl/fl mice had less than 10% retention, adult pancreata of 
knockouts were 60% p120ctn positive, which they posit shows a selection pressure for cells with 
unrecombined p120ctn. Interestingly, we see pressure for retained epithelial properties in multiple 
models. 
1) In the Pdx1-cre; p120ctnfl/fl mice, we see mosaic recombination.  
2) We demonstrate that KCY and KPCY mice with homozygous p120ctn loss are not 
viable. 
3) We see that in a KCY mouse with homozygous E-cadherin loss, there is significant 
retained E-cadherin, suggesting that it is not p120ctn that is selected for but epithelial 
properties overall. 
In summary, our work is consistent with published data on the requirement for epithelial 
integrity in the exocrine, but not endocrine, pancreas and selection pressure for retained epithelial 
properties in the embryonic pancreas. 
Second, of particular interest to us is the Mist1-creER; KRASG12D; p120ctnfl/fl mouse  
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(Hendley et al. 2016). There are significant differences between our model and this mouse, 
however, which require attention before comparing. First, the Mist1-creER; KRASG12D; p120ctnfl/fl 
mouse uses an inducible Cre, which the authors activate between 7-9 weeks of age. We use an 
embryonic Cre activated on day 8.5. Second, our Pdx1 driver is not lineage specific, while the 
Mist1 driver is acinar specific. Third, because they use an inducible model, they are able to study 
biallelic p120ctn loss in the context of KRASG12D. For us, this genotype was an embryonic lethal. 
With these differences noted, our two models are consistent in the most important way: we both 
demonstrate PanIN acceleration upon p120ctn perturbation.  
Third, in our KCYp120ctnwt/fl mouse and ex-vivo recombined KYp120ctnwtlwt, wt/fl, fl/fl cell 
line panel, we have demonstrated four phenotypes, each of which informs our understanding of 
the biological progression of PDAC: 
1) Monoallelic p120ctn loss primes pancreatic cells for oncogenic transformation, but 
not because it causes full EMT, as PanIN, cystic, and the rare metastatic lesions in 
the KCYp120ctnwt/fl mouse are almost entirely characterized by epithelial properties. 
This result is consistent with Mann et al. (2012), who reported that p120ctn was a 
cancer candidate gene in a pancreas Sleeping Beauty mutagenesis experiment. 
Since we know that p120ctn loss alone is not tumorigenic; that oncogenic RAS 
signaling is the single most important event in progressing PDAC (Siveke and 
Crawford 2012); that oncogenic RAS alone is dependent on upstream input such as 
EGFR (Ardito et al. 2012; Siveke et al. 2007; Siveke and Crawford 2012); and that E-
cadherin acts to inhibit EGFR signaling (Hoschuetzky et al. 1994; Perrais et al. 2007), 
we can conclude that partial adherens junction destabilization likely acts 
synergistically, potentially through EGFR, to potentiate KRAS and drive PanIN 
development.  
2) Monoallelic p120ctn loss primes KRASG12D transformed cells for both the IPMN/MCN 
and PanIN pathway (Figure 3-4). To my knowledge, there are only four published 
cystic GEMM models (Bardeesy, Cheng, et al. 2006; von Figura et al. 2014; 
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Izeradjene et al. 2007; Siveke et al. 2007), so comparing and contrasting our model 
with these four deserves attention.  
a. Likely most relevant to us is the Ptf1α-cre; KRASG12D; Elastase-TGF-α (KTC) 
mouse, which both accelerates PanIN/PDAC development as well as 
encourages the development of IPMN lesions (Siveke et al. 2007). TGF-α is 
a known agonist for EGFR signaling in the context of pancreatic cancer (Pino 
et al. 2006), and the KTC mouse exhibits activated EGFR signaling as 
measured by phosphorylated EGFR and downstream effectors. The overlap 
between the cystic lesions in our model and those seen in the EGFR-
dependent KTC mouse therefore supports two conclusions: A) the tentative 
conclusion above that 120ctn loss potentiates KRAS signaling through EGFR 
and B) that EGFR signaling is a key effector of the cystic lesion pathway. 
b. Both Bardeesy, Cheng, et al. (2006) and Izeradjene et al. (2007) report that 
SMAD4 loss promotes cystic lesion development in the context of a mutant 
RAS. Interestingly, without a third hit, RAS activation and SMAD4 loss 
overwhelmingly lead to IPMN, whereas the addition of a p16 deletion shifts 
the pathology to PDAC (Bardeesy, Cheng, et al. 2006). Our KCYp120ctnwt/fl 
and KCYp120ctnwt/fl GEMMs display a similar phenomenon, where the 
removal of the p53 tumor suppressor shifts pathology away from cystic 
lesions and towards PanIN-PDAC. Izeradjene et al. (2007) suggest that one 
of the decision points between the cystic and PanIN-PDAC pathway is the 
order in which mutations are acquired. The loss of p53 or p16, they suggest, 
prior to the loss of SMAD4, drives the PanIN-PDAC sequence. Our work, 
therefore, appears to confirm that the order in which mutations are acquired 
matters with regards to cell-fate decision making (Figure 3-5). Additionally, it 
is tempting to consider whether our KCYp120ctnwt/fl mice exhibit a molecular 
profile consistent with SMAD4 loss or TGF-β perturbations. 
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c. The Brg1 knockout model of IPMN demonstrates the differences between 
duct and acinar cells with regards to cystic versus PanIN cell fate decision 
making (von Figura et al. 2014). I will discuss the issue of cell-of-origin in the 
limitations section, as our Pdx1 driver does not permit us to make any 
conclusions on this. 
3) We demonstrate that IPMN/MCN development depends on epithelial plasticity. Mice 
orthotopically injected with either KYp120ctnwt/fl or KYp120ctnfl/fl cells give rise to 
dramatically different primary lesions. Whereas KYp120ctnwt/fl exhibit evidence of both 
cystic and solid primary masses, KYp120ctnfl/fl cells give rise to only solid tumors. 
Interestingly, Izeradjene et al. (2007), in their work on the SMAD4 knockout MCN 
model, suggest that pancreatic cells that have not undergone EMT go down the 
cystic route whereas those that have undergone EMT go down the PanIN-PDAC 
route, a hypothesis our data support. We can therefore conclude that some baseline 
level of epithelial plasticity is required for the IPMN/MCN-pathway, which we 
confirmed in a large cohort of human IPMN tissue.  
 Fourth, we demonstrate, using independent genetic and transplantation mouse models, 
that liver metastasis in pancreatic cancer requires epithelial properties. I have already discussed 
these findings prior and only include them here to emphasize that, within the context of pancreatic 
cancer mouse models, our lung-primed KPCYp120ctnwt/fl mouse could be a useful complementary 
tool to the primarily liver-tropic KPCY mouse for groups interested in studying the mechanisms 
behind tropism. 
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Figure 3-4: Effect of p120ctn loss on 
cell fate. Cell fates in pancreatic 
tissue are compartment and 
mutation-specific. First, in the 
context of a mutant KRASG12D, 
acinar tissue gives rise to early 
PanINs; duct cells, however, are 
resistant to transformation. Second, 
when monoallelic p120ctn loss is 
added, late PanINs arise, likely from 
the acinar compartment, and 
frequent IPMN/MCN, likely from the 
duct compartment. Third, biallelic 
p120ctn loss was only investigated 
in the context of orthotopic and not 
genetic models, and these cells give 
rise to entirely dedifferentiated 
tumors. Because these ex-vivo 
recombined cells were generated 
from whole digested pancreas, it is 
not possible to know if acinar or duct 
cells generate these dedifferentiated 
tumors, though acinar tissue is more 
likely due to work by Kopp et al. 
(2012). 
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Figure 3-5: Effect of 
Mutation Order on Cell Fate. 
KRASG12D paired with 
monoallelic p120ctn loss 
drives both later PanINs and 
IPMN/MCN. With the 
addition of p53 loss, PDAC 
penetrance increases, 
occasionally with some 
cystic qualities. This 
suggests, either, that the 
order of mutations matter 
and drives the PanIN-PDAC 
sequence or that the 
IPMN/MCN lesions in these 
mice give rise to the same 
PDAC that the PanINs give 
rise to. 
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Limitations and Future Directions 
 First, even though Hendley et al. (2015) are in agreement with much of our data, there 
are some discrepancies. They report that their homozygous p120ctn null mice “display…chronic 
pancreatitis, acinar to ductal metaplasia, and mucinous metaplasia that resembled…PanIN1A.” 
While we also see fatty degeneration (presumably secondary to inflammation) of the pancreas 
and a decrease in amylase levels, we do not detect PanIN lesions and very rarely saw ADM. It is 
therefore unclear why our model is less severe than their report, despite similar aging, especially 
since we used the same cre driver.  
 Second, the differences between our KCYp120ctnwt/fl mouse and the Mist1-creER; 
KRASG12D; p120ctnfl/fl model developed by Hendley et al. (2016) make direct comparisons difficult. 
There is however one major differences that should be noted. They report, remarkably, that 
delaminated p120ctn deficient cells are able to stabilize E-cadherin and suggest that KRASG12D 
may have a role in this. Our work is not consistent with this observation, as ex-vivo recombined 
KYp120ctnfl/fl cells show marked reduction in E-cadherin and entirely undifferentiated histology 
upon orthotopic transplantation. One possible explanation is that p120ctn family members are 
able to stabilize E-cadherin in their context, though they report in their other p120ctn mouse 
model that this happens only in the embryo and not the adult (Hendley et al. 2015). A limitation of 
our work is therefore the discrepancy with Hendley et al. (2016) regarding E-cadherin stability in 
KRASG12D-transformed, p120ctn-deficient pancreatic cells. 
Third, despite the multiple complementary mouse models used, there remain significant 
questions about the mechanisms behind our phenotypes. 
1) A core limitation of our study is the absence of a KCYp120ctnfl/fl mouse, which is an 
embryonic lethal. This prevented us from directly comparing the KCYp120ctnwt/fl 
mouse to its ideal matched control. Even though we were able to use orthotopic 
transplantation of ex-vivo recombined cell lines, this is clearly inferior to a genetic 
model. Using an inducible model to generate post-embryonic recombination would 
have been one method of working around this limitation.  
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2) The lack of the KCYp120ctnfl/fl mouse meant our RNA-Seq had to be performed on 
ex-vivo recombined cell lines. While this has certain advantages, such as prioritizing 
cell-intrinsic pathways, it means we lost any chance to pick up differences in the 
effects of in vivo education on KRASG12D cells with differing p120ctn statuses. 
3) I speculated above, based on previous cystic lesion GEMMs (Izeradjene et al. 2007; 
Siveke et al. 2007), that the combination of enhanced EGFR signaling and retained 
epithelial integrity drives KCYp120ctnwt/fl cells down the cystic lesion pathway. This, 
however, leaves unaccounted for observations, including the fact that cells which 
give rise to PanINs also retain p120ctn and E-cadherin yet do not give rise to IPMN 
or MCN. We therefore do not really understand why some mice give rise to PanINs 
while others give rise to IPMN/MCN – in fact, we see both lesions in the same 
mouse. One major limitation of this study, which may help explain our ignorance on 
this point, is that we used a pan-lineage driver that recombines cell compartments. 
There, is, however, data that the cell of or origin for PanINs is different than the one 
for MCN/IPMN (Reichert et al. 2016). A duct-specific Sox9 promoter paired with 
KRASG12D was ineffective at transforming pancreatic epithelium, whereas an acinar-
specific Ptf1α driver was much more effective (Kopp et al. 2012). Meanwhile, using 
the duct-specific Hnf1β cre driver, von Figura et al. (2014) demonstrate that duct 
cells, not acinar cells, give rise to IPMN lesions in their Brg1 knockout model. Our 
use of a pan-lineage Pdx1 therefore prevents us from unraveling the origin of PanIN 
and IPMN/MCN lesions in our model. A valuable experiment would be to use duct 
and acinar specific Cre promoters with both KRASG12D and heterozygous p120ctn 
loss. Based on the published data, I would posit that the acinar-specific driver will 
lead to PanINs whereas the duct promoter would show IPMN/MCN. 
4) von Figura et al. (2014) show that the chromatic remodeler Brg1 regulates duct tissue 
differently from acinar tissue – specifically, while Brg1 blocks IPMN transformation of 
duct tissue, it promotes PanIN development in acinar tissue. While not a limitation per 
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se, it would be informative to see whether our IPMN/MCN lesions and PanIN lesions 
exhibit chromatin properties consistent with Brg1 knockout, which would suggest 
convergence on the same biological pathways. 
5) Even though I have so far been referring to IPMN/MCN as one entity, IPMN and 
MCN lesions exhibit differing molecular characteristics. Our phenotyping was based 
only on histological characteristics. Proving a pathological entity is IPMN or MCN 
requires appropriate characterization of mucin patterns as well as estrogen and 
progesterone receptor. A limitation of our work, therefore, is that we did not perform 
the appropriate molecular characterization of these lesions. In von Figura et al. 
(2014), for example, the authors characterize their Brg1 knockouts using estrogen 
and progesterone receptors, which are specific for MCN but not IPMN. Siveke et al. 
(2007) show that the IPMNs in their TGF-α express Mucin1 and Mucin5A but not 
Mucin 2, which is the pattern they observe in pancreatobiliary IPMN. Therefore, even 
though our pathologist collaborator confirmed these lesions by histology, we have not 
fully characterized these cystic entities with the appropriate markers. 
6) I have so far speculated that enhanced EGFR signaling, owing to destabilized 
adherens junction stability and relief of E-cadherin-mediated EGFR inhibition, acts 
synergistically with KRAS to drive accelerated neoplasia in our KCYp120ctnwt/fl 
GEMM (Figure 3-6). There, are however, other plausible explanations for our 
phenotype: in particular, bypassing of oncogene-induced senescence in KRASG12D-
transformed epithelium, which is thought to arise due to increased p16, p19, and p53 
activity (Lee and Bar-Sagi 2010; Lowe, Cepero, and Evan 2004). This is supported 
by several lines of evidence.  
a. As Lee and Bar-Sagi (2010) summarize in the introduction of their paper, 
“mouse models of oncogenic KRas-driven tumorigenesis have documented 
the presence of senescent preneoplastic lesions in the lung, colon, and 
[pancreas].” KRASG12D-transformed colonic epithelium exhibit p16 
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accumulation and senescence, which can be bypassed by loss of p16 
(Bennecke et al. 2010). Similarly, p53R172H promotes malignancy in KRASG12D 
-transformed pancreatic epithelium through bypass of senescence (Morton et 
al. 2010). 
b. Tuveson et al. (2004), however, report that they were unable to detect 
evidence of senescence, as determined by p16, p19, and p53 levels, in lung, 
colon, and pancreas-transformed epithelium. Additionally, Lee and Bar-Sagi 
(2010) suggest that KRASG12D promotes senescence bypass by upregulating 
Twist1 and suppressing p16. It is therefore not clear whether oncogenic 
KRAS promotes senescence or the overcoming of senescence and the 
context in which each acts. 
Even though we do not have proof, based on growth patterns in vitro, where 
KRASG12D pancreatic epithelial cell lines are far harder to culture without p120ctn 
loss, it is reasonable to assume oncogene-induced senescence in our model. If we 
take this for granted, we can hypothesize that p120ctn loss may aid in the 
overcoming of oncogene-induced senescence. One likely mechanism for this is 
through loss of E-cadherin-mediated contact inhibition, which signals through the 
Hippo-YAP pathway (Kim et al. 2011). Briefly, Hippo loss or YAP overexpression 
bypasses the effects of adherens junction contact inhibition. Crucially for us, Yap 
amplification permits PDAC escape from oncogene-addiction (Kapoor et al. 2014). 
Therefore, I propose that p120ctn loss permits escape from oncogene-induced 
senescence through destabilization of the adherens junction and activation of the 
YAP pathway (Figure 3-7). This may or may not act in conjunction with the EGFR 
pathway speculated about above. Unfortunately, we have not yet interrogated any of 
these likely relevant pathways, and our inability to say which contributes is a major 
limitation of this work. 
158 
 
7) In addition to EGFR and Hippo/YAP signaling, there is one more pathway worth 
considering. In order for this section to make sense, I need to introduce a dichotomy 
between membranous and cytoplasmic p120ctn: cytoplasmic p120ctn is an activator 
of the small G-protein Rac1, whereas membranous p120ctn is an inhibitor of Rac1. 
p120ctn-knockdown in MDA-MB-231 human breast cancer inhibits Rac1 activity 
(Yanagisawa and Anastasiadis 2006). Because MDA-MB-231 cells are E-cadherin 
deficient, their p120ctn is cytoplasmic (Shibata et al. 2004). However, membranous 
p120ctn does not inhibit Rac1 directly but, instead, through E-cadherin stabilization, 
inhibits Rac1 (Soto et al. 2008). Since our ex-vivo recombined cells have 
membranous p120ctn, loss of p120ctn would activate Rac1. Rac1, in turn, is a known 
activation of PAK1, which feeds into MAPK signaling. Therefore, Rac1 activation 
could function in a similar way to loss of E-cadherin-mediated EGFR inhibition, 
namely by potentiating MAP signaling and overcoming the crucial KRAS threshold 
level needed to initiate late-stage PanINs and PDAC (Figure 3-8).  
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Figure 3-6: EGFR and the Adherens Junction. In an early PanIN with intact adherens junction, 
EGFR inhibition prevents potentiation of KRAS signaling. With partial adherens junction loss, 
however, EGFR potentiation drives KRAS signaling to threshold needed to drive high-grade 
PanINs and neoplasia. 
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Figure 3-7: YAP Signaling and the Adherens Junction. In an early PanIN with intact adherens 
junction, oncogene-induced senescence blocks neoplasia. The intact adherens junction ensures 
Hippo signaling, which prevents YAP nuclear translocation. With partial adherens junction loss, 
however, Hippo signaling stops and unphosphorylated YAP translocates to the nucleus driving 
proliferation. 
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Figure 3-8: Rac/PAK1 Signaling and the Adherens Junction. In an early PanIN with intact 
adherens junction, Rac1 inhibition by E-cadherin prevents PAK1 potentiation of MAPK. With 
partial adherens junction loss, however, activated Rac leads to PAK1 signaling to RAF and MEK, 
which drives later PanIN development by reaching the crucial signaling threshold.  
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p120ctn and E-cadherin: Structure and Function at 
the Adherens Junction 
Contributions  
 Our work used p120ctn as a tool to study the effect of epithelial plasticity on pancreatic 
cancer dissemination. In some ways, we bypassed questions about p120ctn biology as long as 
we satisfied ourselves with the cancer phenotypes we observed. Therefore, this section will 
delineate our findings related to p120ctn biology while discussing the questions we bypassed. 
  First, unsurprisingly and entirely consistent with the literature, we demonstrate that 
p120ctn is absolutely required for E-cadherin stability at the adherens junction. We show this not 
only in our Pdx1-cre; p120ctnfl/fl model but also in our ex-vivo recombined KYp120ctnwtlwt, wt/fl, fl/fl 
cell lines. Additionally, using a 3D organoid system, we prove that p120ctn loss functionally 
abrogates cell-to-cell contacts.  
 Second, our p120ctn mouse models are broadly consistent with other conditional 
knockouts. We show, along with skin (Perez-Moreno et al. 2006) and salivary gland (Davis and 
Reynolds 2006) knockout models, that p120ctn loss alone does not give rise to cancer. In all 
organs, except the esophagus, where p120ctn loss gives rise to esophageal squamous cell 
carcinoma (Stairs et al. 2011), this is true. One reason for this is likely the nature of the 
esophagus – as a lumen in close contact with the outside, it is especially susceptible to 
inflammatory insults and barrier defects. Interestingly, p120ctn loss in the colon is a strange case 
(Smalley-Freed et al. 2011): while this model does in fact show adenomas, these adenomas are 
actually p120ctn-positive. This suggests that the barrier defect leads to inflammatory insults 
which, in turn, promotes transformation of the non-recombined epithelium. We can therefore 
conclude that adherens junction destabilization is additive with other oncogenic insults and not 
itself transformative outside of the esophagus. 
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Limitations and Future Directions 
 First, I have outlined multiple pathways related to EGFR, HIPPO/YAP, and Rac/PAK1 
that might mediate the phenotypes we have seen. Despite the plausibility of these pathways 
based on the literature, we do not know which is relevant in our models.  
Second, we suggest that p120ctn1A is able to stabilize E-cadherin. This is supported by 
in vivo data showing overwhelmingly epithelial liver metastasis in orthotopic models injected with 
p120ctn1A-rescue cells; however, the majority of the primary tumor is not differentiated and does 
not express membranous E-cadherin, and the lung metastases in the p120ctn1A-rescue model 
are dedifferentiated. We therefore are incapable of explaining the rules governing p120ctn 
localization.  
Third, both we and Hendley et al. (2015) demonstrate that p120ctn loss in the pancreas 
is not embryonically lethal, and Hendley et al. (2015) show that, in the embryo, p120ctn family 
members can compensate for p120ctn loss by stabilizing E-cadherin. We add on these 
observations the fact that the addition of a mutant KRAS in the context of homozygous p120ctn 
loss is not viable. Since pancreatic agenesis is not embryonically lethal, the non-viability of this 
genotype must be due to other reasons. Timed matings, with analysis of embryos, would permit 
us to determine the timing and reason for lethality. 
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